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Abstract 
 
 
Kaposi’s sarcoma-associated herpesvirus, is a double-stranded DNA γ -
herpesvirus and the main causative agent of Kaposi’s sarcoma (KS).  γ -
herpesviruses undergo both lytic and latent replication cycles; and encode proteins 
that modulate host transcription at the RNA level, by inducing decay of certain 
mRNAs. Here we describe a mechanism that allows the viral endo-/exonuclease 
SOX to recognise mRNA targets on the basis of an RNA motif and fold. To induce 
rapid RNA degradation by subverting the main host mRNA degradation pathway 
SOX was shown to directly bind Xrn1. This may shed light as to how some viruses 
evade the host antiviral response and how mRNA degradation processes in the 
eukaryotic cell are involves in this. 
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Chapter	  1:	  Introduction	  
1.  
1.1. Kaposi's Sarcoma-associated Herpesvirus  
  
 The herpesviridae comprise over 130 viruses, which target a wide range of 
host’s covering invertebrates and vertebrates, from amphibians to humans and 
livestock (Brown and Newcomb, 2011). Herpesviridae are well adapted to evade 
the immune response and as such, following the primary infection, establish 
lifelong latent infections in the host, which can reactivate to lead to recurrent 
infections and chronic diseases (Malik and Schirmer, 2006). Each individual 
herpesvirus is well adapted to its specific host and target tissues. The primary 
and/or recurring infections are frequently asymptomatic, but in immunosuppressed 
individuals herpesviruses can be life-threatening, where infections can lead to 
different types of cancer or autoimmune diseases (Desailloud and Hober, 2009, 
Caselli et al., 2012). Herpesviruses have a double stranded linear deoxyribonucleic 
acid  (DNA) genome, which is contained in an icosahedral capsid wrapped in viral 
proteins and viral messenger ribonucleic acids (mRNA) (tegument), which then is 
enveloped by a lipid bilayer membrane to form the virion. 
 
 Eight human herpesviruses (HHVs 1-8) have been identified to date. There 
are three subfamilies α-, β- and γ-herpesviridae. The α-herpesviridae contains 
herpes simplex virus types 1 and 2, (HSV-1 and 2 or HHV-1 and 2), varicella zoster 
virus (VZV or HHV-3), whose primary target is the mucoepithelial tissue and 
latency is established in neurons. The β-herpesviridae includes human 
cytomegalovirus (HCMV or HHV-5), which targets monocytes and lymphocytes 
(in which it establishes latency) as well as epithelial cells. This subfamily also 
includes roseoloviruses (HHV-6 and HHV-7), which target and establish latency in 
T cells (Levy, 1997, Dockrell, 2003, Salahuddin et al., 1986). Finally the γ-
herpesviridae that encompasses the Epstein–Barr virus (EBV or HHV-4) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV or HHV-8), both of which 
establish latency in B cells and target lymphocytes and epithelial cells. The animal 
model for KSHV is the murine herpesvirus 68 (MHV68) in mouse. 
 
 KSHV is the most recently identified human herpesvirus, which, due to its 
lymphotropism and its intense immune evasion strategies, establishes lifelong 
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infections (Boshoff and Chang, 2001). Hence, the viral proteins and mechanisms 
that are involved in establishing latency and immune evasion are critical for KSHV 
pathogenesis (Dourmishev et al., 2003, Gray et al., 2012). Through its infection of 
endothelial cells, KSHV is the main causative agent of Kaposi’s sarcoma (KS), 
which is associated with immunosuppressed patients and the most common human 
immunodeficiency virus (HIV) associated cancer. KSHV infection has also been 
linked to other lymphoproliferative disorders that include primary effusion 
lymphoma and multicentric castleman’s disease (Boshoff and Weiss, 1998, 
Arvanitakis et al., 1996, Cesarman and Knowles, 1999).    
 
 KSHV, EBV and MHV68 are closely related γ-herpesviruses that share 
many proteins and molecular mechanisms and are thus intensively studied. They 
have a biphasic life cycle, hence undergo both a lytic and latent phase. During 
latency, the viral genome is circularised and found as a nuclear episome, which is 
tethered via the histone to the chromatin during mitosis (Rezaee et al., 2006). In the 
latency phase viral gene expression is repressed by the limited expression of genes 
in a small subjection of the episome. The viral genome is approximately 165 to 170 
kilobases (kb) in length (Renne et al., 1996) and contains 86 mainly intronless 
genes (Rezaee et al., 2006). The lytic phase is characterized by increased viral gene 
expression and rapid and global host mRNA decay prior to viral replication, which 
climaxes with cells lysis and release of the viral progeny (Glaunsinger and Ganem, 
2004). The rapid and global decay of host mRNA transcripts is a conserved 
mechanism amongst the herpesviridae and has been termed host shutoff (HSO) 
(Glaunsinger and Ganem, 2006). Viral genome maturation, a process required for 
encapsidation following replication of the viral genome, and HSO during the lytic 
cycle, are both dependent on a single nuclear and cytoplasmic protein called shutoff 
and exonuclease (SOX).   
 
 
1.1.1. SOX: Role in the Lytic Phase 
 
HSO, the rapid and global degradation of host mRNA transcripts is thought 
to serve two main purposes. These are to promote the evasion of host anti-viral 
response whilst enabling re-deployment of the transcriptional and translational 
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machinery for the overproduction of viral mRNA transcripts and proteins (Buisson 
et al., 2009).  Although SOX, an alkaline 5’ to 3’ exonuclease, has been implicated 
in this process, it is likely to work in conjunction with other cellular factors (Clyde 
and Glaunsinger, 2011). Homologues of SOX have been identified in MHV68 
(called muSOX) and in EBV (called BGLF5), whose mechanisms of action closely 
resemble those identified in SOX. It was shown in mice that viral pathogenesis, 
establishment of latency and reactivation was influenced by the HSO activity of 
muSOX and vhs (the homologue of SOX in HSV-1) (Richner et al., 2011, Strelow 
and Leib, 1995, Strelow and Leib, 1996, Strelow et al., 1997). The direct 
involvement of SOX in mRNA decay was demonstrated when the half life of a 
reporter green fluorescent protein (GFP) mRNA was reduced in the presence of 
SOX, compared with experiments where SOX was knocked out in (human 
embryonic kidney 293 T) HEK293T transfected cells (Glaunsinger et al., 2005). 
 
 
1.1.2. SOX: Structure and Conserved Motifs 
 
 SOX and its γ-herpesvirus homologues have 67% identity within a set of 
seven motifs that are highly conserved. These seven motifs are important for their 
common nuclease function and have been confirmed by both biochemical and 
structural studies involving wild-type proteins and a complex involving duplex 
DNA (Goldstein and Weller, 2004, Glaunsinger and Ganem, 2004, Bagneris et al., 
2011). Motif I contains the residues S144, S145 and S146, which together with 
S219 of motif II form a “serine cluster”. The residues within the conserved 
PD(D/E)XK  sequence that has an essential catalytic role are located within motifs 
II and III. Where the D (D221) and the D/E (E244) and K (K246) residues are 
found respectively in motifs II and III. Motif III has been implicated in DNA 
binding along with motif VI (K246, F249, K250 and Y373). Motifs III, IV (E300) 
and VI (R370) are located in a cleft at the centre of the SOX molecule termed “the 
canyon” that harbours the active site and DNA binding interface. This canyon 
effectively subdivides SOX into two lobes (one formed by the N-terminus of the 
molecule, the other by the C-terminus) that are effectively spanned by a polypeptide 
“bridge loop” (P164-G180) that resides directly above the active site and is thus 
thought to be involved in nuclease activity. At the base of the active site canyon, 
between motifs IV and V, SOX has a second nuclear localization signal (NLS)  
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A  
  
B  
 
C  
  
Motif Name Corresponding Residues in SOX 
Motif I V122 - F148 
Motifs II G206 - D221 
Motif III Y243 - E257 
Motif IV F281 - W311 
Motif V N335 - L345 
Motif VI V365 - I388 
Motif VII I433 - F444 
Bridge Loop Q154 - G180 
NLS P315 - K320 
 
Figure 1-1: SOX Motifs and Residues Involved in Nucleotide Recognition 
and Nuclease Activity 
 
A) The seven motifs in SOX, NLS and “bridge loop”. Motif I in red, motifs II) 
in orange, motif III in yellow, motif IV in green, motif V in pink, motif VI in 
blue, motif VII in dark orange, “bridge loop in black and NLS in magenta. B) 
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The N-terminal (in green T24 and A61) and C-terminal (in blue D474 and 
Y477Stop) mutants involved in HSO, the catalytic residues involve in 
deoxyribonuclease (DNase) and HSO activity (in black D221, E244 and K246) 
and the catalytic DNase mutant (in pink Q129). C) Table clarifying the 
residues involved each SOX motif. 
 
 
(315-PRKKRK-320). This NLS is also found in BGLF5 and is highly conserved 
among the γ -herpesvirus homologues (Glaunsinger et al., 2005, Buisson et al., 
2009, Bagneris et al., 2011) (Figure 1-1A).  
 
 
As SOX was originally shown to function in the resection of newly 
replicated viral genomes (Buisson et al., 2009) the presence of the PD-(D/E)XK  
motif resulted in its original classification as a type II restriction DNA 
endo/exonuclease (Bujnicki and Rychlewski, 2001). RNA endonucleolytic activity, 
however, has been found in several viral ribonucleases (RNase) that contain this 
motif (Yuan et al., 2009, Morin et al., 2010). They can harbour within their active 
site both RNA endonuclease and exonuclease activities (Covarrubias et al., 2011, 
Yang et al., 2009, Mathy et al., 2007). The apo and holo double stranded 
deoxyribonucleic acid (dsDNA) bound structures of SOX were obtained and the 
residues involved in the catalytic site were confirmed as D221, E244 and K246 
(Figure 1-1 B) (Protein Data Bank (PDB) ID: 3fhd and 3pov, respectively) 
(Bagneris et al., 2011, Dahlroth et al., 2009). Furthermore, SOX was confirmed to 
have RNase activity in addition to its DNase activity. In vitro experiments in which 
D221 and E244 were mutated to S221 and S244 in SOX confirmed that the same 
catalytic machinery is utilized for both 5’ to 3’ exonucleolytic RNase and DNase 
activities in SOX, muSOX and BGLF5 (Buisson et al., 2009, Glaunsinger et al., 
2005, Bagneris et al., 2011). Experiments in which these residues were mutated 
resulted in inhibition of HSO in vivo (Covarrubias et al., 2011, Buisson et al., 
2009). In addition, a number of SOX non-catalytic residues have been identified 
that when mutated are HSO defective in vivo (HEK 293T cells), but DNase active. 
These are referred to as HSO mutants. They map to the N-terminus (T24I and 
A61T), the C-terminus (V369I, D474N and Y477Stop) and the “Bridge Loop” 
(P176S) of the protein and suggest that RNA binding involves recognition by 
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distinct structural motifs to those required for DNA (Q129H) (Figure 1-1 B). These 
differences in modes of association between RNA/DNA and SOX were consistent 
with studies on BGLF5 (Buisson et al., 2009) and could indicate the involvement of 
host/viral cofactors interaction to further mediate HSO (Bagneris et al., 2011, 
Glaunsinger et al., 2005).  
 
 
1.1.3. SOX: HSO and the Involvement of SOX and Host Co-Factors 
 
Although knockdown of SOX by small interfering RNA (siRNA) silencing 
is alone sufficient to eliminate HSO (Covarrubias et al., 2011), the extent of its 
participation in this mechanism remains to be fully established. The HSO mutants 
nor the D221S catalytic mutant, while leading to abrogation of HSO and RNase 
activity, did not lead to mislocalisation of SOX within the cell. Experiments in HEK 
293T cells with a GFP reporter mRNA demonstrated that SOX decreased the 
cytoplasmic presence of GFP mRNA, but not the nuclear fraction, while decreasing 
the overall cellular GFP reporter mRNA quantity. This is an indication that even 
though SOX contains an NLS and is found in the nucleus, its RNA degradation 
activity is likely to be occurring in the cytoplasm, where host mRNA degradation 
takes place (Glaunsinger et al., 2005). 
 
 The degradation of host mRNA is uninhibited by the presence of the mRNA 
5’ cap (Covarrubias et al., 2011). In addition SOX was shown to specifically 
degrade RNA transcribed by the RNA polymerase II (pol II), which is responsible 
for transcription of mRNA and most small nuclear ribonucleoproteins (snRNA) and 
microRNA (miRNA) (Covarrubias et al., 2011). This was demonstrated by 
constructing GFP reporters that were pol I or pol III transcribable while expressing 
SOX, which did not lead to GFP reporter RNA turnover (Covarrubias et al., 2011). 
Pol I and pol III transcription does not result in the addition of the 5’ cap and 
polyadenylation tail (poly(A)tail), nor does the RNA transcript go through the same 
mRNA maturation pathways, e.g. nuclear splicing. In addition, it was shown that 
these mRNA transcripts needed to be translationally competent, as they co-
sedimented with the ribonucleoprotein (RNP), the eukaryotic small ribosomal 
subunit (40S) pre-initiation complex (eIF3j, eIF2a and RPS3) and eukaryotic 
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ribosome (80S) complex. Further analysis also revealed a decreased polysome 
population and increased 80S monosome population, in response to SOX over 
expression, which is consistent with degradation of actively translating mRNAs 
(Covarrubias et al., 2011). Recently Hendrickson et al. (2009) reported that the bulk 
of cytoplasmic mRNAs are polysome-associated, suggesting that targeting 
translationally active mRNAs would allow the virus to target the majority of host 
mRNA for degradation as observed in HSO (Hendrickson et al., 2009). The link 
between translation and degradation is reminiscent of host mRNA surveillance 
mechanisms, such as nonsense mediated decay (NMD), which works with the 
exosome and exoribonuclease 1 (Xrn1). 
A depletion study of host RNA degradation enzymes revealed that the 5’ to 
3’ exonuclease Xrn1 was necessary for complete mRNAs degradation in SOX-
expressing cells. Further, yeast two hybrid assays carried out by collaborators 
(Ebrahimi, B.; unpublished work) indicated that human Xrn1 and SOX were 
interacting. In the absence of Xrn1, the mRNAs were only partially degraded and 
the degradation intermediates of the SOX mRNA targets accumulated (Covarrubias 
et al., 2011, Kronstad and Glaunsinger, 2012). Xrn1 was also shown to co-sediment 
in both the RNP and 40S fractions, akin to SOX. It was suggested that SOX’s 
RNase activity could not account for the rapid and global SOX-induced mRNA 
degradation owing to its poor affinity for single stranded RNA (ssRNA) substrates 
(Bagneris et al, 2011). Additional experiments with siRNA demonstrated the 
reliance of the SOX-induced HSO degradation pathway on Xrn1 (Covarrubias et 
al., 2011). Xrn1, which is highly conserved in eukaryotes, is an 5’-3’ 
exoribonuclease that functions to degrade cytoplasmically localised mRNAs, as part 
of the host mRNA surveillance pathways (Garneau et al., 2007). Xrn1’s 5’ to 3’ 
exonuclease activity generally requires initial deadenylation and decapping of 
mRNAs, but notably, this rate-limiting step appears not to be required for SOX-
induced turnover (Garneau et al., 2007). One way to make mRNAs accessible to 
Xrn1 turnover, prior to or without deadenylation or decapping, is via 
endonucleolytic cleavage, which is similar to mechanisms in the host mRNA 
surveillance pathways. Intriguingly, recent evidence suggests that this mechanism 
of viral nuclease cleavage followed by Xrn1 mediated degradation appears to be 
27	  
ubiquitous amongst the herpesviridae and coronaviridae (Gaglia et al., 2012, 
Kronstad and Glaunsinger, 2012).  
 
 
1.1.4. SOX: SOX-Mediated mRNA Decay and Target Sequences  
 
Previous published experiments from the Barrett Group that focused on the 
ability of SOX to turnover single stranded RNA showed that the HSO mutants did 
not abrogate ssRNA degradation (Figure 1-2) (Bagneris et al., 2011). This was in 
contradiction to the previously published in vivo work, which showed that HSO 
mutants did abrogate GFP-mRNA turnover (Glaunsinger et al., 2005). This was 
suggestive of the need for either a specific RNA sequence element, a structured 
motif or a co-factor.  
A 
 
B 
 
 
Figure 1-2: HSO SOX Mutants do not Abrogate ssRNA Turnover  
 
A) The TBE-Urea gel from the Bagneris et al., 2011 publication showing that the 
HSO mutants (A61T, D474N and Y477Stop) do not abrogate the turnover of ssRNA 
in vitro. B) Oligonucleotides used in assays in Bagneris et al., 2011. 
 
 As previously mentioned, in the absence of Xrn1, mRNAs were only partially 
degraded and shorter RNA degradation intermediates were seen to accumulate 
(Covarrubias et al., 2011, Kronstad and Glaunsinger, 2012). In experiments with the 
three reporter mRNAs GFP, red fluorescent protein (DsRed2) and β-globin (HBB), 
frequently used in these studies, the accumulation of degradation intermediates of 
28	  
defined length was also observed (See Appendix A). These intermediates are 
reminiscent of the morphogenetic effect on genitalia 6 (SMG6)-cleavage products 
seen during NMD (Eberle AB et al., 2009, Kashima et al., 2010). The GFP and 
DsRed2 reporter mRNAs are of similar length (1.2-1.5 kb), whilst the lengths of 
their degradation intermediates varied (GFP fragment ~ 1.1 kb and DsRed2 
fragment ~ 600 base pairs (bp)). Furthermore, the degradation intermediates for 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and HBB were similarly 
varied (Covarrubias et al., 2011). This indicates that the generation of the 
intermediates is not controlled by a positional cue around or by the translation 
initiation site. The fact that the degradation intermediates for each reporter gene 
have a consistent defined-length was indicative of cleavage being directed to a 
specific location or sequence within the mRNA (Covarrubias et al., 2011). The 
Glaunsinger group sequenced the degradation intermediates for the three reporter 
mRNAs. All three mRNAs had only a UGAAG sequence in common 2-3 
nucleotides upstream of the cleavage site (Covarrubias et al., 2011). Interestingly, 
transposition of the 201-nucleotide long sequence containing the UGAAG was 
sufficient to prevent cleavage and subsequent degradation by Xrn1 in cells 
transfected with SOX and GFP-containing vectors. However, when a 25 nucleotide 
construct encompassing the UGAAG motif was used, this proved to be insufficient 
(Covarrubias et al., 2011, Clyde and Glaunsinger, 2011). These results thus suggest 
a structural element to the SOX mRNA recognition process in conjunction with a 
requirement for the conserved motif. In addition, it was suggested that HSO is a 
two-step mechanism requiring initial cleavage of mRNAs by SOX to catalyse 
substrates for Xrn1. It would thus appear that SOX subverts the normal functioning 
of Xrn1 since this process occurs in the absence of deadenylation and decapping. 
 
 
1.2. mRNA and mRNA Decay   
 
Large-scale studies and analyses indicate that as many as half of all changes in 
the transcriptome and proteome can be attributed to altered rates of mRNA decay 
(Garneau et al., 2007). From transcription, 5’capping, splicing, polyadenylation, 
mRNA export to translation, at every point a transcript is subject to elaborate 
control leading to varied protein expression and altered signals. Thus, many cellular 
mechanisms and proteins are solely dedicated to tune the rate of mRNA degradation 
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(Jinek et al., 2011, Schoenberg, 2011). It is becoming increasingly apparent that 
these finely tuned mechanisms are the targets for pathogenic viruses, which through 
their subversion are able to promote replication of the viral genome through re-
deployment of the host cell translational mechanism. These host mechanisms will 
therefore be reviewed along with their recently discovered involvement in the 
pathogenicity of the KSHV virus, the focus of this thesis. 
 
 
1.2.1. Host pre-mRNA 
 
 As previously mentioned, eukaryotic mRNA undergoes maturation, including 
precursor mRNA (pre-mRNA) splicing within the nuclei. The first maturation step 
is the addition of a 7-methylguanosine (m7G) via a 5’-5’ triphosphate linkage to the 
first nucleotide of the transcript, which cannot be easily degraded by 5’ to 3’ 
exonucleases. This 5’ cap is thus a protective element that also functions as a 
recognition motif for proteins involved in nuclear export, 5’ proximal intron 
excision, translation initiation and translation (Shatkin and Manley, 2000). The 
poly(A)tail is added to the maturing mRNA at the end of transcription. The 
poly(A)tail also protects the mRNA from cytoplasmic mRNA degradation and is 
involved in mRNA export and translation mechanisms (Kapp and Lorsch, 2004, 
Konarska et al., 1984). mRNA splicing and transport across the nuclear pore 
complex (NPC), are intrinsically linked and subject to quality control (Houseley et 
al., 2006, Fasken and Corbett, 2005, Dimaano and Ullman, 2004, Saguez et al., 
2005, Vinciguerra and Stutz, 2004). The vast majority of human genes contain 
introns and express more than one mRNA by a process called alternative splicing, 
which is highly regulated (Maquat, 2004, Kan et al., 2001). This process allows the 
translation of functionally diverse protein isoforms. Splicing has to be precise and is 
a complex process, but has the advantage of diversifying the proteome (Black, 
2003, Hastings and Krainer, 2001, Burge et al., 1999). When splicing is inefficient 
or inaccurate, this can lead to a shift in the translational reading frame, which then 
introduces a premature termination codon (PTC). mRNA transcripts that contain a 
PTC are detected by cellular control mechanisms and are targeted for NMD. 
 
 
30	  
1.2.1.1. mRNA Splicing 
 
 The average human gene contains 9 exons and 8 introns (Sakharkar et al., 
2004). An exon is the nucleotide sequence of the pre-mRNA that remains present 
within the final mature RNA product, while the intron is removed from the mRNA. 
The exons are defined by short classical splice-site sequences at the intron/exon 
borders, which are GU at the 5’ splice site and AG at the 3’ splice site (Figure 1-3) 
(Black, 2003, Hastings and Krainer, 2001). The 3’ splice site can be further defined 
by an upstream polypyrimidine tract (PPT), which recruits factors to the 3' splice 
site and to the A branch site sequence (BPS). snRNA bind the splice-site sequences 
and promote the assembly of the spliceosome, a large ribonucleoprotein complex. 
This ribonucleoprotein complex is made up of five small nuclear ribonucleoproteins 
(snRNP) and another 100 other proteins (Maquat, 2004) . 
 
 
 
Figure 1-3: pre-mRNA and Splicing Signals 
 
pre-mRNAs contain exons and introns, the latter are excised so that the exons on 
each side of the intron regions form an mRNA. To facilitate excision of the intron, 
the splice site contains a 5’ GU dinucleotide, an A branch site, a polypyrimidine 
tract and a 3’ splice site. Additional cis elements can be found in the exons, such as 
exonic splicing enhancer and silencer (ESE and ESS) and intronic splicing 
enhancer and silencers (ISE and ISS). 
 
 The spliceosome firstly recognizes the intron/exon boundaries and secondly 
catalyses the excision reaction, removing the introns and joining exons. Each 
snRNP contains a single uridine rich snRNA. The U1 snRNP binds the 5’ splice 
site, while U2 snRNP binds the branch site (Liu, 2002, Du and Rosbash, 2002). 
Binding occurs via RNA-RNA interaction between the snRNA and the pre-mRNA 
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(Faustino and Cooper, 2003). Following recognition, pre-mRNA is bent to bind the 
three other RNPs to form the spliceosome. The final spliceosome complex 
undergoes a conformational change to cleave the RNA at the 5’ GU splice site and 
forms a lariat at the A branch site. The intron is then cleaved out at the 3’ AG splice 
site, where the two exons ligate together (Burge et al., 1999, Liu, 2002, Lallena et 
al., 2002, Du and Rosbash, 2002). 
 
 The short and degenerate splice sites are not sufficient for splice-site 
recognition (Lim and Burge, 2001) and must be distinguished from pseudo splice 
site sequences that resemble classical splice sites but are never used (Black, 2003).  
Additional cis elements, such as exonic and intronic splicing enhancers (ESEs and 
ISEs) and exonic and intronic splicing silencers (ESSs and ISSs), build a network of 
interactions across exons as well as across introns to allow the correct exon 
recognition and hence accurate splicing (Berget, 1995, Reed, 1996).  
 
During the second splicing step the exon junction complex (EJC) is 
deposited 20-24 nucleotides upstream of each exon-exon junction, when the lariat 
has formed and the exons are ligated together (Le Hir et al., 2000, Shibuya et al., 
2004). The EJC remains bound to the mRNP, during nuclear export and in the 
cytoplasm. Proteins bind or get released from the EJC during the transport. The EJC 
has major influences on surveillance and localization of the spliced mRNA and 
leads to translation enhancement (Tange et al., 2004). Recent sequencing research 
by various groups have identified purine-rich sequences flanking the EJC binding 
sites, which showed a high GAAGA content and is thought to be a binding site of 
EJC associated factors (Long and Caceres, 2009, Singh et al., 2012, Saulière et al., 
2012). This motif resembles known binding sites for several serine-arginine–rich 
proteins (SR proteins), serine/arginine-rich splicing factor 1 (SRSF1) (Sanford et 
al., 2009). SR proteins bind with very high specificity to purine­rich sequences in 
RNA and are important for both constitutive and alternative splicing (Long and 
Caceres, 2009). In other studies, purine-rich GAAG repeats were identified as 
exonic splicing regulatory elements in plants and animals and as exonic splicing 
enhancers in other vertebrates (Chasin, 2007, Tacke and Manley, 1995, Thomas et 
al., 2012, Pertea et al., 2007). SRs also function as exonic splicing regulatory 
proteins, such as in alterative splicing. 
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1.2.1.2. Alternative Splicing 
 
 Alternative splicing allows one gene to express multiple mRNAs that encode 
proteins with diverse and even antagonistic functions, by the joining of different 5’ 
and 3’ splice sites thereby skipping exons and thus e.g. a potential regulatory 
domain of a protein. Alternative splicing can also lead to altered translation, 
stability and/or localization of the mRNA by removing or inserting regulatory cis 
elements. Alternative splicing itself is regulated by ESEs and ISEs and ESSs and 
ISSs (Grabowski, 1998, Smith and Valcarcel, 2000). It is cell specific and can lead 
to mis-spliced transcripts with deleterious effects. These deleterious transcripts are 
detected and processed by the cellular posttranscriptional quality control 
mechanism, NMD (Danckwardt et al., 2002). 
 
1.2.1.3. mRNA Nuclear Export 
 
 All mRNA needs to pass through the NPCs to exit the nucleus to the 
cytoplasm, where they can be translated. mRNAs pass through the NPC as large 
RNPs complexes. These become export-competent by associating with the export 
adapter transcription-coupled export (TREX) complex and the export receptor 
tandem affinity purification protein (TAP), which targets the mRNA to the NPC 
(Soller, 2006, Schumann et al., 2013). 
 
 As mRNAs vary greatly in sequence, length and structure, their recognition 
by the TREX complex must target common features of the host mRNAs. In 
eukaryotes, mRNA export is intrinsically linked to mRNA maturation, i.e. 
5’capping and splicing, leading to the stepwise assembly of the export-competent 
mRNP. The TREX complex gets localized to the 5' end of the mRNA in a splicing 
dependent manner by Aly/REF export factor (Aly) and THO, two components of 
the TREX complex, which bind directly to the cap binding protein 80 (CBP80), 
which in turn is part of the cap-binding complex (CBC) (Cheng et al., 2006, 
Lejeune et al., 2002, Chi et al., 2013).  It has been shown that Aly, together with the 
Asp-Glu-Ala-Asp box helicase (DEAD-box helicase) UAP56, interact with the 
EJC, which is known to influence translation, surveillance and localization of the 
spliced mRNA (Chang et al., 2007, Giorgi and Moore, 2007, Nott et al., 2004). 
Thus both capping and splicing are crucial for formation of the TREX complex 
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leading to nuclear export of the host mRNA (Zhou et al., 2000, Masuda et al., 
2005). Finally to be considered export competent by the NPC, the TREX containing 
mRNP needs to be “handed over” from Aly to TAP, the export receptor (Jackson	  et	  al.,	  2012,	  Stewart,	  2007)	  (Figure	  1-­‐4).  
 
A B 
 
 
Figure 1-4: RNA Processing and Nuclear Transport for Host and Viral mRNA 
 
A) On the left the host mRNA processing and export is represented. Here EJC is 
recruited onto the mRNA at the vicinity of the introns, to be spliced by the 
spliceosome, with whom it interacts. Once the introns are removed the spliceosomes 
release leaving the EJCs at the exon junctions. The TREX complex then binds EJC 
and the 5’ CBC. It is the ability of TREX to bind EJC that allows it to recognize 
spliced mRNAs and thus makes these exportable. The binding of TAP to Aly and 
THO induces a conformational change leading to the release of UAP56 and to the 
translocation through the NPC. B) On the right KSHV mRNA is intronless and thus 
is not bound by EJC. ORF57 binds the KSHV mRNA and recruits the TREX 
complex the mRNA, allowing the viral mRNA to export. 
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1.2.2. KSHV mRNA 
 
To achieve effective viral proliferation, gene expression and viral replication 
are intimately linked and tightly regulated. This is achieved by timely viral gene 
expression with 4 stages of transcription; latent, immediate early lytic, early lytic, 
and late lytic gene expression. To achieve a high level of replication the virus takes 
over the host gene expression machinery during lytic infection. The KSHV 
transcripts are translated in a cap-dependent manner (Conrad and Steitz, 2005) and 
most KSHV mRNAs are intronless. The host machinery by default tends to express 
intronless genes at much lower levels than intron-containing mRNAs (Conrad and 
Steitz, 2005). In host and KSHV and other viruses, intronless genes often contain 
cis-acting elements, which allow enhanced gene expression despite the missing 
introns (Donello et al., 1998, Huang and S., 1995, Huang and Liang, 1993).  
 
To overcome this, KSHV also has the immediate-early protein open reading 
frame 57 (mRNA export factor ICP27 homologue) (ORF57) (Boyne et al., 2010, 
Jackson et al., 2011), which is a trans-acting regulatory protein that enhances 
expression of intronless viral genes and allows the export of viral intronless 
mRNAs (Malik and Schirmer, 2006). Interestingly the ORF57 gene itself is 
monocistronic and contains one intron. This allows ORF57 to be efficiently 
expressed and processed prior to its action to allow viral early and late lytic 
intronless transcripts to be transcribed and translated (Jackson et al., 2012).  
 
 As previously mentioned, host mRNA transcription, post transcription 
modification, nuclear export, translation, localization, protein stability and the 
quality control mechanisms are intrinsically linked (Luo and Reed, 1999, Valencia 
et al., 2008). The recruitment of TREX to EJC, that allows nuclear export of 
mRNAs for translation, is splice-dependent (Masuda et al., 2005, Schumann et al., 
2013), which in turn explains the preference for intron-containing transcripts (Nott 
et al., 2004). This poses a significant stumbling block for KSHV lytic intronless 
mRNAs as they do not undergo splicing and therefore cannot recruit TREX via the 
splicing-dependent mechanism (Schumann et al., 2013). To overcome this, KSHV 
uses ORF57 (Luo and Reed, 1999, Valencia et al., 2008) allowing the viral 
intronless transcripts to bind the TREX complex (Tunnicliffe et al., 2010, Boyne et 
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al., 2008). ORF57 interacts directly with the RNA and with the export adapter 
protein Aly, recruiting it to the 5′ end of the RNA. Aly is normally recruited in a 
splicing-dependent manner. ORF57 in conjunction with Aly then recruits the 
remaining TREX complex allowing the viral mRNAs to translocate through the 
nuclear pore in a TREX RNP complex (Malik et al., 2004, Boyne and Whitehouse, 
2009, Boyne and Whitehouse, 2006, Jackson et al., 2012). KSHV ORF57 mediated 
mRNA export appears to be highly complex and has yet to be fully understood 
(Malik et al., 2004, Jackson et al., 2012, Stutz and Izaurralde, 2003). But Jackson et 
al. were able to determine that ORF57 recruits only TREX and not EJC to the viral 
intronless mRNAs, and that ORF57 is able to enhance translation of viral 
transcripts, thus overcoming the lack of translation enhancement by EJC (Jackson et 
al., 2012). 
 
Finally ORF57 regulation and disruption of viral and host RNA processing, 
leading to the export of the viral intronless genes (Hardy and Sandri-Goldin, 1994) 
may also contribute to HSO together with SOX to give the virus a kinetic edge over 
the host cell in gene expression (Hardy and Sandri-Goldin, 1994, Whitehouse et al., 
1998, Ruvolo et al., 1998, Jackson et al., 2012). 	  	  
1.2.3. mRNA Decay 
 
1.2.3.1. mRNA Decay in Host Homeostasis  and Antiviral and 
Proviral Response   
 
mRNA stability is assured by the 3’ poly(A) tail and the 5’ cap, each 
associate with protein stability factors, the poly(A)-binding protein (PABP) and 
eIF4E, respectively (Schoenberg, 2011, Garneau et al., 2007). These two protective 
systems at the ends of mRNA tend to inhibit exonucleolytic decay. Thus there are 
two main directions in which mRNA degradation can be initiated: a) a 3’ to 5’ 
decay pathway where the 3’ end is deadenylated, followed by 3’ to 5’ degradation 
by the exosome, a large complex of 3’ to 5’ exonuleases and b) 5’- 3’ decay 
pathway exists in which the 5’ cap is cleaved followed by degradation by the 5’ to 
3’ exonuclease Xrn1. After decapping and/or deadenylation, degradation can occur 
in a 3’ to 5’ or 5’ to 3’ direction. Another alternative to exonucleolytic degradation 
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of mRNA is endonucleolytic decay in which an endonuclease would need to cleave 
internally, followed by exonucleolytic degradation (Garneau et al., 2007).  
 
Different mRNAs within the same cell have distinct lifetimes (stabilities). In 
mammalian cells, mRNA lifetimes range from several minutes to days. The limited 
lifetime of mRNA enables a cell to alter protein synthesis rapidly in response to its 
changing needs. There are many mechanisms that lead to the destruction of an 
mRNA or sequestering of the mRNA to stress granules. Besides interfering with 
cellular mRNA trafficking, viruses can stimulate mRNA turnover (Walsh and 
Mohr, 2011) and host mRNA decay pathways, which had been thought to serve 
primarily in an antiviral manner. 
 
 
1.2.3.2. 3’ to 5’ mRNA Decay – Deadenylation and Exosome 
  
 Nearly all mammalian mRNA decay is initiated by poly(A)-tail shortening; 
deadenylation (Yamashita et al., 2005, Chen et al., 2002, Zheng et al., 2008). This 
includes decay mediated by adenylate-uridylate-rich elements (ARE) in the 3’ 
untranslated region (3’-UTR), by destabilizing elements in the protein coding 
regions and NMD. Deadenylation predominantly leads to decapping by the 
nucleases RNA-decapping enzyme 1- mRNA-decapping enzyme 2 (Dcp1-Dcp2) at 
the 5’ end followed by 5’ to 3’ exonucleolytic degradation by the main cytoplasmic 
5’ to 3’ exonuclease Xrn1 (Parker and Song, 2004, Beelman and Parker, 1995, 
Coller and Parker, 2004, Cougot et al., 2004). Alternatively, deadenylation can be 
followed by 3’ to 5’ exonucleolytic degradation by the exosome in a 3’ to 5’ fashion 
(Allmang et al., 1999, Mitchell et al., 1997). 
 
 Deadenylation is biphasic (Yamashita et al., 2005). C-C chemokine receptor 
type 4 NOT (CCR4–NOT), PAB-dependent poly(A)-specific ribonuclease subunit 2 
-PAB-dependent poly(A)-specific ribonuclease subunit 3 (PAN2–PAN3) and 
poly(A)-specific ribonuclease (PARN) are characteristic eukaryotic deadenylases, 
each with unique properties. PAN2–PAN3 activity is not inhibited by the PABPs, 
while CCR4–NOT and PARN activity is inhibited by it (Chen and Shyu, 2010). In 
the first phase PAN2–PAN3 carries out the initial shortening of the poly(A)tail to a 
length of 100-80 nucleotides (Mangus et al., 2003). In the second phase the 
37	  
deadenylation of the now shortened and PABP free poly(A)tail is presented to 
another deadenylase, CCR4–NOT or PARN. Deadenylation by CCR4-NOT is 
coincident with 5’decapping and 5’ to 3’ exonucleolytic decay by Xrn1. PARN’s 
deadenylase activity is enhanced by the presence of the 5’ cap on the mRNA, but  
 
 
 
Figure 1-5: mRNA Decay Mechanisms 
Most mRNA decay is deadenylation-dependent, where the poly(A)-tail is removed 
by a deadenylase activity (CCR4–NOT, PAN2-PAN3 or PARN). This is followed by 
two degradation mechanisms: one is the 5′→3′ decay and the other is 3′→5′ decay. 
In the first mechanism the mRNA is bound by the Lsm1–7 complex inducing 
decapping by Dsp1–Dsp2 rendering it susceptible to decay by the 5′→3′ 
exoribonuclease Xrn1. In the second mechanism the mRNA is degraded in the 
3′→5′ direction by the exosome, where DcpS hydrolyses the remaining 5’ cap. 
Another way to initiate mRNA decay is endonucleolytic cleavage by an 
endonuclease (e.g. IRE1, PRM1 or SMG6), which generates two fragments that a 
susceptible degradation Xrn1 and the exosome, while still bearing the protective 
5’cap and poly(A)-tail (Garneau et al., 2007).  
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inhibited by nuclear CBC (Brawerman, 1981, Wilusz et al., 2001, Wickens et al., 
1997). Enhanced deadenylase activity has been detected for mRNAs that are subject 
to NMD and contain destabilizing ARE (Wilson and Treisman, 1988, Shyu et al., 
1991, Lykke-Andersen and Wagner, 2005) (Figure 1-5). 
 
 After deadenylation the mRNA gets 3’ to 5’ degraded by the exosome, a 
complex of 10-12 subunits. Each of the core exosome subunits has an RNase PH 
domain, which is thought to either contribute to catalytic activity or play a role in 
substrate recognition and placement (Mitchell et al., 1997, Houseley et al., 2006). If 
the 5’ cap is still present after 3’ to 5’ decay, it is metabolized by the scavenger 
mRNA-decapping enzyme (DcpS) (Liu et al., 2002). 
 
 
1.2.4. 5’ to 3’ mRNA Decay – Decapping and Xrn1 
 
 Although 5’ to 3’ mRNA decay is initiated by the 5’ cap removal by the 
decapping enzymes Dcp1-Dcp2, several accessory factors are required for efficient 
decapping, e.g. the Lsm1-7 complex, which binds the deadenylated 3’ end of the 
mRNAs promotes decapping (Wilusz et al., 2001, Cougot et al., 2004, Tharun and 
Parker, 2001). Decapping is then followed by 5’ to 3’ degradation by the 
exonuclease Xrn1. 
 
 
1.2.4.1. Xrn1 
 
The 5’ to 3’ exonuclease Xrn1 is conserved across eukaryotes and it is involved 
in RNA transcription, metabolism and interference. Xrn1 (ca. 175 kilo Dalton 
(kDa)) is the main cytoplasmic RNase, involved in the degradation of decapped 
mRNAs, NMD and miRNA decay. These take place in the cytoplasm (Parker and 
Sheth, 2007), where the enzymes Dcp1-Dcp2 decap the mRNA. This generates a 5’ 
monophosphorylated RNA intermediate (Jinek et al., 2011), which irreversibly 
commits the mRNA for degradation, as Xrn1 recognizes specifically 5’ 
monophosphorylated RNA which is rapidly degraded to mononucleotides without 
partially degraded intermediates. As a result, Xrn1 plays a central role in the 
controlled turnover of the mRNA transcriptome (Chang et al., 2011). Xrn1’s 
activity normally requires prior deadenylation and decapping of mRNAs, which are 
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rate-limiting steps of normal decay, except when endonucleolytic cleavage occurs. 
Xrn1 also participates in degrading RNA intermediates generated by 
endonucleolytic mRNA cleavage. Xrn1 has been shown to have an antiviral activity 
by virtue of its exonuclease activity and to act as a potent suppressor of viral RNA 
recombination in viruses, such as tomato bushy stunt virus. However, in 
flaviviruses, Xrn1 is subverted into producing a subgenomic flavivirus RNA, which 
is essential for viral cytopathogenicity in cells and pathogenicity in mice (Silva et 
al., 2010). This appears to be facilitated by a highly stable pseudoknot in the viral 
RNA that stalls Xrn1 and suggests that Xrn1 paradoxically may have important pro 
and anti-viral roles.  
 
 
1.2.5. Endonucleolytic Decay  
 
 Endonucleolytic cleavage is an efficient mean of destroying mRNAs as it 
produces two fragments that are susceptible to 5’ and 3’ exonuleases; e.g. Xrn1 and 
the exosome. Endonucleolytic cleavage is involved in NMD in mammals, where 
PTC recognition leads to endonucleolytic cleavage in the vicinity of the aberrant 
stop codon and induces accelerated deadenylation (Eberle AB et al., 2009, Cao and 
Parker, 2003, Chen and Shyu, 2003). Certain cellular endonucleases that target 
mRNA have been characterized, such as SMG6, serine/threonine-protein 
kinase/endoribonuclease (IRE1) and polysomal ribonuclease 1 (PMR1). As cellular 
endonucleases are very potent they are highly regulated and/or specific (Hollien and 
Weissman, 2006, Yang et al., 2004).  
 
 IRE1 targets actively translating mRNAs in the endoplasmic reticulum during 
unfolded protein stress response. IRE1 endonuclease activity was shown to catalyse 
splicing of the X-box-binding protein 1 (XBP1) mRNA (Hollien and Weissman, 
2006, Yoshida et al., 2001).   
 
 PMR1 endonucleolytically cleaves actively translating mRNAs on polysomes 
(Yang and Schoenberg, 2004). The cleavage site on the targeted mRNAs was 
between the UG dinucleotides of two overlapping repeats of AYUGA, which were 
found in the loop region of a stem-loop structural element (Chernokalskaya et al., 
1997). Mutations to either element did not abrogate endonucleolytic cleavage 
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providing the bases remained unpaired in the loop. When the sequence was mutated 
so that these bases became paired to prolong (elongate) the stem, endonucleolytic 
cleavage was abrogated. This showed that endonucleolytic cleavage in this instance 
not only requires a specific sequence, but that this sequence has to be in the right 
structural context (Chernokalskaya et al., 1997). Further research by Brock and 
Shapiro found that the 3’ UTR of the vitellogenin mRNA contained  PMR1 
cleavage sites, but this transcript was protected from PMR1 endonucleolytic 
cleavage in the presence of PMR1 (Brock and Shapiro, 1983). The protein vigilin 
was demonstrated to bind the region of the PMR1 cleavage sites in the 3’UTR of 
the vitellogenin mRNA thereby blocking the PMR1 cleavage site from being bound 
and cleaved by PMR1, thus stabilizing the vitellogenin mRNA (Dodson and 
Shapiro, 1997, Cunningham et al., 2000).  
 
 
1.2.5.1. Nonsense Mediated Decay and Links to Splicing and 
Translation 
 
 At each step during transcription and maturation of mRNA errors can be 
introduced into the transcript. To protect the cell from potential deregulation and 
toxic protein products surveillance mechanisms have evolved that couple translation 
to degradation pathways, such as non stop decay (NSD), no go decay (NGD) and 
NMD. These mechanisms occur in the nucleus, while most discovered degradation 
pathways are translation dependent and occur in the cytoplasm. NMD is the most 
studied of these pathways (Gebauer and Hentze, 2004, Moore, 2005).  
 
 NMD was demonstrated to be crucial in embryogenesis and embryonic 
viability (McIlwain et al., 2010, Hwang and Maquat, 2011). Hence NMD not only 
functions in the surveillance of deleterious transcripts, but also plays an important 
role in the regulation of normal gene expression by degradation (Gardner, 2010). It 
is thought that alternative splicing can regulate gene expression by targeting 
mRNAs for NMD (Gardner, 2010). Thus there are different ways in which NMD 
can be initiated and thus function to facilitate degradation. In mammalian cells, one 
well-defined NMD is EJC-dependent NMD, which is discussed below. 
 
 NMD detects and degrades mRNA transcripts that contain PTCs, which can 
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be introduced by mutations, inefficient splicing and leaky translation initiation. 
Core to the NMD complex are the proteins up-frameshift factor 1 (UPF1), UPF2 
and UPF3, which are highly conserved (Conti and Izaurralde, 2005). UPF1 is 
recruited by the release factors to stalled ribosomes, where the transient SURF 
complex (SMG1 -UPF1-eRF1-eRF3) forms. UPF1 is required for all known NMD 
pathways, whereas the other components may vary dependent on the NMD 
substrates and the downstream pathways. The SURF complex associates with EJC 
through UPF2 leading to assembly of an UPF1-UPF2-UPF3 surveillance complex, 
allowing initiation of NMD, once UPF1 is phosphorylated (Conti and Izaurralde, 
2005, Amrani et al., 2006, Lejeune and Maquat, 2005, Behm-Ansmant et al., 2007). 
The EJCs are deposited 20-24 nucleotides upstream of every exon junction and thus 
EJCs are the markers of splicing (Le Hir et al., 2000). Most introns are found in the 
protein coding region where the EJCs are displaced by the ribosomes during 
translation. However, when an mRNA transcript is mis-spliced leading to PTCs, 
EJC remains located 50-55 or more nucleotides downstream from the PTC site, 
which facilitates recognition of the EJC by the SURF complex. PTC increases the 
distance between the terminating ribosome to the poly(A) tail, this resultant mRNP 
conformation is also recognized as abnormal triggering NMD (Gardner, 2010, 
Gatfield et al., 2003). SMG5, SMG6 and SMG7 recognize phosphorylated UPF1 
and are thought to be the link to the mRNA degradation machinery. 
 
 In human cells, SMG6 as part of the NMD process, catalyses endonuclease 
cleavage of PTC-containing mRNA (Eberle AB et al., 2009), followed by 
exonucleolytic decay, by e.g. Xrn1, of the resultant fragments (Doma and R., 2006). 
It had thus been now hypothesized that mammalian NMD may be initiated by 
SMG6-mediated endonucleolytic cleavage (Eberle AB et al., 2009). The 
endonuclease cleavage sites of SMG6 were found both upstream and downstream 
of the PTC on the target mRNAs. The molecular basis for the clustering of cleavage 
sites around the PTC is explained by the specific binding of SMG6 to the EJC 
(Kashima et al., 2010). 
 
 
1.2.7. AU-rich Elements in mRNA Stability and Decay  
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AREs are found in the 3' UTR of many protooncogenes, nuclear 
transcription factors and cytokines mRNAs. And AREs play a role in gene 
transcription regulation in neurons and the immune system (Chen and Shyu, 1995, 
Barreau et al., 2006). They are one of the most common determinants of RNA 
stability in cells, which is usually determined by regulation of degradation of the 
transcript (Chen and Shyu, 1995).  
 
Three classes of AREs have been identified with different canonical 
sequences. The most are characterized by the canonical ARE, containing the core 
AUUUA ARE motif within a AU rich sequences; WWWUAUUUAUUUW 
(Khabar, 2005). AREs are highly variable and the neighbouring sequences 
influence AREs effect on mRNA stability (Chen and Shyu, 1995).  
 
AREs are bound by a number of proteins, such as human antigen R (HuR) 
and AU-rich element RNA-binding protein 1 (AUF1) (Gratacós and Brewer, 2010). 
AUF1 affects changes in ARE mRNA degradation rates by binding to ARE in a 
complex with proteins, such as HuR, which is known to stabilize mRNAs and gene 
expression (Gratacós and Brewer, 2010). Since ARE binding proteins can interact 
directly or indirectly with mRNA decay machinery, recognizing AREs can lead to 
enhanced decay of ARE containing transcripts, e.g. AUF1 interacts with the 
exosome (Chen et al., 2001). ARE binding proteins that stabilize mRNA have been 
shown to work by two means. The first is the removal of the mRNA from the sites 
of decay by competing for the binding site of destabilizing factors, which link to the 
decay machinery. The second is to strengthen the PABP poly(A) interaction thereby 
inhibiting the deadenylation dependent mRNA decay machinery. HuR has been 
shown to compete for binding sites with the destabilizing proteins, such as AUF1 
(Lal et al., 2004). 
 
 
1.2.7.1. IL-6 mRNA Transcript 
 
It has long been known that the interleukin-6 (IL-6) mRNA transcript 
evades turnover in KSHV infected cells and that KSHV also has its own viral 
version of IL-6; vIL-6 (Hutin et al., 2013, Rezaee et al., 2006). IL-6 is a cytokine 
that acts both in a pro-inflammatory and an anti-inflammatory way (Moonga et al., 
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2002). It can be secreted, bind intracellular and extracellular receptors and affect 
cells from the innate, adaptive immunity system and other cell types. IL-6 
overexpression is linked to cell proliferation, proliferative diseases and plays a 
prominent role in the pathogenesis of KSHV-induced Diseases, such as Castleman’s 
Disease, Kaposi Sarcoma and Autoimmune Diseases (Burger et al., 1994, Miles et 
al., 1990, Jones et al., 1999, Oksenhendler et al., 2000, Aoki et al., 2000).  
 
Several transcripts that are known to be processed by SOX preferentially 
have been shown to contain several UGAAG and GAAGU motifs, within the 5’ 
untranslated region (5’ UTR), protein-coding region and often in the 3’UTR 
(Covarrubias et al., 2011, Clyde and Glaunsinger, 2011). IL-6 contains one 
UGAAG and one GAAGU motif in the 3’UTR. A recent paper (Hutin et al., 2013), 
has demonstrated that IL-6 contains a so-called SRE1 (SOX-resistant element 1) in 
its 3’UTR. This SRE1 contains a non-canonical ARE, which is a stretch of AU-rich 
sequence, containing the core AUUUA ARE motif, and is bound by AUF1 and 
HuR. Hutin et al. (2013) demonstrated that the protection of IL-6 from SOX 
mediated decay was observed in the presence of AUF1 and HuR. But when AUF1 
and HuR were silenced using siRNA (Hutin et al., 2013), Il-6 was susceptible  to 
SOX-mediated decay. 
 
 
1.3. RNA Folds and in silico Folding 
 
1.3.1. RNA Folds 
 
 The biological importance of RNA has grown as more and more functions 
and roles are discovered such as those in replication, translational regulation and 
viral propagation. These functions, as in proteins, are transduced by their folds. 
Most recently, a new field has opened up focused on RNA and viruses. RNA 
pseudoknots in retroviral mRNAs have been found to cause programmed 
frameshifts (Silva et al., 2010, Chamorro et al., 1992). These have been shown to 
produce the correct ratios of proteins required for viral propagation (Chamorro et 
al., 1992, Tinoco Jr and Bustamante, 1999). In addition, correlations between host 
temperature and viral infectivity owing to the stability of RNA structure have also 
been discovered putting knowledge of the way in which RNA folds at the forefront 
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of addressing key questions in virology (Brower-Sinning et al., 2009). 
 
It has been shown that RNA folds hierarchically and co-transcriptionally 
(Walter et al., 2009, Brion and Westhof, 1997). This first involves folding of the 
much more stable secondary structure compared to its denatured state, which acts as 
an initiator for its assembly into subsystems of increasing size and complexity, 
leading to the formation of tertiary structure (Zemora and Waldsich, 2010, Brion 
and Westhof, 1997, Tinoco Jr and Bustamante, 1999). The tertiary folds are less 
stable and more susceptible to ion concentration and temperature changes than the 
secondary folds, which are strengthened by base pairing interactions and π stacking. 
The tertiary fold interactions can also be interrupted by RNA binding proteins, 
thereby allowing the protein to bind the secondary structures and/or their primary 
sequence motifs found in loops and bulges (Figure 1-6). 
 
 
 
Figure 1-6: RNA Secondary Structure Elements 
 
Five different RNA secondary structure elements are represented: stem (helix), stem 
loop, bulge loop, internal loop and multi branch loop (Ding and Lawrence, 2003). 
 
 
1.3.2. In silico Folding of RNA 
 
 As for proteins, the secondary structure of RNAs confers their function, and 
fold is more conserved than sequence (Capriotti and Marti-Renom, 2010). Thus 
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tertiary and secondary structures predictions can be used instead to find or refine 
regulatory elements that are evolutionarily conserved, and hence, potentially 
functionally conserved. In genomics, dinucleotide content is often used to predict 
protein-coding regions and plays an important role in the stability of RNA 
secondary structures (Birney et al., 2007). Dinucleotide content considerably can 
affect the stability scores of secondary structure and energy predictions. 
Dinucleotide content is an important contributing factor in the calculation of the 
folding energy, because of their stacking energy contributions (Washietl et al., 
2005, Workman and Krogh, 1999). With the recent advances in RNA research and 
increased RNA X-ray crystal and nuclear magnetic resonance (NMR) structures the 
need for in silico RNA fold prediction software has increased in numbers and 
accuracy. 
 
 
1.3.2.1. Secondary Structure Prediction - mfold 
 
To date the most widely used structure prediction algorithm is the minimum 
free energy (MFE) method folding single sequences. This method is implemented 
in one of the longest existing RNA secondary structure prediction programs mfold 
(Tinoco Jr and Bustamante, 1999, Workman and Krogh, 1999). Mfold uses the 
Zuker-Stiegler algorithm for MFE computing using every possible base-pairing, 
which is forced one-by-one and using empirical estimates of thermodynamic 
parameters for interactions and loop entropies to score structures (Zuker, 2003b, 
Zuker and Stiegler, 1981, Mathews et al., 1999). Hence mfold secondary structure 
results are ranked by their MFE. 
 
 
1.3.2.2. 3D Secondary Structure Prediction - Mc-Sym 
 
 Current 3D (Three-Dimensional) RNA folding algorithms require manual 
manipulation or are generally limited to simple structures in terms of size and 
topology. The prediction accuracy improves with added knowledge from the 2D 
(Two-Dimensional) structure, but still fails in the prediction of long-range contacts, 
which are involved in establishment of the tertiary structure (Laing and Schlick, 
2011, Mathews et al., 2010). RNA structures that are much longer than 50 
nucleotides cannot be predicted with great confidence, because of an increase in 
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complexity of the probabilistic model, which would have to account for the 
topologies such as junctions and long-range contacts. 3D structures of RNAs less 
than 20 nucleotides are better predicted with all-atom knowledge based approaches 
(such as fragment assembly of RNA with full-atom refinement (FARFAR)), while 
structures of longer RNAs are better predicted by coarse graining approaches (such 
as Mc-Sym) (Parisien and Major, 2008, Laing and Schlick, 2011). As mentioned, 
Mc-Sym uses a Mc-Sym coarse graining approach to allow conformational 
sampling. It generates 3D structure models from small-residue fragments.  
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Chapter 2: Biophysics Background Theory 
5.  
2.1. Macromolecular X-ray Crystallography  
 
3.2.1. X-ray Diffraction to Solve Molecular Structures 
 
X-ray crystallography is a method that is prolifically used to produce atomic 
or near-atomic resolution structures in academic and industrial research. The 
immense technological advents in synchrotron tools (such as microfocus high-
intensity X-ray source and charge-coupled device (CCD) detectors) (Adams et al., 
2010, Arndt et al., 1998, Fischetti et al., 2009, Phillips et al., 2002), in computation 
power, data storage space and crystallographic software packages (XDS, CCP4 
suite, Phenix) have lead to an explosion in X-ray crystal structures of biological 
macromolecules, macromolecular assemblies and membrane proteins being 
deposited in the PDB (Adams et al., 2010, Winn et al., 2011, Kabsch, 2009). These 
3D atomic or near-atomic resolution models have allowed elucidation of the 
mechanisms behind biochemical life, such as enzymatic activity, binding of small 
ligands, of macromolecules and formation of macromolecular assemblies, whose 
functions are related to their structures.  
 
The distance observed between atoms in macromolecules is between 1-2 10-
10 m (or 1-2 Ångström (Å)), thus this is the resolution range that is needed to get a 
better understanding of the biochemical mechanisms. X-rays have wavelengths of 
up to 10 pm allowing X-ray crystal structures to be solved to resolutions of up to 
0.48 Å. To obtain such a crystal structure, a crystal made of exact repeats of the 
molecules is needed to amplify the signal of the X-ray scattering. The crystal 
composition has to be characterized from the diffraction data. Finally due to lack of 
an X-ray lens, the phase problem has to be solved to produce a structure that can be 
refined and validated so that it can be used to explain the mechanisms of life.  
 
 
3.2.2. The Real Crystal Lattice 
 
In X-ray crystallography the physical properties of X-rays and crystals are 
exploited. The diffraction from a single macromolecule in a crystal would be too 
weak to be measured, but the signal is amplified, as the array of macromolecules 
diffracts the same image multiple times. A crystal is made up of a symmetrical set 
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of repeating units, which contain the macromolecule of interest, in a lattice (Figure 
2-1). A lattice can be characterised in terms of its dimensions, morphology and the 
relationship of the unit cells to each other and in relation to sets of parallel planes in 
space. These are called unit cells and each can be rotated or translated onto another 
by mathematical operators. The space group describes the morphology and 
symmetry. The asymmetric unit is the smallest repeating unit the crystal can be 
divided into using the crystallographic symmetry operations of the space group. 
This allows the crystallographer to provide a mathematical description of a crystal 
system and a physical description of the atomic arrangement in the asymmetric unit, 
which includes solvents, amino acids and nucleic acids (Rhodes, 2006, Drenth, 
2007, Rupp, 2010).  
 
 
 
Figure 2-1: Crystal Systems  
 
A crystal lattice is made up of repeating units termed unit cells, which can also 
contain repeats of a unique object, generally DNA, RNA or protein. This minimal 
repeat is called an asymmetric unit. The asymmetric units and unit cells within a 
crystal lattice are symmetrically related and can be superposed using mathematical 
operators, rotations or translations. 
 
 
 
 
49	  
3.2.3. X-ray Scattering and Bragg’s Law 
 
X-rays are a form of electromagnetic radiation, which when they pass 
through matter interact with the electrons around the nuclei. X-rays are generated 
by accelerating electrons in a vacuum using an electric field directed against an 
anode (a metal, i.e. Copper (Cu)), leading to multiple collisions (Rhodes, 2006, 
Rupp, 2010). On collision, some electrons convert their energy via an inverse 
photoelectric effect into a continuum of X-rays. When the incident X-ray beam 
enters a crystal, it is partly absorbed by the atoms in its path and will scatter X-ray 
radiation to produce secondary waves in all directions. Waves are characterized by 
their frequency, amplitude and phase. Some scattered waves will be subject to 
constructive interference or destructive interference depending on their relative 
phase. During the latter case the scattered waves are out of phase by π or any odd 
multiple of π  (180°) and thus cancel out (Rhodes, 2006, Drenth, 2007, Rupp, 
2010).  
 
 
Figure 2-2: Constructive and Destructive Interference of Waves 
 
In both A) and B) the waves have the same amplitudes and frequencies. In A) the 
waves scattered by the electron density are in phase and constructively interfere, 
whereas in B) the scattered waves are out of phase by π or 180°. Thus, as they have 
the same amplitude the waves cancel each other out by destructive interference. 
These phenomena are described by Bragg’s Law and are influenced by the angle θ. 
 
Sir W.H. Bragg (1862-1942) and Sir W.L. Bragg (1890-1971) proved that 
X-rays reflected from the atoms in a crystal could be treated as if they were 
reflected by a set of atoms on parallel planes (Figure 2-2). Bragg’s law defines the 
conditions that lead to diffraction by constructive interference. This law states that 
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only scattered waves where the path length difference corresponds to an integral 
number of wavelengths will produce diffraction (Equation 2-1). 
 
Equation 2-1: Bragg’s Law of Diffraction 
 2!!!" sin!   = !  ! 
 
where  
 
θ     is the incident angle of the wave  
dhkl  is the spacing between lattice planes on which atoms reside !      is the integer  !     is the wavelength of incident wave. 
 
 
 
Figure 2-3: X-rays Crystallography Experimental Set Up 
 
A diffraction pattern is made of diffraction maxima that produce a pattern of spots 
on a detector. These can be viewed as originating from each atom that contributes 
to the scattering of X-rays from a potentially infinite number of parallel planes 
(reflections). Thus reflection Fhkl corresponds to all atoms that affect the scattering 
along an identical set of lattice planes hkl in the crystal. 
 
When the scattered waves are subject to constructive interference, a single 
diffraction spot is the result of positive reinforcement of the scattered waves from 
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atoms within a set of parallel planes, which outweigh the contributions of random 
noise atoms (Rhodes, 2006, Rupp, 2010). The diffraction pattern collected (Figure 
2-3) when using X-rays in crystallographic experiments is hence the result of 
contributions from all atoms within the macromolecule that when repeated in 3 
dimensions, forms the crystal. 
 
 
3.2.4. Characterization of the Real and Reciprocal Space 
 
3.2.4.1. Symmetry, Space and Point Groups 
 
The first step in solving a crystal structure after collecting the diffraction 
data is the determination of a set of indices that describe the sets of lattice planes 
(hkl, referred to as reflection indices) to calculate the unit cell dimensions (a, b, c 
and angles α, β, γ) and the point group ultimately leading to space group 
identification (Rhodes, 2006). 
 
 
 
Figure 2-4: The General Geometry of a Unit Cell  
 
A unit cell is characterized by six parameters: three sides (a, b and c) and three 
angles (α, β and γ). 
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Each crystal is defined by its geometry; three faces (a, b and c, one for each 
spatial dimension, x, y and z) and three angles (α, β and γ) (Figure 2-4). The 
crystal’s geometry and morphology can be associated with one of the seven crystal 
systems (Table 2-1). Associated with these crystal systems are potential lattice 
centrings, these are termed face-centred (F)-, C-centred (A, B or C) or body-centred 
(I) points of symmetry (Figure 2-5). The fourth is referred to as primitive (P) as 
there are no centres of symmetry.  All crystals have at least a primitive Bravais 
lattice (Rhodes, 2006, Rupp, 2010). 
 
 
 
Figure 2-5: The Set of Bravais Lattices of an Orthorhombic Crystal System 
 
A crystal lattice can have: primitive (P) symmetry, where only the corners of the 
system correspond to elements of symmetry, body-centred (I), where in addition to 
the corners there is one additional lattice point at the centre of the cell, base-
centred (A, B or C), where in addition to the corners there is a further lattice point 
at the centre of each of one pair of the cell face, (i.e. face A, B or C) and face-
centred (F) where in addition to the corners (vertices) there is also a lattice point at 
the centre of each of the faces of the cell. All A- or B-centred lattices can be 
described by C-centring. 
 
The crystal is constructed by applying lattice translations to the unit cell 
contents to fill 3D space.  The various asymmetric units can be related by screw 
axes or pure rotations. In either event, the space group is the combination of lattice 
translations and any centring if relevant, combined with the operators relating the 
asymmetric units. The space group notation contains the Bravais lattice type (TB) 
and set of mathematical operators (i.e. screw axis) in the Hermann-Mauguin 
notation (!! !, !! !, !! !) along the x (i.e face a), y (i.e face b) and z (i.e face c) 
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axis (formula 2-1). The screw axis operators combine rotation with fractional 
translation when applied to the asymmetric units forming the unit cell (Formula 2-1).  
 
Formula 2-1: Space Group in Hermann-Mauguin notation 
 !!!! !!! !!! ! where	  !!      is the Bravais lattice type, e.g. P, C, I, … ………………………………… !! !  is the screw axis along face a, i.e. the x axis, where A is  ! ……..…………… !! !  is the screw axis along face b, i.e. the y axis, where B is  ! ……..………… !! !   is the screw axis along face c, i.e. the z axis , where C is  !  
The number ! denotes the screw axis, where the angle of rotation is 360° ! 
and the degree of translation along the axis of the face is ! !. E. g. for the space 
group P4, the Bravais lattice is primitive, with a rotation of 90° (as 360° 4 = 90°) 
and no translation as no degree of translation is specified, whereas in P41 the 
Bravais lattice is primitive, with a rotation of 90° and a 1 4 (as ! = 1) fractional 
translation along the axis (Figure 2-6).  
 
 
 
Figure 2-6: Screw Axis and Symmetry Operations 
 
When ! is equal 4 then the object is rotated by 90° or 1 4 around the axis on the 
same plane and no translation occurs. When ! is equal 4 and m equals 1, then each 
time the object rotates around the axis by 90°, the object is also translated by 1 4. 
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Table 2-1: The Seven Crystal Systems, their Unit Cell Dimensions and 
associated Point and Space Groups  
 
Crystal System Variations 
Unit Cell 
Faces 
Angles 
Space 
Groups 
Numbers 
Point Group with 
associated Space 
Group 
Triclinic Primitive a ≠ b ≠ c α≠ β ≠ γ ≠ 90° 2 1, (e.g. P1) 
Monoclinic 
Primitive, 
Base-
Centred 
a ≠ b ≠ c 
α = γ = 90° 
β ≠ 90° 
13 2 (e.g. P2, P21, C2) 
Orthorhombic 
Primitive, 
Body-, 
Base- and 
Face-
Centred 
a ≠ b ≠ c 
α = β = γ = 90° 59 
222, (e.g. P222, 
P2221, P21212, 
P212121, C2221, 
C222, F222, I222, 
I212121) 
Tetragonal 
Primitive, 
Body-
Centred 
a = b ≠ c 
α = β = γ = 90° 68 
4 (e.g. P4, P41, P42, 
P43, I4, I41), 442 
(e.g. P422, P4212, 
P4122, P41212, 
P4222, P42212, 
P4322, P43212, I422, 
I4122 
Trigonal 
(Rhombohedral) Primitive 
a = b = c 
α = β = γ ≠ 90° 25 
3, (e.g. P3, P31, P32, 
R3), 32, (e.g. P312, 
P321, P3112, P3121, 
P3212, P3221, R32) 
Trigonal/ 
Hexagonal Primitive 
a = b ≠ c 
α = β = 90° 
γ = 120° 
27 
6, (e.g. P6, P61, P65, 
P62, P64, P63), 622, 
(e.g. P622, P6122, 
P6522, P6222, 
P6422, P6322) 
Cubic 
Primitive, 
Body-and 
Face-
Centred 
a = b = c 
α = β = γ = 90° 36 
23, (e.g. P23, F23, 
I23, P213, I213), 432, (e.g. P432, 
P4232, F432, F4132, 
I432, P4332, P4132, 
I4132) 
 
 
Hence the space group parameters contain all the information needed to 
generate the unit cell from the asymmetric unit and gives an idea of the amount of 
information contained with one unit cell. Thus the determination of the point group 
(i.e. symmetry in the absence of translational elements) is required prior to data 
collection, as it gives an indication of how much angular information has to be 
collected for a complete dataset (Rhodes, 2006, Drenth, 2007, Rupp, 2010). 
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For determination of the unit cell dimensions and space group, software 
such as iMOSFLM (Battye et al., 2011) and the XDS pipeline (Kabsch, 2009) are 
used. They are routinely used for data processing, with their initial task being the 
determination of the unit cell parameters and the identification of potential point 
groups in a process known as autoindexing where reflection indices are assigned to 
each spot. 
 
 
3.2.4.2. Reciprocal Lattice to Real Lattice - Fourier Transform  
 
Once the unit cell parameters and space group have been determined within 
the crystal (real lattice), by using the space observed between the reflections (|Fhkl| 
or structure factors) on the diffraction pattern (reciprocal lattice) (Figure 2-3 and 2-
4), the characterization of the electron density can be undertaken to reconstitute the 
asymmetric unit. 
 
In a diffraction experiment, the intensities and the position of reflections are 
measured or recorded. From the position of the reflection, the index triple (h,k,l) 
can be determined and the appropriate intensity can be assigned. This intensity can 
be truncated to the structure (factor) amplitude, |Fhkl|, which is found in the 
reciprocal space from which the position of the electron density (!) within the real 
space can be deduced. Thus, to reconstitute the asymmetric unit within the unit cell 
the reflection (|Fhkl|) need to be assigned and this is achieved using a Fourier sum 
(Equation 2-2). The Fourier transform and sum were named after J.B.J Fourier 
(1768 –1830) a French mathematician and physicist, who observed and modelled 
heat transfer and vibrations, which are also waves. His work has allowed the 
description of complex waves as a sum of a series of sinusoidal waves (Rhodes, 
2006, Drenth, 2007, Rupp, 2010).   
 
As each diffraction spot (reflection) in the diffraction pattern can be 
represented mathematically as the sum of all the individual trajectories, with the 
sum of those waves being equivalent to what is ultimately represented in a 
diffraction spot, the Fourier summation is used to calculate the amplitudes, |Fhkl|. 
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Equation 2-2: Structure Factor as a Fourier sum  
 !!!" = !!!!!"  (!!!!!"!!!"!)!!!!  
 
where 
 !!!"  is the sum of every atomic structure factor of every atom along a set of 
………parallel planes, thus the average structure factor !      is the number of terms addressed by the total sum !       is a specific atom related to the position at h,k,l !!     is the scattering factor of the atom !, which is determined by the size of its 
……… electron shell and contributes to the amplitude of a constructive wave ℎ!! , !"! , !"! are the fractional coordinates of atom ! in the summation, and h, k, l the 
……… three indices of the corresponding reflection. 	  
Using the structure factors that were obtained using a Fourier sum the 
electron density (!) can be regenerated, with a Fourier transform. This equation is 
called the electron density equation (Equation 2-3). It is used to calculate electron 
density and Patterson maps from structure factors.   
 
Equation 2-3: Electron density equation from a Fourier transform  
 ! !,!, ! =    1!    !!!"   [cos 2! ℎ! + !" + !" − !(ℎ!")]  !!!        
where ! !,!, !  is the electron density at point !,!, !                                                                                                                     !             is the unit cell volume                                                                                                                                                                                                                                     !!!"        is the intensity or structure factor                                                                                                                                                                                                                                    ℎ! + !" + !" are the fractional coordinates and h, k, l the three indices of the                      
………… corresponding reflection                                                                                              ! ℎ!"      is the phase.  
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The electron density equation allows reconstruction of the real space 
density, ! !,!, ! , using the amplitude,   !!!"  , which is proportional to the square 
root of the reflection intensity, where the frequency of each term in the Fourier sum 
is equivalent to the coordinates h, k and l, and lastly the phases, ! ℎ!"  (Drenth, 
2007, Rupp, 2010). A wave has three characteristics its intensity, frequency and 
phase. The diffraction experiment due to its two dimensional setup is able to record 
the intensity and the frequency, whilst the phase information is lost. And as the 
electron density equation needs the derivation of phases to calculate the electron 
density, this is referred to as the phase problem. To solve the phase problem further 
experimental or computational means have to be undertaken.  
 
 
3.2.5. Crystallographic Phase Problem 
 
There are two strategies for solving the phase problem, experimental or 
computational. Each has its own advantages and disadvantages. In experimental 
phasing, datasets are used for heavy atom substituted variants of the macromolecule 
of interest for isomorphous replacement (MIR) or alternatively, anomalous 
scatterers are incorporated for single- or multiple-wavelength anomalous dispersion 
(SAD/MAD) experiments. Heavy atoms can either be incorporated within the 
expression system (e.g. selenomethionine), after crystallisation by soaking existing 
crystals in a heavy atom solution or by co-crystallisation. As the PDB contains 
increasing numbers of macromolecular structures, which represent a wide variety of 
folds, macromolecular structures are being solved by molecular replacement (MR). 
In MR an existing atomic model is used to approximate the phases of an unknown 
homologue. The unknown phases of the new map are substituted in the Fourier 
transform with the phase of the MR model to approximate those of the target 
molecule and thus used to generate electron density. The model is then iteratively 
refined until no further improvements can be made as the initial phases will all be 
error prone, especially when obtained using MIR/MAD/SAD. For both methods 
specialized software is used to obtain the missing phase information. 
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3.2.5.1. Solving the Phase Problem by Experimental Phasing 
 
Maximum likelihood is discussed in the MR section, but it is an approach 
that has been successfully applied to all aspects of structure determination and 
refinement in protein crystallography. Maximum likelihood in MIR/MAD/SAD is 
used in heavy atom parameter refinement and phasing (Fortelle and Bricogne, 1997, 
Otwinowsky, 1991), where it is effective in weighting derivatives. In refinement, a 
maximum likelihood target equation is minimized to maximize the probability of 
obtaining the known observations given the various parameters derived from the 
model (e.g. bond lengths, angles, chirality). 
 
 
5.2.5.1.1. Isomorphous Replacement (MIR) 
 
Experimental phasing techniques exploit the frequent isomorphism of 
datasets to facilitate the process of obtaining starting phases to build a model. Thus 
at least two datasets are needed, firstly one native dataset and secondly one dataset 
carrying heavy atoms. Both datasets must be derived from the same type of crystal. 
Heavy metals are most frequently used as these have a higher atomic number and 
thus have a much greater electron density compared to the atoms normally found in 
biological macromolecules, such as nitrogens, oxygens, carbons and hydrogens. 
This substantial difference in electron density and thus scattering power leads to 
significant differences between the native and atom structure factors. Bromide, 
gold, mercury and platinum are most commonly used for this technique. Mercury or 
gold target histidines and cysteines may form covalent links, while bromide or 
iodide target glutamate and aspartate residues through non-covalent links (Rhodes, 
2006, Rupp, 2010). Heavy atoms are generally introduced into a protein lattice by 
soaking existing crystals in a solution of heavy atoms until all the binding sites for 
the heavy atom are saturated. Unfortunately, this can disrupt the packing of 
macromolecules in the crystal leading to changes in the relative positions and 
orientations of monomers within the asymmetric unit, which can render MIR 
unusable. 
 
In MIR it is assumed that the two crystals used to obtain the differential 
dataset remain isomorphous after soaking with heavy atoms. In this case, the two 
datasets are obtained at the same wavelength and their structure factors are first 
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compared, by looking at the isomorphous difference. Thus, if the structure factor 
expression for the native (FN) is subtracted from the derivative heavy atom (FHN) 
dataset, which in addition contains the structure factor expression for the heavy 
atoms, information is yielded on the location of the heavy atoms in space (FN). For 
this the difference Patterson function is used (Equation 2-4) and it allows the 
determination of the location of the heavy atoms (Figure 2-7). The Patterson 
function is a Fourier sums without the phases. The structure factors, which are 
proportional to the measured reflection amplitudes, in this equation are squared and 
thus correspond to the intensities. This allows us to calculate a series of intensities, 
without the phases. In the difference Patterson function the structure factor is (∆F)! = (|F!"|− F! )!, thus is equal to the lone contribution of the heavy atoms 
(FH) (Fortelle and Bricogne, 1997, Otwinowsky, 1991). This allows the production 
of a vector map that will reveal the location of the heavy atoms within the unit cell.  
 
 
 
Figure 2-7: Obtaining FH - Difference Patterson Function   
 
The difference Patterson map allows removing the noise contributions from the 
native data (FN) in the derivative dataset (FNH) to obtain FH and thus to determine 
the location of the heavy atoms in space.  
 
This vector map was devised by Patterson and corresponds to the 
convolution of electron density (i.e. the electron density at a point x,y,z multiplied 
by the electron density at all other points within the asymmetric unit/unit cell). This 
gives rise to a map in which there are peaks at the ends of interatomic vectors. 
Ordinarily, it would be too complex to analyse if it were computed using the F!’s 
or F!" ’s alone. Using the isomorphous differences, however, the protein 
component is subtracted leaving only the heavy atom contribution. The vectors 
therefore correspond to those between symmetry related heavy atoms from which 
the x,y,z co-ordinates can be calculated.  Another important point is that the phase 
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ambiguity arising from a single derivative is different to the ambiguity arising from 
whether the co-ordinate is x,y,z or –x,-y,-z (Rhodes, 2006, Drenth, 2007, Rupp, 
2010). The latter is resolved by computing maps in both “hands”, the former only 
by using an additional derivative.  
 
Equation 2-4: Difference Patterson function 
 
 ∆P(!,!,!) =   1V    ∆F!"#!! e!!"!(!"!!"!!")    !!  
where  ∆P(!,!,!)           is the Patterson function at point (u, v,w) on the Patterson map                                                                                                                   V                      is the unit cell volume                                                                                                                                                                                                                                     ∆F!"#!                is the intensity or square of structure factor FH                                                                                                                                                                                                                                    hu+ kv+ lw  are the fractional coordinates and h, k, l the three indices of the                      
…………              corresponding reflection  
The Patterson function contains a set of vectors that define all inter-atomic 
interrelations, thus there are more vectors in the Patterson map than there are atoms. 
The sets of heavy atoms can be located by trialing all of the possible arrangements 
of atoms with the distances described by the Patterson map for the arrangements of 
the heavy atoms in a unit cell (Figure 2-7 and 2-8), this is called the Patterson 
superposition. Using an arbitrary heavy atom peak as an origin in the Patterson map 
and then tracing all the remaining vectors for every possible combination of peaks, 
a match to the peaks in the Patterson function is computationally investigated. This 
technique can be used on molecules of up to 1000 atoms. This is not enough for 
proteins but enough to solve the heavy atom substructures for isomorphous 
replacement and anomalous dispersion, although for large substructures, Patterson 
techniques have to be replaced by the direct methods approaches used for obtaining 
small molecule structures. This leads to two possible phase approximations, which 
were deduced from the centrosymmetric Patterson map using the fixed distances 
between the heavy atoms. This is the second source of phase ambiguity; the first is 
due to the nature of the cosine function. The ambiguity is broken by a second or 
sometimes multiple derivatives that for each hkl will have one phase in common or 
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by incorporating anomalous data (SIRAS). The requirement for a second derivative 
is graphically represented in figure 2-9 in what is known as the Harker construction.  
 
 
 
 
Figure 2-8: Difference Patterson Map of a Three-Atom Coordinate System  
 
Taking all vectors between the heavy atoms and plotting them from the origins of 
the unit cell, as in a simple coordinate system, can construct a Patterson map. This 
allows the determination of the absolute and relative locations of the heavy atoms. 
All of the possible combinations of atoms can be probed for the correct 
arrangement of the heavy atoms in the unit cell. On the left, 3 heavy atoms found in 
a unit cell and their 6 inter-atomic vectors are represented. The vectors are 
coloured by originating atoms. In the Patterson map, on the right, atoms were each 
placed at the origin, one corner of the unit cell. The Patterson peaks that were 
overlapping with the atoms obtained using the vectors are coloured according to 
the vectors used. 
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Figure 2-9: Harker Diagram for the Determination of the Two Possible Phase 
Angles for FNH  = FH + FN  
 
The vectors in the Harker diagrams represent the amplitude, in length, and phase 
(Φ), in isomorphous replacement. The vector FNH (orange arrow), which represents 
the heavy atom dataset, is a summation of the vector FN (blue arrow), of the native 
dataset and the vector FH (black arrow) of just the heavy atom contribution. The 
Harker diagram can be constructed from a single derivative by tracing a circle with 
a radius equal to FN (blue arrow and circle) at the origin of the arbitrary origin of a 
2D coordinate system, and a circle with a radius equal to FNH (orange arrow and 
circle), offset from the origin by FH. The circles represent all the possible phases 
that the vector could have. The two intersections that the circle produces represent 
the two possible phase angles of the vector FN (Drenth, 2007, Rupp, 2010). In order 
to definitively identify the phase, a second derivative dataset can be obtained. 
 
 
5.2.5.1.2. Anomalous Scattering (SAD/MAD) 
 
Isomorphous replacement relies on the heavy atom derived crystal 
remaining isomorphous to the native crystal, despite changes within the crystal. 
Sometimes, these changes can be so extensive that the difference between FN - FNH 
is compromised and even maximum-likelihood based methods cannot compensate 
for the difference. In these cases, the anomalous signals from atoms such as 
mercury and selenium, which produce an anomalous scattering signal at specific 
wavelengths, are obtained at synchrotron X-ray sources. These wavelengths are 
chosen as their energies cause an electronic transition in the anomalous scatterer in 
63	  
the range covered by synchrotron radiation, leading to small changes in the 
scattering intensity, which can be measured and used to solve the phase problem. 
The most common atom used in this method is selenium, which is incorporated into 
the protein using recombinant expression in the presence of selenomethionine. 
Selenomethionine substitutes the native methionines (Hendrickson et al., 1990). 
Instead of the terminal sulphur group selenomethionine contains a selenium group. 
 
An anomalous dispersion experiment is carried out using a wavelength close 
to the absorption edge of the specific anomalous scatterer. At this edge appreciable 
absorption occurs where the emitted X-ray emerges. This results in the loss of 
centrosymmetry in the diffraction pattern, which is manifested by a breakdown in 
Friedel’s law. Friedel’s law states that |Fhkl| = |F-h-k-l|. This breakdown leads to small 
but measureable differences between the |Fhkl|’s measured at different wavelengths.  
Datasets collected at different wavelengths close to and around the absorption edge 
therefore can be effectively used as a series of MIR datasets due to changes in the 
scattering correction where these experiments are referred to as multiple-
wavelength anomalous dispersion (MAD) (Rupp, 2010). Single anomalous 
dispersion where data from only a single wavelength, however, is often sufficient to 
obtain a preliminary set of phase estimates. Although there is still a phase 
ambiguity, the phase probability distribution in SAD is often slightly skewed 
towards the correct phase. Interpretable maps can therefore be frequently obtained 
using density modification techniques. Due to the technical advances made and 
when the anomalous scattering signal is strong enough, the use of just a single 
wavelength is possible to phase a map. 
 
A Friedel’s pair of reflections is centrosymmetric under normal scattering 
conditions (Drenth, 2007, Rupp, 2010). The anomalous scattering leads to subtle 
but measureable differences in amplitudes. As the wavelength used in these 
experiments is fixed, the magnitude of the anomalous signal is constant. Thus it can 
be read from reference table, detailing the information for all atoms. The anomalous 
signal is represented as the addition of vector FH to the normal scattering vector FN, 
resulting the vector FNH (Drenth, 2007, Rupp, 2010). And thus these differences are 
used to obtain the starting phases. As in isomorphous replacement, in anomalous 
64	  
scattering replacement, a Patterson difference map is used to locate the origin of the 
anomalous scattering, the position of the anomalous scatterer. Using the established 
standard of absorption magnitude for the anomalous scatterer and the identified 
change in the phase of the Friedel pair using the Patterson difference map, the 
approximate phases can be calculated and used for the initial electron density map 
and initial model building. The model the will then have to go through iterative 
refinement steps.   
 
 
5.2.5.1.3. Solving the Phase Problem by Molecular 
Replacement (MR) 
 
When using MR to solve the phase problem, phases of a structurally related 
molecule from the PDB are used to substitute for the unknown phases of the target 
macromolecule. When the crystals share the same crystal system, point symmetry 
and space group, then the packing of the macromolecule is going to be of close 
similarity, thus the phases of the structurally related structure can be used directly in 
completing the electron density function of the unknown target macromolecule 
(Driessen and Tickle, 1996). However, even if a high sequence identity or a similar 
tertiary structure is available, this does not necessarily mean that these will 
crystallize in the same way, as protein concentration, domain truncations and even 
slight changes in surface residues mediating crystal contacts, affect the 
crystallization process.  
 
MR is trying to find the orientation and location of the target using the co-
ordinates of a closely related molecule (model). This is a six dimensional problem 
that can be broken down into two, each of 3 dimensions. The first involves finding 
the correct orientation of the target and traditionally relied on the fact that the model 
and target have similar atomic distributions and therefore share intra-atomic 
vectors. As for MIR, a Patterson Function (Equation 2-4) can be used for this 
(Rhodes, 2006, Rupp, 2010). This, in this case, is a flattening of the 3D structure to 
allow comparison and superposition of the two structures. The Patterson maps of 
the two structures with their collections of inter-atomic distance vectors can be 
matched. Some of the vectors will be the same, while others will be different, due to 
small structural differences between the structures. Thus a certain level of similarity 
65	  
has to be present to elevate the signal of the same vectors above the noise of the 
dissimilar vectors. Molrep (Vagin and Teplyakov, 1997) is a program that attempts 
to match the two Patterson maps through a series of rotations and translations until 
the two are superimposed. Then the phases of the model are recalculated and used 
to build an initial electron density map for the unknown structure. As previously 
mentioned if there is a greater difference between the two structures or the content 
of the crystal is very complex, this method is less amenable and becomes 
computationally intensive.  
 
To alleviate this, programs like Phaser (McCoy et al., 2007) can be 
employed. These use maximum-likelihood statistics to increase the probability of 
finding an MR solution. The maximum-likelihood method targets the MR issue 
more comprehensively by calculating how well the solution predicts the 
observations used to obtain it. The higher the equivalence in reflections in each 
rotation and translation, is the higher the probability that the solution is correct. 
Rotational or translational matches with poor statistical significance are discarded. 
To differentiate between all the possible solutions Phaser uses Z-scores and log-
likelihood gain (LLG). LLG measures randomness and a negative LLG value would 
indicate that the input search model is worse than a random collection of atoms at 
describing the target data. But with every rotation or translation step in the right 
direction the LLG should increase, as randomness decreases. As many of the results 
may have a high LLG score as they all match some proportion of the data, the Z-
score measures the number of standard deviations of these statistical likelihoods 
above the mean; thus the signal to noise ratio. Z-score compares the LLG values 
from the rotation or translation search with LLG values of a set of random rotations 
or translations. The more significant the match is, the greater the Z-score and the 
better the solution, the higher the LLG. 
 
MR allows solving any structure bearing a certain degree of homology 
(above 20 % similarity) to a known model. When the fold is thought to be highly 
conserved homology can be increased by either truncation of all side chains, thus 
just using the backbone, thereby removing the noise contribution due to poor 
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sequence identity to the target. Also highly conserved residues between the target 
and the model can be maintained increasing the possible LLG score.  
 
 
3.2.6. Refinement and Validation of Macromolecular Models 
 
Once the initial electron density map has been phased, the aim is to improve 
the model in iterative steps such that it more accurately agrees with the 
experimental data. This iterative process aims to minimize the differences between 
the observed and the calculated structure factors and is called refinement. 
Refinement should combine with maximum likelihood and weighted difference 
maps. This is needed, as the phases have been produced by either experimental 
methods or MR and are either inaccurate or biased.  
 
Refinement uses two main aspects, geometry of the atoms and agreement 
between model and electron density. Coot (Emsley et al., 2010) is generally used to 
manually manipulate the structure residue by residue; using the available tools to 
regularize the stereochemical properties of peptides, such as bond angles, bond 
lengths and likely side chain rotamers. The Ramachandran plot (Ramachandran and 
Sasiskharan, 1968), which plots the relative ψ and ϕ angles of each residue 
highlighting atomic steric hindrance, is used to further improve the geometry of the 
model. Coot, PROCHECK (Laskowski et al., 1993) and MOLPROBITY (Chen et 
al., 2010) all offer graphic and tabulated views of the stereochemical properties of 
the model.  
 
Real space refinement is very specific and involves fitting atoms to electron 
density (Diamond, 1985), although most refinement is now performed in reciprocal 
space. Further constraints or restraints can be used during the refinement process 
depending on the nature of the molecule(s) being refined. These include non-
crystallographic symmetry (NCS) constraints. Molecules, which are related 
chemically, but not by crystallographic symmetry operators are related in 
refinement terms by NCS. NCS constraints will constrain areas of density that are 
similar, but will allow other regions to differ. As such, it can be modified to 
accommodate conformational differences between molecules within the asymmetric 
unit.  
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The success of a refinement strategy is judged using the !!"#$%& and the !!"## regardless of the program used. The !!"#$%& is a measure of the agreement 
between the observed structure factors and the calculated structure factors from the 
model (Equation 2-5). The !!"##   is by far the most important parameter, but there 
are other factors such as quality of density, B-value distribution, overall fit to the 
electron density and co-ordinate error. 
 
Equation 2-5: !!"##   and !!"#$%& 
 
 ! =    (|!!"#|− |!!"#!|)!!" |!!"#!|!!"  
 
where  
 !!"#    are the observed structure factors !!"#! are the calculated structure factors 
 
Using this equation (Equation 2-5), a !!"#$%& should be below 50%, 
otherwise the input model is not any more significant than a random model. There 
are two types of R-factors that measure the progress of refinement: the !!"#$%& and 
the !!"## (Brunger, 1992). The !!"#$%&‘s purpose is to give a sense of the agreement 
between the diffraction data and the model. The data used to calculate the !!"#$%& is 
derived from the same data that is being refined, it is prone to over fitting. Thus a 
more sensitive measure of phase error is the !!"## (Brunger, 1992) as it is 
calculated using 5% of the experimental reflection that are not used for the 
refinement and hence is free from model bias. A convergence between the two R-
factors of less then 5% is aimed for towards the end of the refinement. At this point 
the model is said to be ready for deposition in the PDB, providing that the 
stereochemistry is in the acceptable parameters from e.g. PROCHECK. 
 
 
2.2. Fluorescence Anisotropy Background Theory 
 
3.2.1. Fluorescence Anisotropy  
 
 Fluorescence Anisotropy (FA) is a well-established method for studying 
binding events between proteins and other macromolecules, such as RNA (Shi and 
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Herschlag, 2009, Singh et al., 2000). Using fluorescence anisotropy measurements 
to establish dissociation constants between proteins and other macromolecules is 
useful as anisotropy is independent of the overall protein concentration and varies 
with the rotational correlation time (Jameson and Sawyer, 1995). The rotational 
correlation time is linked to the rotation rate of the molecule, which changes upon 
binding (Lakowicz, 2006). The rotational correlation time is related to the viscosity 
of the solvent (η), the molecular volume (V), the gas constant (R) and the 
temperature (T in kelvin).  
 
When a fluorophore is excited by polarized light the light emitted is also 
polarized. The degree to which this light is polarized is described as anisotropy (r) 
(Perrin, 1926, Weber, 1953). The emission can become depolarized by a number of 
processes, such as binding events, which in turn will change the measured 
anisotropy (Cantor and Schimmel, 1980).  
 
 
 
Figure 2-10: Effects of Polarized Excitation and Rotational Diffusion on the 
Polarization or Anisotropy of the Emission 
 
As a consequence of excitation, there is an angular displacement between 
absorption and subsequent emission of the photons, due to the rotational diffusion 
of the molecule. The anisotropy measurements therefore depict the average angular 
displacement of the excited fluorophore population. This angular displacement is 
dependent upon the rate and extent of rotational diffusion during the lifetime of the 
excited state (Perrin, 1926, Weber, 1953, Weber and Hercules, 1966). The rate of 
rotational diffusion depends on the viscosity of the solvent and the size and shape of 
the rotating molecule.  
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In a homogeneous solution, fluorophores are randomly oriented in the 
ground-state. Following irradiation with polarized light, those that have their 
absorption transition moments aligned with the electric vector of the light are 
preferentially excited and are thus no longer randomly oriented; they are then 
referred to as the excited-state population (Jameson and Sawyer, 1995, Cantor and 
Schimmel, 1980) (Figure 2-10). 
 
 When the fluorophores freely rotate before re-emitting the photons, the degree 
of polarization of the emitted light will be reduced compared to the original light 
used for excitation. This difference in anisotropy depends on the fluorophores 
rotational correlation time (θ) during the fluorescence lifetime (τ) (Alcala et al., 
1987, Perrin, 1926, Weber and Hercules, 1966). Assuming no other processes result 
in loss of anisotropy, the expected anisotropy is given by the Perrin equation 
(Equation 2-6). 
 
Equation 2-6: Perrin Equation 
 ! =    !!1+   !/! 
where  
 
r   is the observed anisotropy 
r0  is the intrinsic anisotropy of the molecule 
τ   is the fluorescence lifetime  
θ is the rotational correlation time for the diffusion process 
 
 
3.2.2. Fluorescence Anisotropy Apparatus Setup 
 
In the experimental set-up, the sample is excited with vertically polarized 
light. The electric vector of this light is oriented parallel to the vertical (z-axis) 
(Figure 2-11). The intensity of the emission is measured through a polarizer. When 
the emission polarizer is oriented parallel (VV) to the direction of the polarized 
excitation, the observed intensity is IVV. Likewise, when the polarizer is 
perpendicular (VH) to the excitation, the intensity is IVH. These intensity values are 
used to calculate the anisotropy experimentally (Equation 2-7) (Lakowicz, 2006, 
Jameson and Sawyer, 1995). 
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Figure 2-11: Experimental Setup of Fluorescence Anisotropy Apparatus 
 
 
Equation 2-7: Anisotropy  
 ! =    !!! − !!"!!! + 2!!" 
 
where  
 
r      is the observed anisotropy !!!  is the observed intensity at VV !!"  is the observed intensity at VH 
 
In order to obtain the dissociation constants, the change in anisotropy is 
measured for samples in a titration series where the ligand concentration is kept 
constant, but the protein concentration increased (Lakowicz, 2006, Pollard, 2010). 
The dissociation constant (Kd) is the equilibrium constant of the reversible 
propensity of a complex to dissociate into 2 components. The Kd (M) corresponds 
to the concentration of ligand needed so that half of the binding sites of the protein 
are occupied. Which means, the smaller the Kd value is the higher the affinity of the 
ligand for the protein. (Equation 2-8) (Pollard, 2010). 
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Equation 2-8: Dissociation Constant - Kd 
 
 !! = [!][!][!]  
where 	  
Kd the dissociation constant (M) 
[P] the molar concentration of the Protein (M) 
[L] the molar concentration of the Ligand (M) 
[C] the molar concentration of the Complex (M) 
 
 
2.3. Microscale Thermophoresis Background Theory 
 
3.2.1. Microscale Thermophoresis  
 
Microscale thermophoresis (MST) is a recently pioneered method allowing 
measurement of the dissociation constant of macromolecules in solution on the 
microliter scale. Thermophoresis is the movement of molecules along a temperature 
gradient (Duhr and Braun, 2006). Thermodiffusion is labelled "positive" when 
particles move from a hot to cold region and "negative" when the reverse is true. 
Thermophoresis depends on changes in size, charge and the solvation shell of 
molecules. These effects are monitored in a capillary setup outlined in figure 2-12. 
Prior to thermophoresis, a homogenous molecular distribution is observed inside the 
capillary. By focusing an Infrared (IR)-Laser onto a specific point on the capillary, 
a microscopic temperature gradient of 2K-6K (Kelvin) is created (Zillner et al., 
2011). The macromolecules respond to this change by moving from the locally 
heated region to the outer cold regions and thus the concentration of 
macromolecules in the locally heated region decreases until it reaches a steady state 
determined by mass diffusion. The movement can also occur towards the locally 
heated region. This change in concentration can be quantified using the Soret 
coefficient (ST) (Equation 2-9) (Duhr and Braun, 2006, Reineck et al., 2010). The 
Soret coefficient takes into account the size, charge and hydration shell of the 
macromolecule to be studied at a set temperature. 
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Equation 2-9: The Concentration Ratio under Thermophoresis 
 
 !!!"!!"#$ =   !(!!!  .    !!  ) 
 
where  
 !!!"   is the observed concentration of the labelled macromolecule at increased 
              temperature (in μM) !!"#$  is the observed concentration of the labelled macromolecule at normal  
              temperature (in μM) 
ST      is the Soret coefficient (in K-1) 
ΔT    is the difference in temperature between !!!" and !!"!" (in K) 
 
 
3.2.2. Microscale Thermophoresis Apparatus Setup 
 
 In a typical experiment, either the macromolecule of interest or its ligand is 
labelled with a fluorophore (Figure 2-12). The fluorescent molecules 
thermophoretic movement is subsequently followed using the fluorescence 
distribution F inside a capillary (Baaske et al., 2010). As the thermophoresis is 
monitored using the fluorescence of the labelled molecule, any changes in its 
thermophoretic mobility on addition of its ligand or target can only arise from 
changes in the size, charge or solvation entropy due to binding, as the buffer is kept 
constant (Wienken et al., 2010, Baaske et al., 2010, Duhr and Braun, 2006). 
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Figure 2-12: Experimental Setup of the Microscale Thermophoresis Apparatus 
 
The Kd is obtained from a serial dilution of the binding substrate. By plotting the 
measured fluorescence against the logarithm of the different concentrations of the 
dilution series, a sigmoidal binding curve is obtained. This binding curve can be 
directly be fitted with the nonlinear solution of the law of mass action, which gives 
the Kd. 
 
 
2.4.Aims 
 
To better understand how KSHV infections lead to global and rapid mRNA 
decay the importance of the UGAAG motif in sequence terms, the involvement of 
RNA secondary structure and UGAAGs motifs involvement in the secondary 
structure were investigated via computational, biochemical and biophysical means.  
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Chapter 3: Materials and Methods 
6.  
3.1. Computational Analysis 
 
3.1.1. Distribution of UGAAG Motif in Host and Viral Genomes 
 
The EMBOSS web server tool compseq (Williams, 2001) was used to 
calculate the actual and expected frequencies of the UGAAG motif and inverse 
GAAGU motif in a file containing all mRNAs from the human genome. The files 
refseq_HHV8 (Rezaee et al., 2010) and refseq _HS (Pruitt et al., 2013) were used, 
containing respectively the KSHV genes and Homo sapiens mRNAs. The Homo 
sapiens mRNAs were retrieved by using the following search parameters 
(srcdb_refseq[prop] AND biomol_rna[prop] AND ("last 30 days"[PDAT])) AND 
"Homo sapiens"[porgn:__txid9606]. 
 
 
3.1.2. Alignment and in silico Folding of mRNAs 
 
The full mRNA sequences for GFP, DsRed2 and HBB from Genbank 
(Benson et al., 2012) that were identified by the Glaunsinger Group as targets for 
SOX were obtained (Covarrubias et al., 2011) (Table 3-1). These were checked 
against the sequence published by Glaunsinger using nucleotide basic local 
alignment search tool (Blast) (Altschul et al., 1990), as no accession numbers were 
mentioned in the publication. The three sequences were aligned using the web 
server MView (Brown, 2013, Brown et al., 1998) and T-coffee (Notredame, 2013, 
Notredame et al., 2000). 
 
A cycle of in silico RNA folding was then performed using the web server 
mfold (Zuker, 2003a). First, the whole sequence was folded and the number of 
possible folds in the region targeted for cleavage quantified, thereafter restricting 
the sequence to 201 nucleotides as used by Covarrubias et al., 2011. Finally, the 
sequences were truncated to a length that would maintain the identified 
characteristic fold and would be amenable to biochemical and structural studies.  
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Table 3-1: Genbank IDs of mRNAs with an Identified Endonucleolytic 
Cleavage Site 
 
Target Name Genbank ID 
GFP GI:371926914 
DsRed2 AAY25372.1 
HBB GI:28302128 
 
 
Mutant and shorter engineered variants of the GFP construct were also 
folded using this protocol. Further RNA sequences and mutant GFP RNA 
sequences were subsequently in silico folded and analysed as mentioned above; the 
sequence names, accession numbers and compositions can be found in table 3-3 in 
section 3.2.2.1. 
 
 
3.1.3. Tertiary Structure Prediction  
 The web server MC-Fold | MC-Sym (Parisien and Major, 2008) was used to 
obtain tertiary structure predictions for the RNA folds identified . MC-Fold | MC-
Sym explores probabilistically	   the	   conformational space	   for	   RNA using input 
constraints	   and	   taking	   into	   account	  Watson-­‐Crick	   and	   non	  Watson-­‐Crick	   base	  pairing. The RNA sequences containing the UGAAG motif that had been 
sequentially reduced in length were used as input (Table 3-1) into Mc-Fold 
(http://www.major.iric.ca/MC-Fold/) for MC-Sym (http://www.major.iric.ca/MC-
Sym/) to obtain the 3D	  RNA	  structures.  	  
 
3.1.4. Fitting the RNA in the Active Site of SOX 
 
The 114 tertiary structures for the 51 nucleotides RNA sequence of GFP was 
then used to model the interaction between SOX and the RNA using as a template 
the crystal structure of SOX in complex with dsDNA (PDB ID: 3pov) (Bagneris et 
al., 2011). The Chimera software (Pettersen et al., 2004) was used for modelling.  
The density for the DNA derived from the SOX-DNA structure was used as a 
template to fit the RNA stem loop into the active site. Atomic clashes were taken 
into consideration where the most favourable model was retained.  
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3.1.5. Generation	  of	  SOX	  Conformers	  using	  tCONCOORD	    
tCONCOORD (Seeliger and DeGroot, 2009) was used to produce 
alternative conformations for the native wild type protein (3fhd). tCONCOORD 
builds a library of distance constraints based on the observed interatomic distances 
in the original structure. Interactions deemed to be stronger are given tighter 
constraints. The program then produces randomly a large number of potential 
conformations, and attempts to correct structures with atom-pair distances falling 
outside the allowed regions. 1000 iterations were applied of the correction 
algorithm per structure, and the structures were rejected whose interatomic 
distances violated the original distances by more than 3 nm in total. tCONCOORD 
was set to an output of 250 novel conformations for the native wild type protein 
(3fhd), which fulfilled the distance constraints. All computationally produced 
conformers were superimposed on the native wild type (3fhd) using the structalign 
program.  
 
3.2. Biophysical and Biochemical Characterisation of SOX, Xrn1, 
SOX:RNA and SOX:Xrn1 Interactions  
 
3.2.1. Protein Expression and Purification 
 
3.2.1.1. Plasmid Purification and Quantitation  
 
3.2.1.1.1. SOX: Plasmid Purification and Quantitation  
 
Plasmid stocks were prepared from 5 mL lysogeny broth-luria (LB) (10 g/L 
tryptone; 5 g/L yeast extract; 10 g/L sodium chloride at pH 7.5, autoclaved) cultures 
of NEB 5-alpha Competent E. coli grown overnight at 37 °C. DNA purification was 
conducted using the Wizard® Plus SV Minipreps DNA Purification System 
(Promega) using the standard operating protocol for centrifugation. 
 
The quantity and purity of DNA yield from plasmid purification was 
assessed using the ‘Nucleic Acid’ program in the NanoDrop software using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific) and the Promega DNase 
free buffer as blank. Concentrations were measured in μg/μL.  
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3.2.1.1.2. Xrn1: Plasmid Purification and Quantitation  
 
The same protocol as in section 3.2.1.1.1 was applied to the Xrn1 containing 
plasmid; pET26b-Xrn1. 
 
 
3.2.1.2. Transformation of Chemically Competent Cells by Heat 
Shock 
 
3.2.1.2.1. SOX: Transformation of Chemically Competent 
Cells by Heat Shock 
 
 
The SOX plasmid pETM6T1-SOX (Bagneris et al., 2011) was co-
transformed into BL21(DE3) Star (Invitrogen) with the plasmid pRARE encoding 
the rare tRNAs extracted from RosettaTM 2(DE3) cells (Novagen).  The plasmid 
pETM6T1-SOX contained an N-terminal His-tag, followed by a N-utilization 
substance protein A (NusA) Tag with a tobacco etch virus protein (TEV) cleavage 
site linker to the full length SOX gene (See Appendix B for plasmid details).    
 
Wild type or mutant SOX proteins (A61T, D221S, E244S, Y373A, H450A, 
R451A, N458A, R462A, D474N, Y477Stop) were expressed and purified using the 
same protocol. The mutants were previously produced by Dr. Claire Bagnéris from 
the Barrett Group. 
 
Transformation of chemically competent of the E. coli strain for expression 
was conducted as follows: 50 μL of competent BL21(DE3) Star cells were thawed 
on ice for 10 minutes. After thawing, 1 μL of each pRARE (containing a 
chloramphenicol resistance gene and coding for rare tRNAs) and pETM6T1-SOX 
(containing a kanamycin resistance gene) plasmids were added and the mixture 
incubated on ice for 30 minutes. The cells were rapidly transferred to a water bath 
at 42°C for 30 seconds, then transferred back on ice for 5 minutes. 200 μL of room	  temperature	  SOC	  media were then added to the competent cell mix. The media and 
transformed cells were placed in an incubator for 1 hours (h) at 37°C and 250	  rpm. 
250 μL of recovered cells were then spread onto pre-prepared agar plates containing 
kanamycin at 25 μg/mL and chloramphenicol at 34 μg/mL final concentrations. 
Plates were incubated at 37°C overnight. 
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3.2.1.2.2. Xrn1: Transformation of Chemically Competent 
Cells by Heat Shock 
 The Xrn1 plasmid pET26b-Xrn1 (a kind gift from Professor Liang Tong) 
was co-transformed into BL21(DE3) Star (Invitrogen) with a plasmid encoding the 
rare tRNAs extracted from RosettaTM 2(DE3) cells (Novagen).  The plasmid 
pET26b-Xrn1 contained residues 1–1,245 of K. lactis Xrn1 with a C-terminal 
hexahistidine tag. 
The same protocol as in section 3.2.1.2.1 was applied for the transformation 
of pET26b-Xrn1. 
 
 
3.2.1.3. Recombinant Expression 
 
3.2.1.3.1. SOX: Recombinant Expression 
 
A colony of BL21(DE3) Star containing the pETM6T1-SOX and pRARE 
plasmids was picked from the agar plate and used to inoculate 100 mL of LB to 
which chloramphenicol (34 μg/mL) and kanamycin (25 μg/mL) were added to yield 
a seed culture, which was grown overnight at 37°C, at 225 rpm (Certomat BS1 
Shaker incubator). 5 mL of this culture were then inoculated into each of 12 x 500 
mL volumes of LB/chloramphenicol/kanamycin in 2 L shaker flasks. These cultures 
were grown as for the seed culture until they reached an optical density at 600 nm 
(OD600) of 0.8. At this stage, synthesis of recombinant SOX was induced by the 
addition of 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) and the cultures 
were grown overnight at 18 °C. Cells were harvested by centrifugation (5000 g, 40 
mins, 4 °C on the Beckman Avanti J-20 I rotor then at 4000 g for 20 minutes at 4 
°C on the Hettich Rotina 420R to collect the cell pellets in 50 mL centrifuge tube 
for snap freezing). The pellet was stored at -80 °C. 
 
 
3.2.1.3.2. Xrn1: Recombinant Expression 
 
 The expression protocol was adapted from previous publications (Bagneris et 
al., 2011, Chang et al., 2011). Recombinant Xrn1 was overexpressed in E. coli 
BL21(DE3) Star. 50 μL of these cells stored in 10% glycerol were inoculated into 
100 mL of LB (10 g/L tryptone; 5 g/L yeast extract; 10 g/L sodium chloride at pH 
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7.5, autoclaved), chloramphenicol (34 μg/mL) and kanamycin (25 μg/mL), and a 
seed culture grown overnight (37°C, 225 rpm - Certomat BS1 shaker incubator). 5 
mL of this culture were then inoculated into each of 12 x 500 mL volumes of LB/ 
chloramphenicol/kanamycin in 2 L shaker flasks. These cultures were grown as for 
the seed culture until they reached an OD600 of 0.8 . At this stage, synthesis of 
recombinant Xrn1 was induced by the addition of 0.5 mM IPTG and the cultures 
were grown for 4 hrs at 20 °C. Cells were harvested by centrifugation (5000 g, 40 
mins, 4 °C on the Beckman Avanti J-20 I rotor then at 4000 g for 20 minutes at 4 
°C on the Hettich Rotina 420R to collect the cell pellets in 50 mL centrifuge tube 
for snap freezing). The pellet was stored at -80 °C. 
 
 
3.2.1.4. Purification Protocols 
 
3.2.1.4.1. SOX: Purification 
 
 All chromatography columns described in this thesis were used according to 
the manufacturer’s specifications. All were attached to an ÄKTA automated 
chromatography system for purification using the UNICORN control software.  
 
 Samples were loaded on to equilibrated chromatography columns (except the 
gel filtration column) using a peristaltic pump at flow rates between 0.5 and 1.0 
mL/min and the unbound fractions were collected. For those involving gel filtration, 
samples were loaded using the ÄKTA inbuilt syringe injection loop system. 
 
 The purification protocol was adapted from previous publications (Bagneris et 
al., 2011). Cell pellets were first resuspended in nickel buffer A (300 mM NaCl, 25 
mM Tris pH 7.2) supplemented with DNase I (10 μg/mL final concentration 
(NEB)) and an Ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor 
cocktail tablet (Roche). After the cells were lysed using a cell disruptor system (3C 
High Pressure Homogeniser) on ice, the lysates were clarified by centrifugation (46 
000g for 1 h at 4 °C, Beckman Avanti J-20 XP rotor) and the supernatant filtered 
through a 0.45mm filter prior to loading onto two 5 mL HisTrap FF column (GE- 
Healthcare). The columns were washed with 20 column volumes (CVs) of buffer A 
containing 50 mM imidazole and the protein eluted using 60 CVs of buffer B (300 
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mM NaCl, 25 mM Tris pH 7.2, 500mM imidazole). The eluate was diluted to a 
concentration of 200 mM NaCl and a pH of 8.5 by using a dilution buffer (0 mM 
NaCl, 25 mM Tris pH 8.5) and then loaded onto a 5 mL HiTrap Q HP column (GE-
Healthcare) previously equilibrated in 25 mM Tris, 50 mM NaCl, pH 8.5. The 
fusion protein was then eluted using a 50-1000 mM NaCl linear gradient. Eluted 
fractions were assessed for their protein composition by Sodium Dodecyl Sulphate - 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) gels. Fractions containing 
protein with a molecular weight consistent with recombinant His-NusA-SOX (114 
kDa) were pooled. The tag was removed by the addition of TEV protease to the 
pooled fractions during overnight dialysis in Pierce snakeskin membrane (3 kDa 
molecular weight cut off (MWCO)) in a buffer comprising 25 mM Tris pH 8.5, 200 
mM NaCl, 1 mM dithiothreitol (DTT). The solution was diluted to a concentration 
of 200 mM NaCl using pH of 8.5 Tris-HCl buffer and then applied to a 5 mL 
HiTrap Q HP column. The untagged protein eluted using a 50–500 mM NaCl linear 
gradient. Fractions containing the purest protein were pooled and concentrated 
using a 30 kDa cut-off Vivaspin centrifugal concentrator (Vivascience) (3000 g, 
Hettich Rotina 420R). The protein was then loaded onto a gel filtration column 
(Superdex200 HR 26/60) that had been pre-equilibrated in a buffer consisting of 32 
mM Tris pH 8.5, 189 mM NaCl, 1.6 ug bovine serum albumin (BSA) and 10 mM 
DTT. Fractions were analysed on SDS–PAGE gels and those containing pure 
protein were concentrated to 4 mg/mL using a 30 kDa cut-off spin cartridge 
(Vivascience) (3000 g, Hettich Rotina 420R), aliquoted and stored at -80!°C.  
 
 
3.2.1.4.2. Xrn1: Purification 
 
 Cell pellets were resuspended in nickel buffer A  (20 mM Tris pH 7.5, 100 
mM NaCl and 10 mM β-mercaptoethanol) supplemented with DNase I (10 μg/mL 
final concentration) and an EDTA-free protease inhibitor cocktail tablet (Roche). 
After lysis using a cell disruptor system (3C High Pressure Homogeniser) on ice, 
the lysates were clarified by centrifugation (46 000g for 1 h at 4!°C, Beckman 
Avanti J-20 XP rotor) and the supernatant filtered through a 0.45mm filter prior to 
loading onto one 5 mL HisTrap FF column (GE-Healthcare). The column was 
washed with 20 CVs of buffer A containing 50 mM imidazole and the protein 
eluted using 20 CVs of buffer B (20 mM Tris (pH 7.5), 100 mM NaCl, 10 mM β-
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mercaptoethanol and 500 mM imidazole). Fractions containing the purest protein 
were pooled and concentrated using a 30 kDa cut-off Vivaspin centrifugal 
concentrator (Vivascience) (3000 g, Hettich Rotina 420R). The protein was then 
loaded onto a gel filtration column (Superdex200 HR 26/60) that had been pre-
equilibrated in a buffer consisting of 20 mM Tris pH 7.5, 200 mM NaCl, 2 mM 
DTT and 5% (v/v) glycerol. Fractions were analysed using SDS–PAGE gels and 
those containing protein, concentrated to 4 mg/mL using a 30 kDa cut-off spin 
cartridge (Vivascience) (3000 g, Hettich Rotina 420R), aliquoted, flash frozen with 
liquid nitrogen and then stored at −80 °C. 	  	  
3.2.1.5. Quantitation of Protein Yield from Recombinant 
Expression and Sample Concentration 
 
The protein concentration, for the final eluent pool from the purification and 
for each experiment, was measured using the ‘Protein A280’ program in the 
NanoDrop software using a NanoDrop 1000 spectrophotometer (Thermo Scientific) 
using the Gel Filtration Buffer as blank. Concentrations were measured in mg/mL.  
 
Each sample was measured three times and the average value of these was 
then used in the calculation of the protein concentration. 
 
The protein concentration was calculated using the rearranged Beer-Lambert 
equation (Equation 3-1). 
 
Equation 3-1: Rearranged Beer-Lambert Equation 
 
[C] (mg/mL) = !!"#!!.!%.!   ⇒ !!"#!!.!%  
 
where 
 
[C]    is the protein concentration in mg/mL ε0.1%	  	  	  is the wavelength-dependent molar absorptivity coefficient for each 
             specific protein in (mg/mL)-1cm-1 A280   is the measured absorbance value at a wavelength of 280 nm l	  	         is the path length (cm), which was set to 1 cm 
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3.2.1.6. Analysis of Proteins by Sodium Dodecyl Sulphate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
 
The purified protein was tested for its identity and its purity using SDS-
PAGE gel analysis. The purified protein was positively identified on the basis of 
size and in comparison to previous purified samples. The SDS-PAGE gels were 
either pre-cast Invitrogen, 1 mm, 4-12% (v/v) acrylamide Bis-Tris SDS gels or 
hand-cast 1 mm SDS-PAGE gels, see table 3-2 for composition. The reagents for 
the hand-cast SDS-PAGE gels were combined to produce the gel by adding 
tetramethylethylenediamine (TEMED) and 10% Ammonium Persulfate  (APS) 
solutions last prior to pouring. 
 
Both types of gels were prepared and run as instructed in the Invitrogen 
manufacturer’s guide book for SDS-PAGE analysis using NuPAGE® MES (2-(N-
morpholino)ethanesulfonic acid) SDS Running Buffer. The pre-cast gels were run 
in an Invitrogen-specific tank and the hand-cast gels in the Tetra Electrophoresis 
system (BioRad). 
 
Table 3-2: Composition of Hand-cast Polyacrylamide Gels for SDS-PAGE 
 
 Resolving Gel Stacking Gel 
Gel Percentage (%) 11.4% 4.0% 
Reagent   
  30% Polyacrylamide Solution  3.8 mL 670 μL 
  1.5 M Tris-HCl pH 8.8 2.5 mL - 
  1.0 M Tris-HCl pH 6.8 - 630 μL 
  10% APS 100 μL 50 μL 
  10% SDS 100 μL 50 μL 
  dH2O 3.5 mL 3.6 mL 
  TEMED 12 μL 8 μL 
Total Volume (mL) 10.0 mL 5.0 mL 
 
The crude soluble, insoluble and flow through fractions were diluted to 1:20 
to a volume of 12 μL to which 3 μL of 5X NativePAGETM sample loading buffer 
(Invitrogen) were added. 12 μL of partially purified protein samples were used in a 
1:1 volumetric ratio of sample to which 3 μL of 5X NativePAGETM sample loading 
buffer were added. 15 μL were loaded into the wells of SDS-PAGE gels and 5-10 
μL page ruler prestained protein ladder (Thermo Scientific) were used as molecular 
weight markers. Electrophoretic separation was undertaken using a PowerPacTM 
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basic power supply (BioRad) at 180 V typically for 35-40 minutes depending on the 
percentage of the resolving gel. Gels were stained with Instant Blue (Expedeon). 
Gels were visualised on a light box or scanned for electronic visualization.  
 
 
3.2.2. SOX:RNA Binding and Activity Assays 
 
3.2.2.1. RNA Preparation 
 
The RNA oligonucleotide sequences (Table 3-3) were purchased from 
Eurogentec (Belgium). The lyophilized RNA was dissolved in RNA-annealing 
buffer (100	  mM	   NaCl,	   20	  mM	  MgCl2,	   20	  mM	   Tris	   HCL	   at	   pH	   7.4; RNase and 
DNase Free) to a concentration of 1 mM. The RNA was annealed using the Peqlab 
Primus 96 Gradient PCR-machine by heating the mixture to 90 °C for 1 minute, 
followed by a decrease of 1 °C every minute until 4 °C was reached. 	  
All RNAs were synthesized, so that they did not contain a 5’ 
monophosphate or fluorescent tag, since they would then be targets for single 
stranded exonucleolytic cleavage by SOX. For the Tris/Borate/EDTA (TBE), TBE-
Urea and Fluorescence anisotropy experiments, all synthesised RNAs were 
substituted with a 3’ 6-­‐carboxyfluorescein (6-FAM) label. The sequences used in 
the studies described are given in table 3-3. 
 
Table 3-3: RNA Sequences of Identified Structured Target Fold 
 
RNA 
Name RNA Sequence 
Purification 
Method 
51 GFP 5’-UAC-GGC-AAG-CUG-ACC-CUG-AAG-UUC-AUC-UGC-ACC-ACC-GGC-AAG-CUG-CCC-GUG- 3’ HPLC-IEX 
51 GFP 
UCUCU 
5’-UAC-GGC-AAG-CUG-ACC-CUC-UCU-UUC-
AUC-UGC-ACC-ACC-GGC-AAG-CUG-CCC-GUG-3’ HPLC-IEX 
23 GFP 5’-AGC-UGA-AGU-UCA-UCU-GCA-CCA-GC-3’ HPLC-IEX 
58 HBB 
5’-AGG-UGA-AGG-CUC-AUG-GCA-AGA-AAG-
UGC-UCG-GUG-CCU-UUA-GUG-AUG-GCC-UGG-
CUC-ACC-U-3’ 
HPLC-IEX 
 
N.B.:   51 GFP UCUCU is a construct in which the UGAAG motif was   
      mutated into UCUCU.  
23 GFP is a construct in which the original GFP sequence was     
      shorted. 
High-Performance Liquid Chromatography Ion Exchange (HPLC-IEX) 
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3.2.2.2. TBE Gel – RNA Electrophoretic Mobility Shift Assays  
 
Electrophoretic mobility shift assays were performed to assess protein-RNA 
binding using a TBE gel system. The TBE gels were either pre-cast (Invitrogen), 1 
mm, 6% (v/v) acrylamide TBE gels or hand-cast 1 mm TBE gels, see table 3-4 for 
composition. The reagents for the hand-cast TBE gels were combined to produce 
the gel by adding TEMED and 10% APS solutions last prior to pouring (Hellman 
and Fried, 2007).  
 
Both types of gels were prepared and run as instructed in the Invitrogen 
manufacturer’s guide book for TBE analysis using 4% ficoll as a loading buffer and 
Orange-G in a separate lane, as a running marker. 1 times TBE (89 mM Tris-Base, 
89 mM Boric Acid, 2 mM EDTA) buffer was used as running Buffer. The pre-cast 
gels were run in an Invitrogen-specific tank and the hand-cast gels in the Tetra 
Electrophoresis system (BioRad) (Hellman and Fried, 2007). 
 
 
Table 3-4: Composition of Hand-cast TBE Gels 
 
 Resolving Gel 
Gel Percentage (%) 4.0% 
Reagent  
  30% Polyacrylamide Solution  1.6 mL 
  5X TBE 2.4 mL 
  10% APS 120 μL 
  dH2O 7.8 mL 
  TEMED 14.4 μL 
Total Volume (mL) 12.0 mL 
  
  
 Binding assays were performed using the structured 51 nucleotides GFP, 
mutated UCUCU GFP and 58 nucleotides HBB RNA (Table 3-3 for sequences). 20 
pmol of RNA were incubated with 150 pmol of SOX for 1 h in a buffer (Table 3-5) 
at room temperature. First the optimal binding condition was assessed using a range 
of NaCl concentration and pH range (Table 3-5), thereafter buffer B. TBE D was 
used. Subsequently, 4% ficoll and 1 mM EDTA were added to each sample prior to 
loading onto 6% TBE gels or hand-cast 4% TBE gels (Invitrogen) (Buisson et al., 
2009, Bagneris et al., 2011, Hellman and Fried, 2007).  
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15 μL of RNA, EDTA and ficoll mixture were loaded into the wells of TBE 
gels and 10 μL of 4% ficoll. A solution of 2 % Orange-G was used as a running 
marker. Electrophoretic separation was undertaken using a PowerPacTM basic power 
supply (BioRad) at 50 V typically for 120-180 minutes depending on the percentage 
of the gel. Gels were scanned using a FLA300 (Fujitsu) Imager, at an excitation 
wavelength (λex) of 490 nm and emission at λem of 520 nm. 6-FAM has an 
excitation and emission wavelength of 492 nm and 517 nm respectively. 
 
Table 3-5: TBE Binding Buffers 
 
Buffer 
Name Buffer Composition pH 
B. TBE 
St. 
50 mM Tris–HCl, 200 mM NaCl, 20 mM, β-mercaptoethanol, 
50 mM EDTA, 10 mM MgCl2 9 
B. TBE A 100 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6 
B. TBE B 100 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6.5 
B. TBE C 100 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 7 
B. TBE D 100 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 7.5 
B. TBE E 100 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 8.5 
B. TBE F 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6 
B. TBE G 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6.5 
B. TBE H 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 7 
B. TBE I 300 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 8.5 
B. TBE J 400 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6 
B. TBE K 400 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6.5 
B. TBE L 400 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 7 
B. TBE M 400 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 8.5 
 
 
 
3.2.2.3. TBE-Urea Gel – RNA Electrophoretic Activity Assays  
 
Endonuclease activity assays were performed using TBE-Urea gel analysis. The 
assays were performed using the structured 51 nucleotides GFP, mutated UCUCU 
GFP and 58 nucleotides HBB RNA. 20 pmol of RNA were incubated with 150 
pmol of SOX for 1 h in a buffer (Table 3-6) at 37 °C. First the optimal binding 
condition was assessed using a range of NaCl concentration and pH range (Table 3-
6), then the B. TBE St.’ Buffer was subsequently used. The RNA reactions were 
halted by the addition of 50 mM EDTA and 7.5 µl of each reaction mixture were 
combined with 7.5 µl of Novex TBE-Urea sample buffer (Invitrogen), heated at 
70°C for 3 mins, prior to loading onto pre-cast 1 mm, 15% TBE-Urea gels 
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(Invitrogen) (Hellman and Fried, 2007, Buisson et al., 2009, Bagneris et al., 2011). 
Electrophoretic separation was undertaken using a PowerPacTM basic power supply 
(BioRad) at 100 V typically for 120 minutes. Gels were scanned using a FLA300 
(Fujitsu) Imager, at an excitation wavelength (λex) of 490 nm and emission at λem 
of 520 nm. 
 
Table 3-6: TBE-Urea Buffers 
 
Buffer 
Name Buffer Composition pH 
B. TBE St.’ 50 mM Tris–HCl, 200 mM NaCl, 20 mM β-mercaptoethanol, 10 mM MgCl2 9 
B. TBE A’ 100 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6 
B. TBE B’ 100 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6.5 
B. TBE C’ 100 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 7 
B. TBE D’ 100 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 7.5 
B. TBE E’ 100 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 8.5 
B. TBE F ‘ 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6 
B. TBE G’ 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6.5 
B. TBE H’ 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 7 
B. TBE I’ 300 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 8.5 
B. TBE J’ 400 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6 
B. TBE K’ 400 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 6.5 
B. TBE L’ 400 mM NaCl, 50 mM bis-tris, 15 mM DTT, 50 mM EDTA 7 
B. TBE M’ 400 mM NaCl, 50 mM Tris, 15 mM DTT, 50 mM EDTA 8.5 
 
 
3.2.2.4. Fluorescence Anisotropy – SOX:RNA Interaction (RNA 
Kd) 
  
 Fluorescence anisotropy assays were conducted at 25 °C using a fluoromax-3 
spectrofluorimeter (Jobin Yvon Horiba), and the data fitted using GraFit (Erithacus 
Software). Serial dilutions of SOX were incubated for 30 min with 50 nM of 
structured 51 nucleotides RNA, in a binding buffer comprising 25 mM Tris–HCl 
pH 8.5, 200 mM NaCl and 10% glycerol in a final volume of 60 µL (Bagneris et al., 
2011). These were then transferred to 60 µL quartz cuvettes for anisotropy 
measurements that were repeated six times at each concentration of SOX. 
Experiments were conducted with a slit width of 5 nm with the excitation (λex: 492 
nm) and emission (λem: 515 nm). The changes in anisotropy following titration of 
SOX into the RNA were used to calculate the affinity constants. All data were fitted 
to a one site binding equation. 
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3.2.3. SOX:Xrn1 Interaction 
 
3.2.3.1. Pull Down Assay – SOX:Xrn1 Interaction 
 
Purified his-tagged Xrn1 was incubation with a 4 times excess of purified 
nonhis-tagged SOX in buffer A  (20 mM Tris pH 7.5, 100 mM NaCl and 10 mM β-
mercaptoethanol). The solution was loaded onto a 1 mL HisTrap column (GE 
Healthcare) and the protein-complex eluted using a 0-500mM Imidazole linear 
gradient in buffer A over 20 CVs. The complex eluted at 500 mM imidazole, where 
the presence of both Xrn1 and SOX was verified via SDS-Page Gel (Pollard, 2010). 
 
 
3.2.3.2. Microscale Thermophoresis – SOX:Xrn1 Interaction 
(RNA Kd) 
 
 A titration series of 16 dilutions was prepared, where KHSV-SOX was kept 
constant at 20 nM, while Xrn1’s concentration was varied from 2 nM - 17.5 μM. 
KHSV-SOX was fluorescently labelled with blue n-hydroxysuccinimide 
(NanoTemper Technologies) that specifically targets lysine. 10 μl of the serial 
dilution of the non-labelled molecule were mixed with 10 μl of the diluted 
fluorescently labelled molecule (Jerabek-Willemsen et al., 2011, Wienken et al., 
2010). Mixed samples were loaded into glass capillaries and the MST-analysis was 
performed using a Monolith.N115 Series spectrometer (NanoTemper 
Technologies). 
 
 
3.2.4. Crystallization of SOX complexes  
 
3.2.4.1. SOX WT/SOX 244:RNA 
 
The RNA oligonucleotides 51 nucleotides GFP, 23 nucleotides GFP and 58 
nucleotides HBB were added to SOX WT/SOX 244 at a concentration of 2 mg/mL 
and concentrated to 8 mg/mL. The resulting RNA-SOX WT/SOX 244 complexes 
were formed in a 1.2:1 ratio and left to incubate for 1 h at 4 °C. Complexes were 
also formed by adding the RNA to SOX WT/SOX 244 at high concentration to 
yield complexes at 8 mg/mL without the requirement for further concentration. As	  previously	  described,	  all	  complexes	  were	  subjected to crystallisation trials using 
commercially available, sparse matrix suites (Proplex and JCSG+ from Molecular 
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dimensions) in sitting drop 96 well plates via vapour diffusion at 16 °C (100 nL 
drops in a 1:1 and 1:2 (v/v) ratios of mother liquor and sample). Preliminary hits 
were subsequently optimised in 96 well plates using the same complex:precipitant 
ratios (See Appendix C). 	  	  
3.2.4.2. SOX WT/SOX 244:Xrn1 
 
The SOX WT/SOX 244 and Xrn1 complex was buffer exchanged into 
crystallisation buffer (189 mM NaCl, 32 mM Tris pH 8.5, 10 mM DTT and 1.6 ug 
BSA) at concentrations of 2 and 6 mg/mL respectively and were used in vapour 
diffusion crystallisation trials as previously described with optimisation performed 
on initial “hits” (See Appendix C).	  
 
 
3.2.4.3. SOX WT/SOX 244:Xrn1:RNA 
 
The SOX 244 and Xrn1 complex was prepared as above 2.2.4.3. A complex 
was formed for 51 nucleotides GFP, 23 nucleotides GFP and 58 nucleotides HBB. 
The SOX 244:Xrn1:RNA complex was used for a sparse matrix screen using 
commercially available suites (Proplex and JCSG+ from Molecular dimensions) in 
sitting drop 96 well plates via vapour diffusion at 16 °C with a SOX WT/SOX 244 -
Xrn1 (100 nL drops in a 1:1 and 1:2 (v/v) ratios of mother liquor and sample). A 
fine screen of initial hit conditions was undertaken in 96 well formats using the 
same drop ratios (See Appendix C). 
 
 
3.2.4.4. Cryo-cooling Protocol for Macromolecular Crystals 
 
Several cryoprotectant solutions were screened initially for the various 
complexes, but ethylene glycol was found to be the most effective and therefore 
used in cryo-cooling all crystals obtained throughout this study. For crystals 
harvested from commercial screens (JCSG, PACT, Classics or pH screen (Jena 
Biosciences)), 0.5 μL of reservoir solution was added directly to the crystallisation 
drop to aid in the recovery of crystals for freezing using appropriately sized nylon 
or grid loops. 
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Otherwise, a cryoprotectant solution was made up using the components of 
the reservoir solution and 20% (w/v) ethylene glycol where 5 μL drops were placed 
onto 22 mm circular cover slip. Crystals were taken from their drops and soaked in 
the cryoprotectant for 10-30 seconds by depositing the crystal into the solution, then 
rapidly recovered into a loop and flash frozen in liquid nitrogen. Crystals were 
stored in liquid nitrogen until transported to a synchrotron X-ray source. 
 
 
3.2.4.5. Collection and Processing of Macromolecular Diffraction 
 
The diffraction data were collected at the Diamond Light Source 
synchrotron. Following data collection autoindexing, data integration, scaling and 
merging were performed using the XDS Suite (Kabsch, 2009). MR for the dataset of 
the Xrn1 monomer, KSHV WT monomer, SOX 244 monomer, SOX 244 dimer 
were conducted using Phaser (McCoy et al., 2007) as part of the CCP4 GUI (Winn 
et al., 2011) , using the deposited co-ordinates of apo Xrn1 (PDB ID: 3pie) (Chang 
et al., 2011), of SOX WT with dsDNA (PDB ID: 3pov) (Bagneris et al., 2011) and 
the apo X-ray crystal structure of SOX WT (PDB ID: 3fhd) (Dahlroth et al., 2009). 
Refinement was performed using Buster (Bricogne, 1993, Bricogne, 1997) and 
Phenix (Adams et al., 2010) and Coot (Emsley et al., 2010) was used for manual re-
building. 
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Chapter	  4:	  Computational	  Analysis	  of	  the	  UGAAG	  Motif	  and	  SOX	  and	  RNA	  
Interaction	  
4.  
The computational work was undertaken to investigate the discovery of the 
Glaunsinger group that a UGAAG motif was found in the vicinity of the  
endonucleolytic cleavage sites of SOX and the apparent need for this sequence to be 
encompassed within a 25 to 201 nucleotide stretch. Initial indications seemed to 
suggest both sequence and structural components were important to RNA 
processing (Gaglia and Glaunsinger, 2010, Covarrubias et al., 2011). Towards 
investigating these two elements, it was first established whether this sequence was 
over or underrepresented in the host and viral genomes, using the program compseq 
from the EMBOSS software suite. This analysis was performed to ascertain how 
prevalent this motif is in human mRNA transcripts and to establish the extent to 
which KSHV transcripts would also be susceptible to SOX cleavage. The human 
interleukin-6 (IL-6) gene, known to evade SOX mediated degradation, was 
specifically analysed for the presence of UGAAG motifs (Hutin et al., 2013, 
Chandriani and Ganem, 2007). To address the issue of structured elements being 
key to RNA processing, sequences of the known SOX targets were sequence 
aligned and analysed for their propensity to fold into secondary and tertiary 
structures, on the basis of hierarchical folding and local structuring. The most 
energetically favourable of these folds was then assessed on its ability to be 
successfully fitted into the active site of SOX. To investigate the roles that the 
UGAAG motif played within the sequence, a UCUCU mutant was created. A 
shorter GFP stem loop was engineered for crystallography purposes. These were 
also subjected to folding and analysis.  
 
 
4.1. Distribution of UGAAG Motif in Genomes 
 
4.1.1. Representation of UGAAG in Host and Viral Genomes 
 
The web server compseq (Williams, 2001) was used to calculate the 
observed frequency of the UGAAG and GAAGU motifs as well as the expected 
frequency based on the nucleotide content of the submitted genome sequences in 
the Homo sapiens mRNA Reference Sequence (RefSeq) and KSHV genomes 
(Table 4-1). This means that the program uses the frequency of the each nucleotide 
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in the original sequence to then calculate the likely hood of a motif made up of 5 
nucleotides. The observed frequency of UGAAG in the Homo sapiens mRNA 
RefSeq set was ~1.93 times higher than expected (expected = 0. 0010486; observed 
= 0. 0020203). Thus the UGAAG motif appears to be nearly two-fold 
overrepresented in the human genome in the 5’ to 3’ direction. The frequency of the 
UGAAG motif in reverse (i.e. GAAGU) was 1.15 times more frequent than 
expected (expected = 0. 0010486; observed = 0. 0012062). In light of the 
suggestion that SOX targets this sequence motif, one might expect its frequency to 
be lower in the viral genome KSHV. Indeed, UGAAG is only 1.07 times more 
frequent than expected in the viral genome, and the GAAGU motif is 0.76 times 
less frequent than expected. Hence, when looking at the ratio of observed/expected 
(Table 4-1), it can be concluded that overall the UGAAG and GAAGU are 
overrepresented in the Homo sapiens genome and less well represented in the 
KSHV genome, as would be expected for their genomic content.  
 
Table 4-1: Observed versus Expected Frequency of UGAAG and GAAGU 
Motif in Homo sapiens and KSHV Genomes 
 
Genome Motif Observed Frequency 
Expected 
Frequency 
Observed / 
Expected 
Homo sapiens, mRNA RefSeq 
 UGAAG 0.0020203 0.0010486 1.9267378 
 GAAGU 0.0012062  0.0010486  1.1503152 
KSHV, complete genome (NC_009333.1) 
 UGAAG 0.0009060 0.0008501 1.0657304 
 GAAGU 0.0006451 0.0008501 0.7588000 
 
 
The difference in frequencies may explain partly why this motif has been 
selected as a target for endonucleolytic cleavage. But the lone ratio of expected to 
observed occurrence, does not necessarily represent the actual occurrence of the 
motif between the two genomes; viral and host. For this, the observed frequency of 
the UGAAG and GAAGU motifs were compared between Homo sapiens and 
KSHV. As these frequencies are the result of a ratio of observed counts over total 
counts of pentameric sequences, they represent the relative frequency within the 
genome, thus allowing the comparison of frequency between the two species. From 
this it can be observed that the UGAAG motif is present 2.23 times more often in 
the host genome than the viral genome (Table 4-2). Further, the GAAGU motif is 
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1.87 times more often present in the host RNAs then in the viral one.  
 
Table 4-2: UGAAG and GAAGU overrepresentation within the Homo sapiens 
Genomes compared to the KSHV Genomes 
 
Motif ObsV/ObsH  
UGAAG 2.23 
GAAGU 1.87 
 
 
4.1.2. UGAAG and the IL-6 mRNA 
 
It has long been known that the interleukin-6 (IL-6) mRNA transcript 
evades turnover in KSHV infected cells and that KSHV also has its own viral 
version of IL-6; vIL-6 (Hutin et al., 2013, Rezaee et al., 2006). A recent paper 
(Hutin et al., 2013), has demonstrated that IL-6 contains a SRE1 in its 3’UTR. This 
SRE1 contains a non-canonical ARE.  
 
>gi|224831235|ref|NM_000600.3| Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA 
AAUAUUAGAGUCUCAACCCCCAAUAAAUAUAGGACUGGAGAUGUCUGAGGCUCAUU
CUGCCCUCGAGCCCACCGGGAACGAAAGAGAAGCUCUAUCUCCCCUCCAGGAGCCCA
GCUAUGAACUCCUUCUCCACAAGCGCCUUCGGUCCAGUUGCCUUCUCCCUGGGGCUG
CUCCUGGUGUUGCCUGCUGCCUUCCCUGCCCCAGUACCCCCAGGAGAAGAUUCCAAA
GAUGUAGCCGCCCCACACAGACAGCCACUCACCUCUUCAGAACGAAUUGACAAACAA
AUUCGGUACAUCCUCGACGGCAUCUCAGCCCUGAGAAAGGAGACAUGUAACAAGAGU
AACAUGUGUGAAAGCAGCAAAGAGGCACUGGCAGAAAACAACCUGAACCUUCCAAAG
AUGGCUGAAAAAGAUGGAUGCUUCCAAUCUGGAUUCAAUGAGGAGACUUGCCUGGU
GAAAAUCAUCACUGGUCUUUUGGAGUUUGAGGUAUACCUAGAGUACCUCCAGAACA
GAUUUGAGAGUAGUGAGGAACAAGCCAGAGCUGUGCAGAUGAGUACAAAAGUCCUG
AUCCAGUUCCUGCAGAAAAAGGCAAAGAAUCUAGAUGCAAUAACCACCCCUGACCCA
ACCACAAAUGCCAGCCUGCUGACGAAGCUGCAGGCACAGAACCAGUGGCUGCAGGAC
AUGACAACUCAUCUCAUUCUGCGCAGCUUUAAGGAGUUCCUGCAGUCCAGCCUGAGG
GCUCUUCGGCAAAUGUAGCAUGGGCACCUCAGAUUGUUGUUGUUAAUGGGCAUUCC
UUCUUCUGGUCAGAAACCUGUCCACUGGGCACAGAACUUAUGUUGUUCUCUAUGGAG
AACUAAAAGUAUGAGCGUUAGGACACUAUUUUAAUUAUUUUUAAUUUAUUAAUAUU
UAAAUAUGUGAAGCUGAGUUAAUUUAUGUAAGUCAUAUUUAUAUUUUUAAGAAGU
ACCACUUGAAACAUUUUAUGUAUUAGUUUUGAAAUAAUAAUGGAAAGUGGCUAUGC
AGUUUGAAUAUCCUUUGUUUCAGAGCCAGAUCAUUUCUUGGAAAGUGUAGGCUUAC
CUCAAAUAAAUGGCUAACUUAUACAUAUUUUUAAAGAAAUAUUUAUAUUGUAUUUA
UAUAAUGUAUAAAUGGUUUUUAUACCAAUAAAUGGCAUUUUAAAAAAUUCAGCAAA
AAAAAAAAAAAAAAAA	  
 
Figure 4-1: IL-6 mRNA with 3’UTR SRE1, containing ARE, UGAAG and 
GAAGU Motif 
 
The full mRNA sequence for IL-6. The 5’and 3’UTR are in black the protein-coding 
region is in grey. Within the 3’UTR the core ARE motifs AUUUA, which are bound 
by AUF1 and HuR, are highlighted in yellow and bold. The UGAAG and GAAGU 
motifs are found within the ARE, both highlighted in cyan and bold.  
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 Although Hutin et al. (Hutin et al., 2013) demonstrated that the protection 
of IL-6 from SOX mediated decay was observed, when AUF1 and HuR were 
silenced using siRNA (Hutin et al., 2013), analysis of the gene reveals one 5’-
UGAAG-3’ and one 5’-GAAGU-3’ motif in the 3’UTR embedded within the ARE 
region (Figure 4-1). This suggests that the SOX cleavage sites are obscured when 
the IL-6 mRNA ARE sites are sequestered by the HuR and AUF1 complexes.  
Further verification, however, would require the in vivo analysis of IL-6 transcripts 
containing mutations within the UGAAG and GAAGU motifs. 
 
4.2. In silico RNA Folding and SOX-RNA Interaction Modelling  
 
4.2.1. In silico Folding of the UGAAG Target Constructs  
 
To investigate whether the three identified sequences had also other 
characteristics and motifs in common, they were aligned using T-coffee and MView. 
To explore whether cleavage after the consensus sequence was structure dependent, 
in silico folding was performed first on the entire sequence of the mRNA. This 
folding yielded 13 to 46 solutions for the full-length mRNAs. The number of 
solutions increased with the sequence length. For each construct a local secondary 
structure around the UGAAG site was identified. For the GFP sequence the same 
secondary structure centred on the UGAAG motif was identified in 10 out of the 13 
solution folds for the full-length sequence; with the main solution being dominant 
in the population corresponding to the low energy folds. The HBB full-length 
mRNA folding yielded 14 solutions. Within these 14 solutions the same fold was 
identified 10 times around the UGAAG motif, again these folds populated the lower 
energy fold solution. In contrast, for the DsRed2 the highest repeat of the same 
local fold around the UGAAG motif was 5 times out of 39 solutions for the full-
length sequence. When a stable substructure was identified, the sequence was cut to 
a 201 nucleotides sequence encompassing the UGAAG motif, as experiments 
suggested that 201 nucleotides were sufficient to maintain the structure. This 
reduced sequence also showed a preference for the same fold. Using several cycles 
of mfold on the identified sequences allowed us to cut down the RNA sequence to a 
minimal nucleotide length, while maintaining the structure originally observed in 
the full length mRNA. This minimal sequence was also needed to comply with the 
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current limitations in RNA synthesis, which are firstly sequence length, quantity 
and cost. 
 
 
4.2.2. Comparison of the β-globin, DsRed2 and GFP RNA Sequence 
and Folds 
 
When the three sequences were aligned with MView and T-coffee web server 
tools it became appeared that these three sequences shared more than just the 
UGAAG motif. As can be seen in figure 4-2 D, when HBB, GFP and DsRed2 are 
aligned along the UGAAG motif without gaps, the sequence contains a GRYG—
RYY---RR-R--CY-A---UGAAG motif upstream of the cleavage site, which 
contains 12 conserved purines and 6 conserved pyrimidines. When aligned using T-
coffee along the UGAAG motif, but allowing for gaps (Figure 4-2 E), 15 strictly 
conserved nucleotides are purines and 5 were pyrimidines. The nucleotides that 
conserved between DsRed2 and GFP of the sequences are made up of 15 purines 
and 9 pyrimidines in the upstream region of the UGAAG motif. Taken together 
these alignments suggest that conservation of purines is an additional sequence 
characteristic in connection with the UGAAG motif. 
 
The fold of the GFP, HBB and DsRed2 mRNA was investigated. From this 
folding it could be deduced that all 3 sequences had only two characteristics in 
common. Firstly the presence of the UGAAG motif in a stem loop and secondly the 
fact that in all three, the two guanines were always involved in base pairing (See 
secondary structure prediction Figure 4-2 A, B and C). The secondary structure 
prediction (Figure 4-2) agreed with the sequencing results from the Glaunsinger 
Group (Covarrubias et al., 2011), with the cleavage site located towards 
loops/bulges. The cleavage site for the GFP stem loop was found in the upper loop 
bulge (Figure 4-2 C). As the secondary structure prediction for the GFP RNA was 
the most stable and it had the most supporting data in the context of SOX induced 
degradation (Covarrubias et al., 2011), it was subsequently the focus of our 
investigation. 
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Figure 4-2: Comparison of HBB, DsRed2 and GFP Stem Loops Features 
 
The folded RNA in A) is the stem loop of HBB, in B) the stem loop for DsRed2 and in 
C) the stem loop for GFP. The UGAAG motif for each of these is shown in a green box 
and the cleavage site is indicated with a orange arrow.  D) T-coffee aligement of HBB, 
GFP and DsRed2 69 nucleotide seqeunces along the central UGAAG motif without 
gaps. E) MView aligment of the same sequences allowing for gaps. 
 
 
4.2.3. 3D Structure Prediction of the GFP Stem Loop Fits in Active 
Site  
 
An ensemble of 250 SOX conformations was generated from the native wild 
type structure 3fhd using the distance constraints-based method within 
tCONCOORD (Seeliger and DeGroot, 2009). This allowed visualising the 
flexibility of SOX. As it can be seen from the figure 4-3 A, SOX has high flexibility 
in the loop regions, which could be expected. In addition it can be seen that SOX 
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presence a high variability in the N-terminal and C-terminal region. The variability 
of the N-terminal was also seen in the many solved x-ray crystal structures obtain 
during this PhD.	  	  
 
A 
 
 
B Right                                       Front                                           Left 
 
 
Figure 4-3: Exploration of Conformational Space of the RNA Stem Loop and 
SOX 
 
A) tCONCOORD-generated conformers from a native wild type SOX structure 
(PDB: 3fhd). Eight selected conformers depicting the extent to which structural 
variation was simulated. B) Selected GFP 51 nucleotides stem loop structures from 
the 114 samples fitted into the active site of SOX, showing varying degrees of 
curvature. 
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The 3D structure of the GFP stem loop containing the UGAAG motif was 
predicted using Mc-Fold|-Mc-Sym (Figure 4-3 B and 4-4 B-C). The resultant 
structures were then fitted using the Chimera Suite into a map of the double 
stranded DNA of the SOX PDB structure (PDB ID: 3pov), which was co-
crystallised with double stranded DNA. 
 
 
 
 
Figure 4-4: Predicted 3D Structure Fits into the Active Site of SOX 
 
A) The 2D secondary structure prediction for the 51 nucleotides GFP stem loop. B) 
MC-Fold | MC-Sym 3D structure prediction of the 51 nucleotides GFP sequence. 
The UGAAG sequence is highlighted in light green. C) The 3D 51 nucleotides GFP 
RNA structure fitted into the PDB structure of the SOX-DNA complex (PDB ID: 
3pov). Highlighted in light green is the UGAAG motif, the N-terminus is in dark 
green (containing HSO residues T24 and A61), the C-terminus in blue (containing 
HSO residues D474 and Y477Stop) and the NLS loop in orange, with arginines and 
lysines in red. The active site residues are highlighted in black (D221 and E244) 
and these are typically involved in RNA and DNA turnover.  
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The 114 solutions for the GFP sequence showed varying degree of curvature 
and also fitted with more or fewer atomic clashes into the active site (Figure 4-4 A). 
The solution that best fitted is shown in figure 4-4 D. The RNA followed the 
straight pattern of the DNA, with the UGAAG pattern facing the NCL residues 
315–320. This protein sub-sequence contains a number of lysines and arginines 
(Figure 4-4 D). 
 
 
4.2.4. Mutagenesis and Engineering 
 
To investigate the role that the UGAAG motif played in the recognition and 
cleavage motif was substituted with UCUCU. The UCUCU was chosen as this 
sequence was pyrimidine rich versus the purine rich UGAAG. This mutated GFP 
UCUCU sequence showed two alternative folds when folded in silico using mfold. 
These did not maintain the same overall structure as the wild type GFP (Figure 4-5 
A and B). But in both folds one or two stem loops are formed. In the fold in figure 
4-5 A and B UGA is found just before the top loop forms, followed by GAA 
upstream, which again is reminiscent of the wild-type structure and purine rich 
neighbourhood (Figure 4-2 C). The loop downstream of then UGA is bigger and 
thus presents more free base pairs. 
 
A           B 
 
 
Figure 4-5: Effects of the UCUCU Mutation on the GFP Stem Loop Sequence 
 
The UCUCU mutation did not maintain the same structure as the 51 nucleotides wild type 
GFP Stem Loop and presented 2 alternative folds, A) and B) .  
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A shorter version of the 51 nucleotides GFP sequence containing the 
UGAAG motif was engineered. This version was 23 nucleotides long and contained 
an introduced 2 GC base pairs at the bottom of the stem loop to stabilize the 
structure and an adenine overlap at the bottom, which had been reported to help 
with crystallisation (Hoggan et al., 2003) (Figure 4-6). This shorter version was 
later used in crystallisation trials. 
 
 
 
Figure 4-6: Maintained Stem Loop Structure of 
the Engineered 23 nucleotides GFP Sequence 
 
The 23 nucleotides version of the GFP stem loop 
maintained the characteristic fold. 
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Chapter 5: Biochemical and Biophysical Characterisation of SOX, Xrn1 and 
RNA Interaction 
5.  
5.1. SOX WT binds Xrn1  
 
The Xrn1 and SOX proteins, wild type and mutants, used in the biochemical 
and biophysical experiments were all recombinantly produced and purified to a high 
level of purity; Xrn1 was purified to a lesser degree (See Appendix D and E for 
more details). 
 
 
5.1.1. Pull Down Assay of Xrn1 and SOX WT 
 
Despite SOX’s intrinsic endo/exonuclease activities, the rapid and global decay 
of host mRNA transcripts observed cannot be accounted for on the basis of these 
activities alone (Covarrubias et al., 2011, Kronstad and Glaunsinger, 2012). Whilst 
Xrn1 has been shown to be involved in this pathway in other viruses, the nature of 
its involvement in KSHV infection is unclear (Gaglia et al., 2012). Collaborators, 
however, were able to demonstrate a physical interaction between the N-terminal 
region of Xrn1 and SOX using a yeast two-hybrid system (Ebrahimi, B.; 
unpublished work) consistent with the N-terminal region of Xrn1 being highly 
conserved and predicted to be involved in protein-protein interaction. This 
interaction was therefore tested in vitro using a pull down assay. His-tagged K. 
lactis Xrn1 preincubated with untagged SOX was applied to a HisTrap column. 
Both proteins co-eluted following the application of an imidazole gradient (Figure 
5-1) confirming that they are indeed capable of forming a complex in vitro. The 
controls of SOX and Xrn1 on their own were also performed to exclude non-
specific binding to the column. To further validate this interaction, MST 
experiments were undertaken (Figure 5-2). 
 
Having shown that SOX and Xrn1 physically interact, the effects of this 
association on formation of the SOX 51 nucleotides GFP RNA complex and SOX’s 
turnover ability in presence of Xrn1 were subsequently investigated (Figure 5-3 and 
Figure 5-5 respectively).  
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Figure 5-1: Pull Down of Xrn1 and SOX 
 
With the increasing imidazole concentration increased protein bands for Xrn1 and 
SOX became visible; increasing and decreasing stoichiometrically. 
 
 
5.1.2. Xrn1 and SOX WT bind with μM Kd 	  
To further validate the predicted and experimentally demonstrated 
interaction between Xrn1 and SOX, MST was used. The binding data for the SOX 
and Xrn1 interaction showed the characteristic sigmoidal binding curve that was 
fitted with the nonlinear solution of the law of mass action, giving a Kd of 0.865 μM 
(Figure 5-2). 
 
 	  
	  	  	  
Figure	  5-­2:	  Microscale	  Thermophoresis	  Binding	  Curve	  of	  Xrn1	  and	  SOX	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5.2. SOX Binds UGAAG Stem Loop Structures 
 
Based on the TBE gel shift protocol from (Bagneris et al., 2011) preliminary gel 
shifts with  the 51 nucleotides GFP RNA were undertaken to test the prediction 
from the in silico folding studies. Due to recurrent issues in co-crystallisation of 
SOX and the RNA stem loop and suggestions from the literature, that pHs below 
the proteins pI and lower pHs were favourable for binding and RNA stabilisation, a 
range of pHs were tested. It was also noted that SOX’s endonuclease activity would 
potentially be inhibited by a lower pH, as it is known as the alkaline exonuclease 
(Bujnicki and Rychlewski, 2001). Salt concentrations are also known to affect 
binding and as most crystallisation solution contain salts in sometimes very high 
concentrations, salt concentrations were also screened (Lohman, 1986). These gels 
helped to establish conditions for crystallisation trials that would increase the RNA 
stability and the protein-RNA complex (See Appendix F, Figure F-1). From here 
on, the crystallisation and TBE gel buffers contained 100 mM NaCl and a pH 7 
(known as buffer TBE C). 
Having established the optimal conditions for binding using the 51 
nucleotides GFP RNA, the ability of SOX to associate with the UGAAG containing 
stem loop structures identified in silico were next investigated. SOX WT also binds 
the 58 nucleotides HBB RNA (Figure 5-3 D). Interestingly, the different complexes 
show different stabilities. The tightest bands and thus the most stable complexes are 
formed between the WT SOX and the 51 nucleotides GFP RNA (Figure 5-3).  
 
Xrn1 does not bind the stem loop. When WT SOX and Xrn1 are present 
together a major band for SOX binding the stem loop is visible and a smaller higher 
molecular weight band is also forming; the latter could be a complex of SOX, Xrn1 
and RNA (Figure 5-3 B). These gels were also stained for with Instant Blue, the 
sites of RNA shifts corresponded to sites stained for protein by the Instant Blue. 
However titration experiments with Xrn1 should be undertaken to enhance the band 
thought to contain Xrn1-SOX-RNA band. 
 
It was then established whether the mutants identified as having a profound 
effect on HSO (Goldstein and Weller, 2004, Glaunsinger et al., 2005) were 
defective in their ability to associate with 51 nucleotides GFP RNA (Figure 5-3 A).  
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Figure 5-3: TBE Gel Shift of SOX and RNA Binding 
 
A) Representation of SOX, with the active site residues highlighted in black (D221 
and D244) and the C-terminal residues involved in HSO in blue (R462, D474 and 
Y477Stop). B) In the SOX control lane no fluorescence was detected and at the RNA 
control lane fluorescence was detected at the bottom of the gel. It can be observed 
that bands are narrower for the 51 nucleotides GFP RNA complex and less defined 
for the HSO mutants; n=3. C) The active site mutants are not affecting the binding 
ability of SOX to the 51 nucleotides GFP RNA; n=3. D) Whereas the bands for the 
58 nucleotides HBB RNA appear broader, thus indicating a less stable complex. 
This was an individual experiment; n=2.  
 
 
Whilst the catalytic mutants D221S and E244S appear to be completely 
unperturbed in their capacity to associate with the 51 nucleotides GFP RNA as 
would be expected (Figure 5-3 C), D474N and Y477 are significantly disrupted. 
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These two mutants are well known HSO mutants. Whilst D474N has significantly 
reduced affinity for the 51 nucleotides GFP RNA compared to WT, the Y477stop 
shifted is highly smeared suggestive of an inability to form a stable complex (Figure 
5-3 B). Interestingly, both D474 and Y477 are located on the C-terminal helix at the 
bottom of the active site. This region contains a number of lysine and arginine 
residues consistent with an additional nucleotides binding site (Figure 5-3 A). To 
further investigate the role of this region in RNA stem loop recognition, R462, a 
residue in the C-terminal helix was mutated to alanine and its capacity to bind the 
51 nucleotides GFP RNA tested. This revealed that R462A does affect RNA stem 
loop binding and that potentially a greater part of the C-terminal helix is involved in 
binding. 
 
 
5.3. SOX has Enhanced Affinity for UGAAG Stem Loop Structures  
 
Previous research had shown that SOX’s was able to bind double stranded 
DNA, single stranded and double stranded RNA using FA (Bagneris et al., 2011).  
 
 
A B	  
 
	  	  	  
Substrate Kd in μM 
ds-DNA 12.0 
ds-DNA-5’P 6.0 
GFP 51  4.6 
 
 
Figure 5-4: Fluorescence Anisotropy Binding Assay of SOX Involving the 51 
Nucleotides RNA Stem Loop 
 
A) The binding curve of SOX for 51 nucleotide RNA stem loop and for ds-DNA, the 
later was obtained by Dr. Bagneris and published in Bagneris et al., 2011. B) The 
Kd’s obtained for the 51 nucleotide stem loop and those reported for ds-DNA and 
ds-DNA-5’P in Bagneris et al., 2011.  
 
To establish its affinity for the 51 nucleotides GFP RNA stem loop, similar 
studies were performed, as FA is superior to EMSA quantitatively. As for the 
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EMSA experiments titration with non-specific and unlabelled RNA should be 
undertaken to exclude non-specific binding. These experiments reveal that SOX had 
a similar affinity for the stem loop as for ds-DNA-5’P and ds-DNA (Figure 5-4) 
(See figure 1-2 B for sequences). The measured Kd of 4.6 μM was more consistent 
with the Kd observed for ds-DNA-5’P (6 μM) and was ~20 fold greater compared to 
ss-RNA-5’P and ds-RNA-5’P (See Bagneris et al., 2011). 
 
 
5.4. SOX Turns Over RNAs  
 
Having ascertained that SOX was able to bind to the stem loop structures 
identified, it was next established whether the 51 nucleotides GFP RNA was a 
target for endonucleolytic cleavage. Once cleavage had been confirmed (Figure 5-
5), RNA turnover conditions were ascertained since it could not be assumed that 
they would be consistent with those determined for ss-RNA-5’P. In order to 
ascertain the optimal conditions for RNA cleavage and additionally with a view to 
its inhibition for structural studies, different salt concentrations and lower pHs were 
investigated. It was found that higher pHs and lower salt concentrations favoured 
turnover. Based on these results and the previous experimental protocol used by Dr. 
Bagneris, all subsequent cleavage assays were performed using the condition 50 
mM Tris–HCl pH 9, 200 mM NaCl, 20 mM β-mercaptoethanol, 10 mM MgCl2 
(Buffer TBE’ St.) for these gels. Lower pH and higher NaCl concentrations were 
shown to inhibit the activity of SOX, which then lead to lower pHs being used in 
the crystallisation trials. 
 
 
5.4.1. SOX WT Turnover of HBB and GFP RNA 
 
SOX turns over the 51 nucleotides GFP and 58 nucleotides HBB RNA 
(Figure 5-5 A). Although HBB RNA appears to be more susceptible to degradation 
than the 51 nucleotides GFP RNA in the absence of SOX, the reduction in intensity 
of the highest molecular weight band nonetheless suggests that it also is a substrate 
(Figure 5-5 B). The UCUCU mutant GFP RNA is also turned over by SOX (Figure 
5-5 C). SOX has an intrinsic RNA endonuclease activity and RNA exonuclease 
activity. The later relies on a 5’ phosphate for activity and all oligonucleotides were 
synthesised so not to include a 5’phosphate and with the FAM label on the 3’ end. 
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Figure 5-5: TBE-Urea of SOX and RNA Binding  
 
In this figure the RNase activity of SOX can be seen for (A) 51 nucleotides GFP (B) 
the 58 nucleotides HBB and (C) the 51 nucleotides UCUCU mutant RNA. The RNA 
contained no 5’ phosphate, thus the cleavage had to be induced via endonucleolytic 
cleavage by SOX, followed by exonucleolytic cleavage by SOX’s exonuclease 
activity. Though these gels cannot be absolutely conclusive it can be seen that in the 
third lane when SOX is present the RNA on the top and bottom of the gel 
diminished; n=3. 
 
 
5.4.2. SOX HSO Mutants Abrogate or Decrease Turnover of GFP 
RNA  
 
SOX WT turns over the RNA stem loop, while Xrn1 by itself is not able to 
turnover the stem loop RNA. The turnover of the 51 nucleotides GFP RNA by SOX 
appears to be attenuated in the presence of Xrn1 (Figure 5-6). This could indicate 
that either Xrn1 occludes the active site of SOX, or that Xrn1 catalysed cleavage 
involves re-modelling of the cleaved 51 nucleotides GFP RNA substrate facilitated 
by conformation re-arrangement in one or both proteins for handover. This could 
also be the indication of the possible participation of an additional co-factor (Uetz et 
al., 2006). As the optimal conditions for Xrn1 activity only strongly differ in the 
NaCl concentration from 50 mM to 200 mM NaCl, otherwise the MgCl2, pH 8.0 
and reducing agent concentration were comparable (Chang et al., 2011), it is 
possible, but unlikely that the experimental condition interfered with Xrn1’s 
activity. 
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A 
 
B 
 
SOX Mutants Impact on Activity 
A61T Abrogates HSO in vivo 
D221 Abrogates DNA and RNA Catalysis in vivo and in vitro 
E244S Abrogates DNA and RNA Catalysis in vivo and in vitro 
Y373A DNA contact based of Crystal Structure 3pov 
H450A C-terminal Mutant hypothesized to impact RNA binding 
R451A C-terminal Mutant hypothesized to impact RNA binding 
N458A C-terminal Mutant hypothesized to impact RNA binding 
R462A C-terminal Mutant hypothesized to impact RNA binding 
D474N Abrogates HSO in vivo 
Y477Stop Abrogates HSO in vivo 
  
C 
 
 
Figure 5-6: Impact of HSO Mutations and C-terminal Helix Mutation on SOX 
Endonucleolytic Activity 
 
The location of the various mutations (A), the documented effect of the mutants (B) 
and the effects of these on RNA stem loop degradation (C) are shown in this figure. 
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The mutants A61T and Y373A both show the least attenuation in RNase 
activity, A61T is a known HSO mutant, while Y373A is a DNA contact mutant (on 
the basis on the crystal structure PDB ID: 3pov). The mutants D221A, E244S, 
R462A, D474N and Y477Stop inhibited SOX RNase activity. D221A and E244S 
are catalytic mutants, while D474N and Y477Stop are known to be important for 
HSO and RNase activity. Y477Stop is a C-terminal truncation. Further mutants 
were created along the C-terminal helix, which contains the HSO mutants D474N 
and Y477Stop and is situated at the bottom of the active site. R462A found closer to 
the known HSO mutants D474N and Y477Stop shows as strong an inhibition of 
RNase activity as D474N. While N458A and R451A do not appear to have an 
impact on the RNase activity, H450A has a more marked impact on RNase activity. 
This indicates that different areas of the SOX protein participate in the 
endonucleolytic cleavage mechanism, such as certain residues in the C-terminal 
loop associated with HSO and newly identified residues in the two C-terminal 
helices (H450 and R462).  
 
 
5.5. Crystallization 
 
5.5.1. SOX and Xrn1 
 
As SOX and Xrn1 were shown to interact (See Section 5.1), crystallisation 
trials were undertaken. Despite crystals growing overnight in several conditions, the 
typical morphology is shown in figure 5-7 A and B. All crystals, however, 
diffracted only to ~ 6 Å (Figure 5-7 C), which is just within the limitations for MR. 
Once the data was collected and analysed, no complex was observed, and only the 
presence of Xrn1 monomers could be observed. Other crystals grown from the 
complex conditions, but of different morphology, were found to contain SOX 
monomers. 
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A C  
 
 
B 
 
 
Figure 5-7: Crystal obtained when setting up with Xrn1 and SOX  
 
A crystal of Xrn1 and SOX, A) and B), from the following condition 0.1 M Na/-
thiocyanate and 20 % PEG 3350 diffracted to 5.87 Å C). 
 
 
5.5.2. SOX, 51 nucleotides Structured RNA and Other RNAs 
 
Crystals were obtained in many conditions when set up with SOX WT and 
SOX 244 in complex with 51 nucleotides GFP, 23 nucleotides GFP and the 58 
nucleotides HBB RNA oligonucleotides. However, only several apo structures of 
SOX WT and SOX 244 were obtained. All of these contained a single SOX 
molecule in the asymmetric unit whose active site was occluded by neighbouring 
molecules in the crystal lattice. By contrast, crystals grown from 150 mM Malic 
Acid (pH 7) and 20% Peg 3350, using the low salt and low pH crystallisation 
buffer, revealed two SOX monomers in the asymmetric unit (Table 5-1). Following 
MR that confirmed the asymmetric unit composition, it could be seen that the active 
sites of the KSHV monomers were no longer obstructed and able to accommodate 
the stem loop. Furthermore, in the Fo-Fc difference density map (Figure 5-8), a 
density could be observed in the active site region consistent in size with RNA 
nucleotides. Attempts were made to fit either nucleotides or an RNA stem loop into 
the density followed by refinement.  However, subsequent 2Fo-Fc maps failed to  
110	  
 
 
 
Figure 5-8: Dimer Crystal Structure of SOX 244  
 
A) Fo-Fc map (green) is visible within the active site of the protein SOX 244 dimer 
with the catalytic residues D221 and E244 highlighted. B) Fo-Fc map (green) is 
visible at the N-terminus with residues that do not fit the map highlighted. C) SOX 
244 after refinement with absent Fo-Fc map in the N-terminus and active site. 
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show any convincing density when contoured above 1σ. The original difference 
density could therefore have either originated from the solvent, though this seems to 
be unlikely based on its size and shape or be due to partially occupied/highly 
mobile nucleotides. The N-terminal loop of SOX had a conformation that was 
similar to the N-terminal conformation observed previously in the apo structure 
(PDB ID: 3fhd) and thus differed from the conformation seen in then dsDNA bound 
structure (PDB ID: 3pov). On the basis of these results, a 23 nucleotides stem loop 
comprising nucleotides 16 to 34 was engineered for co-crystallisation. It was again 
possible to produce crystals, but these did not contain any ligand bound structures. 	  	  
Table 5-1: X-ray Data Collection and Processing Statistics for SOX 244 Dimer 
 
Space group P 1 21 1 
Cell dimensions (Å, °) a=62.7, b=78.3, c=111.3, 
β = 98.6 
Resolution (Å) 48.59 – 2.96 (3.1-2.96) 
No. of reflections Total 66491 
Unique 22013  
Rmerge  0.17(0.42) 
Completeness  (%) 98.6 (96.6) 
Multiplicity 3.3 
(I/σ(I))  8.26 (2.98) 
R-cryst (%) 22.6 
Rfree (%) 29.9 
 
 
After the computational analysis of the UGAAG containing RNA sequences 
it was possible to determine experimentally using EMSA and FA that SOX binds 
the RNA stem loops with similar affinity to ds-DNA. SOX  is able to induce 
cleavage of the RNA stem loop. Additionally it was demonstrating that the HSO 
mutants D474N and Y477Stop and R462A affect binding and turnover of the RNA 
stem loop by SOX.  Using a pull down assay and microscale electrophoresis it was 
demonstrated that SOX and Xrn1 interact directly. And finally a crystal structure of 
SOX containing the E244S mutation was obtained. 
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Chapter 6: Discussion, Conclusion and Future Work 
6.  
6.1. Discussion 
 
To conquer the cell and its RNA and protein expression machinery, viruses have 
to tap into the regulatory clockwork of the cells that they target (Kronstad and 
Glaunsinger, 2012, Abelson, 1979, Walsh and Mohr, 2011). This regulation occurs 
at the RNA, DNA and protein level. For this the viruses have copied host protein 
coding genes and DNA regulatory elements, adjusted to fit their purposes and 
timing. The DNA and protein level of regulation had been focused upon for many 
years, but with the recent breakthroughs in the RNA field the key role that RNA 
plays in regulating the cell has been shown; via the discovery of RNA and cis, 
trans, stability and degradation regulating RNA elements (Licatalosi and Darnell, 
2010). As more host RNA regulatory mechanisms are elucidated and more viral 
mechanisms are discovered that work on the RNA level, it might help to elucidate 
how viruses with their limited genomes are able to so fundamentally change the fate 
of a cell (Kronstad and Glaunsinger, 2012, Walsh and Mohr, 2011). It is important 
to know how KSHV takes over the host degradation machinery during the lytic 
cycle to facilitate viral proliferation and evasion from the immune system. 
 
The Ganem group first established that the onset of the lytic phase was 
accompanied by the rapid and global degradation of host mRNA transcripts and that 
this also correlated with the expression of SOX (Glaunsinger and Ganem, 2004b, 
Glaunsinger et al., 2005, Glaunsinger and Ganem, 2006). The Glaunsinger group 
described the presence of an UGAAG motif in the vicinity of the cleavage sites of 
mRNA transcripts that were targeted by SOX (Covarrubias et al., 2011). If SOX 
was targeting this pentameric sequence, a reasonable expectation would be for the 
motif to be over-represented in human transcripts whilst under-represented in those 
originating from KSHV. To investigate this, the ratio of observed over expected 
frequency of the UGAAG and GAAGU in the host genome was calculated and 
found to be 1.93 and 1.15 respectively (Table 4-1, Section 4.1.1). UGAAG thus 
occurs twice as frequently than would be expected at random given the nucleotide 
content of the host transcriptome, whilst the GAAGU has a slight increase in 
occurrence compared to expected values. By contrast, UGAAG in the viral genome 
has an observed to expected ratio of 1.07 consistent with random occurrence 
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whereas GAAGU appears less frequently (0.76) (Table 4-1, Section 4.1.1). The 
KSHV sequence that was used was the KSHV genome, as it was not possible to 
retrieve 86 mainly intronless genes (Rezaee et al., 2006). However as the KSHV 
genome contains mainly intronless genes and little intergenic sequence this was 
seen as acceptable as a comparison as SOX operates in the cytoplasm and thus 
would encounter either these sequences as they are found in the genome. These 
results are consistent with the preferential degradation of the host genome observed 
but nonetheless reveal that the viral genome would still be a significant target for 
degradation. This overrepresentation that was found could also be explained by the 
presence of ESE signals in the coding regions of host mRNAs, due to the splicing 
process that the majority of host transcripts undergo. These ESE signals have 
recently been shown to be highly overrepresented in the mRNA transcripts in the 
vicinity of exon-exon junctions. ESEs are motifs that are degenerate, but contain 
GA rich sequence and have been associated with UGAAG and GAAG sequences 
(Chasin, 2007, Pertea et al., 2007, Tacke and Manley, 1995, Thomas et al., 2012). 
The binding of EJC complex on the spliced mRNA has been linked to GAAG and 
GA rich binding elements (Saulière et al., 2012). It is possible that the lack of EJC 
complex association with viral mRNAs would help the viral transcript to evade 
SOX induced degradation in addition to the lower UGAAG ratio, if SOX was to 
target host mRNAs by also binding EJC. Although frequency analysis does indicate 
that the host genome would be preferentially degraded, it does not take into account 
any possible nucleotide changes that could be occurring within the pentameric 
sequence that may be tolerated by SOX in terms of binding, similar to the GA rich 
sequences associated with binding of splicing factors, such as ESS, ESEs and EJC. 
The alignment of the three identified endonucleolytically cleaved mRNAs around 
the UGAAG motif showed that upstream of the cleavage site GA rich elements 
were present (Figure 4-2 D and E). In addition, as this ratio of observed versus 
expected on the basis of the genomes nucleotide content is not the same as observed 
overall frequency, the ratio of host observed versus viral observed frequency may 
shed light into how likely it is that SOX encounters viral or host transcripts. This 
ratio for the UGAAG motif was 2.23 and 1.87 for the GAAGU motif (Table 4-2, 
Section 4.1.1). These ratios assume that the cell would contain equal quantities of 
host and viral transcripts. In the lytic phase the viral genome is highly expressed, 
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both in terms of the number of transcripts per gene and the total number of genes 
expressed (Schumann et al., 2013).  Overexpression of SOX occurs at the beginning 
of the lytic cycle, when the viral genome is just beginning to undergo replication 
and is thus competing with host transcripts for the replication machinery. 
Preferential elimination of host transcripts at this early stage could thus be 
beneficial to the virus further down the lytic cycle. The ratio of host to viral 
transcripts in the cytosol, however, has yet to be reported. Thus it is possible that 
SOX is cleaving its own RNA, if it is not located via protein-protein interaction to 
spliced host mRNA transcripts that are transnationally competent; e.g. via 
association with EJC. It was shown that SOX targets ribosome bound and 
translationally competent mRNAs (Clyde and Glaunsinger, 2011). 
 
Several host transcripts have been identified that evade endonucleolytic 
cleavage by SOX; one of these transcripts is IL-6. IL-6, when membrane bound, has 
an anti-inflammatory effect and is known to evade degradation in several γ-
herpesvirus infections. A single UGAAG motif has been identified in the 3’UTR of 
the IL-6 gene, however, research published in 2013 (Hutin et al., 2013) also 
revealed the presence of a SRE-1 motif in this region. This sequence contains non-
canonical AREs, which play critical roles in mRNA regulation since they can be 
targeted for both degradation and stabilisation by several protein factors. 
Interestingly, studies have shown that the SRE-1 motif of IL-6 forms a complex 
with HuR and AUF1 (Figure 4-1, Section 4.1.2). This would lead to sequestration 
of the UGAAG motif in the 3’UTR and protection of IL-6 from the endonucleolytic 
activity of SOX. Consistent with this, it has been reported by the Glaunsinger group 
that deletion of AUF1 and HuR renders IL-6 transcripts susceptible to SOX induced 
degradation. These studies support the hypothesis that SOX utilises specific motifs 
to degrade the host mRNA, but also illustrates that the global and rapid degradation 
of host mRNA transcripts by SOX is complex and likely to require several host and 
viral target proteins. This is reminiscent of PMR1, which endonucleolytically 
cleaves actively translating mRNAs on polysomes (Yang and Schoenberg, 2004). 
The cleavage site on the targeted mRNAs was between the UG dinucleotides of two 
overlapping repeats of AYUGA, which needs not to be base paired and be part of a 
loop in a stem-loop structure (Chernokalskaya et al., 1997).  Further more it was 
shown that binding of the PMR1 endonuclease to its target stem loop could be 
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abrogated by binding of other proteins to sequences overlapping the stem loop 
structure (Brock and Shapiro, 1983, Dodson and Shapiro, 1997, Cunningham et al., 
2000).  
Given the fact that the UGAAG motif alone appears to be insufficient for SOX 
mediated cleavage, the possibility that target recognition also involves binding of a 
structured RNA element was investigated. Thus to identify whether the pentameric 
sequence was embedded in a structured element, in silico folding studies were 
undertaken on the three identified mRNA sequences (Covarrubias et al., 2011).  
Based on these studies, a persistent fold was observed for the GFP transcript, which 
gave the most consistent stem loop structure when tested over a range of nucleotide 
lengths. As a result, most subsequent biochemical and crystallization studies 
focused on the minimal 51 nucleotides stretch that retained the overall stem loop 
structure in the vicinity of the UGAAG motif. From these in silico studies, the 
cleavage site was predicted to reside within a loop directly downstream of the 
UGAAG motif located in a Watson Crick based paired stem (Figure 4-2 C, Section 
4.2.2). The 3D structure predictions for this stem loop produced 114 structures thus 
reflecting its overall flexibility. The comparison of these structures with the ds-
DNA in the SOX-DNA complex allowed the RNA stem loop to be fitted into the 
catalytic region using the DNA co-ordinates as a guide (Figure 4-4 A, Section 
4.2.3) (Bagneris et al., 2011). The most energetically favourable SOX complex 
model was obtained with a straight stem loop conformation, however, this is very 
much based on the DNA co-ordinates and thus likely to be biased. The contacts that 
are made between SOX and the stem loop are at the NLS loop, which is known to 
bind DNA and could possibly bind RNA as well, but the stem loop does not make 
contact with the C-terminal helix, that contains residues identified as key in HSO. 
These modelling studies nonetheless provide evidence that RNA stem loops can be 
accommodated within the active site of SOX and that the loop containing the 
cleavage site would be appropriately positioned relative to the catalytic residues 
D221 and E244 for processing (Figure 4-4 D, Section 4.2.3). In order to investigate 
whether the 51 nucleotides GFP and 58 nucleotides HBB RNAs were indeed 
substrates for SOX, EMSAs were performed that revealed the formation of shifted 
complexes in both cases using wild-type SOX and the D221S and E244S catalytic 
mutants (Figure 5-3 B). These were followed by RNase assays, which showed 
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unequivocally that the 51 nucleotides GFP stem loop is endonucleolytically 
degraded by wild-type SOX whilst this activity is abrogated in the case of the 
D221S and E244S mutants. Although there is evidence for cleavage of HBB, its 
high susceptibility to degradation renders these results more speculative. On 
aggregate, however, these findings are in agreement with the literature confirming 
that the same catalytic residues are required for both the DNase and RNase 
activities of SOX (Glaunsinger et al., 2005, Glaunsinger and Ganem, 2004). To 
ascertain whether SOX has enhanced affinity for 51 nucleotides GFP stem loop 
over ssRNA and ssDNA substrates, FA was used to determine its Kd. This was 
found to be 4.6 μM (Figure 5-4) and thus represented a 20 fold increase in affinity 
compared to ssRNA-5’P and dsRNA-5’P, which are exonucleotically cleaved by 
SOX (Bagneris et al., 2011). The affinity of SOX for 51 GFP is comparable to the 
affinity of SOX for the ds-DNA-5’P; the latter being the target of SOX during viral 
genome packaging, for which the same catalytic machinery is used (Bagneris et al., 
2011, Glaunsinger et al., 2005).  
 
Several mutants were reported by the Ganem and Glaunsinger labs respectively, 
that negatively impact on HSO, but are otherwise proficient in DNA processing. 
These mutants include A61T, D474N and Y477Stop (Glaunsinger et al., 2005). 
RNase cleavage TBE-Urea gel assays performed using D474N and Y477Stop, 
which are located towards the C-terminus of the molecule, revealed that these 
mutants are attenuated in their ability to associate with 51 nucleotides GFP stem 
loop (Figure 6-1 and Figure 5-6).  
 
 
 
Figure 6-1: HSO SOX Mutants do not Abrogate ssRNA Turnover and do 
Abrogate RNA GFP Stem Loop 
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A) TBE-Urea gel taken from the (Bagneris et al., 2011) showing that the HSO 
mutants (A61T, D474N and Y477Stop) do not abrogate the turnover of ssRNA. B) 
TBE-Urea gel from this study showing that the HSO mutants do abrogate turnover 
of the 51 nucleotides GFP stem loop RNA. 
 
By contrast, A61T, situated at the N-terminus is only marginally perturbed. 
Previously published data from the Barrett Group revealed that these mutants had 
no impact on the ability of SOX to exonucleolytically degrade ssRNA substrates. 
(Figure 6-1) (Bagneris et al., 2011). This is a further indication that a stem loop 
structure is the cognate substrate for SOX, when inducing HSO in vivo. 
 
 As mentioned D474N and Y477Stop were shown to be defective in their 
capacity to endonucleolytically cleave 51 nucleotides GFP stem loop whilst A61T 
has near wild-type activity. These results suggest that the C-terminal helix is 
required for endonucleolytic cleavage. To further investigate the involvement of 
this helix, additional mutations along the helix were constructed that comprised 
H450A, R451A, N458A and R462A. H450A and R462A substantially reduced the 
ability of SOX to turnover the stem loop, while H450A and R451A did not (Figure 
5-6). From the EMSA experiments it can be seen that R462A, D474N and 
Y477Stop affect binding of the RNA stem loop (Figure 5-3), indicating that the 
majority of this helix is involved in binding the RNA stem loop. In order to achieve 
this, the stem loop would have to be substantially bent and would thus have to be 
intrinsically highly flexible, which is in keeping with the tertiary structure 
predictions, in which the RNA property to bend was illustrated (Figure 4-4 A).  
 
 To investigate the importance of the UGAAG motif within the GFP 
sequence the three identified endonucleolytically cleaved mRNA targets containing 
the UGAAG motif were aligned (Figure 4-2 D and E). This allowed the 
identification of conserved GA rich nucleotides in the sequence upstream of the 
cleavage site and the UGAAG motif. Thus a mutant GFP 51 sequence was 
constructed in which UGAAG was replaced by UCUCU to investigate whether the 
UGAAG motif is indispensible. This sequence folded into two possible stem loops, 
containing larger top loops. On contained one stem loop and the other contained 
two stem loops (Figure 4-5 A and B, Section 4.2.4.). The UCUCU construct was 
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efficiently degraded by SOX (Figure 5-5 C). These results suggest that SOX is 
likely to recognise not just the UGAAG motif, but more likely a combination of GA 
rich and structural elements. Many RNA elements are degenerate and thus hard to 
identify. With deeper computational analysis a better motif could be identified 
using published data on SOX induced mRNA depletion in cells. This could also 
mean that SOX recognised structural features that were still maintained despite the 
mutation. This would be at least partially supported by the capacity of SOX to 
degrade the HBB and DsRed2 mRNA transcripts that despite containing stem loop 
structures have quite distinct folding patterns. But in addition to the UGAAG motif 
they have in common a UGA followed by a GAA in the upstream regions of the 
cleavage site. To test this hypothesis more fully, other structured RNA molecules 
lacking the UGAAG motif and/or GA rich elements should be tested for their 
capacity to be endonucleolytically processed by SOX. These experiments were not 
possible within the time constraints of the project. Interestingly UGAAG is a motif 
associated with the splicing mechanism. UGAAG motif is overrepresented in both 
in mice and constitutive and cryptic exons in alternative splicing in Arabidopsis 
(Zavolan et al., 2003, Cech, 1990, Thomas et al., 2012). UGAAG is found in the 3′ 
splice site, as e.g. in the meiotic recombination protein (REC102) gene of 
Trichinella spiralis (Ma and Xuhua Xia, 2011, Pettitt et al., 2008) and exon where it 
is  associated with the EJC and likely to be overrepresented. 
 
SOX is known to solely target mRNAs and to contain a NLS (Glaunsinger et 
al., 2005). Its DNase activity is associated with its export to the nucleus. SOX is 
thus found in both the cytoplasm and the nucleus. Its RNase activity is thought to 
occur in the cytoplasm (Lee and Glaunsinger, 2009). KSHV genome contains 
mainly intronless genes, which are then translated in the cytoplasm by the host 
ribosomes (Rezaee et al., 2006, Schumann et al., 2013). However, the processes of 
transcription, splicing and mRNA nuclear export are intimately linked in the host. 
Thus, this poses a significant barrier to the viral RNA transcript export, translation 
and hence viral replication (Schumann et al., 2013). The issue is overcome by the 
ORF57 KSHV protein, which allows the efficient export of intronless viral mRNA 
from the nucleus to the cytoplasm (Jackson et al., 2012, Malik and Schirmer, 2006, 
Schumann et al., 2013).  
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It had been suggested, in the literature and by collaborators, that the cytoplasmic 
exonuclease Xrn1 was involved in HSO (Covarrubias et al., 2011). Xrn1 is the most 
common and highly conserved 5’ to 3’ exonuclease in eukaryotes. The highest 
conservation is present in the N-terminal region of the protein, which was predicted 
to be the region of Xrn1 most likely to interact with SOX from yeast two hybrid 
experiments conducted by collaborators (data not shown). K. lactis Xrn1 has a 48% 
sequence identity with human Xrn1 (Chang et al., 2011). As it had been suggested 
that though SOX does have an intrinsic 5’ to 3’ exonuclease activity this was not 
sufficient to account for the rapid mRNA decay, thus Xrn1s involvement was 
investigated (Covarrubias et al., 2011, Bagneris et al., 2011). Via the EMSA and 
RNase activity experiments, it could be demonstrated that Xrn1 was not able to 
bind the 51 nucleotides stem loop nor cleave it (Figure 5-3 and Figure 5-6).  This is 
in agreement with Xrn1 being a 5’ to 3’ exonuclease that requires a 5’ 
monophosphate. It was possible to show that SOX and K. lactis Xrn1 did interact 
directly using a pull down experiment (Figure 5-1) and that this interaction could be 
independently confirmed using MST where a binding affinity of 0.865 μM was 
obtained (Figure 5-2). In the RNA binding TBE gel assays, a higher molecular 
weight band appeared when SOX, Xrn1 and the GFP stem loop RNA were 
simultaneously present, which could represent Xrn1 in a complex with SOX and the 
GFP stem loop decay intermediate (Figure 5-3). In the RNase assays, the presence 
of Xrn1 appeared to reduce the endonucleolytic activity of SOX.  This could 
indicate that when the SOX-Xrn1 complex forms the handing over of the cleaved 5’ 
end of the stem loop to Xrn1 is the rate-limiting step. Thus shorter mRNAs would 
lead to a slower turnover. But as SOX and Xrn1 are likely to encounter longer 
RNAs in the cell the slowing hand over will lead to a more rapid degradation of the 
longer cellular RNAs by Xrn1 after initial endonucleolytic cleavage by SOX. This 
could also be an indication that SOX and Xrn1 are part of a wider degradation 
complex, e.g. linked to NMD. 
 
In an attempt to elucidate the nature of the Xrn1, SOX and stem loop RNA 
complex crystallization trials were undertaken. Unfortunately no complex could be 
obtained. Various complex combinations were set up involving Xrn1-SOX, Xrn1-
SOX-Stem Loop RNA (23 and 51 nucleotides GFP RNA and 58 nucleotides HBB 
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RNA), SOX-Stem Loop RNA and SOX 244-Stem Loop RNA. Crystals were 
obtained from set up complex crystallization trials and shot at Diamond Light 
Source (Figure 5-7). The mutant SOX 244 was used to inhibit any potential 
cleavage at 16 °C and the 23 GFP stem loop was engineered as to reduce flexibility 
in the RNA and allow different or tighter packing. It was possible to obtain a dimer 
crystal structure of SOX 244 at 3 Å from trials that contained the 51 nucleotides 
RNA stem loop. Initially positive missing density was visible in the active site of 
one monomer. The active site was not obstructed and would have been able to 
accommodate a shorter version of the stem loop. However, during subsequent 
refinement rounds the 2Fo-Fc maps failed to show any convincing density when 
contoured above 1σ. The original difference density could therefore have either 
originated from the solvent, though this seems to be unlikely based on its size and 
shape or be due to partially occupied/highly mobile nucleotides.  
 
 
6.2. Conclusion 
 
It was possible to determine that the UGAAG motif is overrepresented in the 
host genome. Both UGAAG and UCUCU motifs lead to endonucleolytic cleavage 
of stem loops. The endonucleolytic cleavage of stem loop RNA is inhibited by HSO 
mutants, which do not interfere with exonucleolytic activity seen with dsDNA-5’P 
and ssRNA-5’P. SOX has a 20 fold high affinity to the RNA stem loop then to 
ssRNA-5’P and this affinity is similar to its affinity to dsDNA-5’P. SOX interact 
directly with Xrn1 the 5’ to 3’ exonuclease with an affinity of 0.865 μM.  
 
 
6.3. Future Work 
 
To further substantiate these findings and hypothesis further work is needed. 
Firstly to further strengthen these SOX and RNA stem loop binding results titration 
with other unlabelled RNAs known to not contain the UGAAG motif and not to 
specifically bind SOX should be undertaken to exclude non-specific binding. In 
addition using the FLA300 it should be possible to quantify the shifted RNA in a 
titration experiments, such as titrating Xrn1 to SOX with the RNA stem loop and 
Sox to the RNA stem loop. In attempt to clarify the results a trials with different 
EMSA gel matrices should be undertaken. Secondly, further stem loops need to be 
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tested for their ability to be bound and endonucleolytically cleaved by SOX. It 
would be advantageous to be able to analyse the binding mode of SOX and the 
UGAAG and UCUCU containing stem loops using protein-RNA foot printing, as 
binding of the RNA to the protein is likely to also influence its three dimensional 
structure. Further, efforts will be required to obtain crystal structures of complexes. 
The use of a chimeric RNA-DNA sequence based on the top half of the stem loop 
containing the UGAAG motif and the bottom half of the dsDNA that was 
previously co-crystallized may be advantageous since it may promote favourable 
crystal packing for complex formation. To further the hypothesis that SOX targets 
the mRNAs on the basis of the exonic splicing signals and the linked to UGAAG 
and GA rich motifs, an in depth computational analysis of the host genes and 
mRNAs that are known to be targeted need to be undertaken as well as a detailed 
analysis of the distribution of the UGAAG motif within the viral genome and host 
genome. To further substantiate the Xrn1-SOX complex size-exclusion 
chromatography should be undertaken to test the binding and strength of the 
complex. And finally in vivo experiments should be conducted to localize Xrn1 in 
the presence of SOX and to identify any other possible binding partners that might 
be involved in the host mRNA maturation process, such as EJC. 
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A)	  
>GFP - Expression vector pSYNV-MReGFP-DsRed-P - 
JN377893.1  GI:371926914  
ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCT
GGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATG
CCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTG
CCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTA
CCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACG
TCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAG
GTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTT
CAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACA
ACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATC
CGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACAC
CCCCATCGGCGACGGCCCCGTGCYGCTGCCCGACAACCACTACCTGAGCACCCAGT
CCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTC
GTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAATAAACTAC
AGCCACAACTCTACCTCCCCCACTATGAATAAACGACCTAACATATAATATAAGAA
AAACCAACAGAAATCATAATATTTTATTTGTCTGTTTGTATTATTTGTCTAG 
 
>DsRed2 [Cloning vector pSAT6A-DsRed2-N1] AAY25372 
DQ005468.1  
 
ATGGCCTCCTCCGAGAACGTCATCACCGAGTTCATGCGCTTCAAGGTGCGCATGGA
GGGCACCGT 
GAACGGCCACGAGTTCGAGATCGAGGGCGAGGGCGAGGGCCGCCCCTACGAGGGCC
ACAACACCGTGAAGCTGAAGGTGACCAAGGGCGGCCCCCTGCCCTTCGCCTGGGAC
ATCCTGTCCCCCCAGTTCCAGTACGGCTCCAAGGTGTACGTGAAGCACCCCGCCGA
CATCCCCGACTACAAGAAGCTGTCCTTCCCCGAGGGCTTCAAGTGGGAGCGCGTGA
TGAACTTCGAGGACGGCGGCGTGGCGACCGTGACCCAGGACTCCTCCCTGCAGGAC
GGCTGCTTCATCTACAAGGTGAAGTTCATCGGCGTGAACTTCCCCTCCGACGGCCC
CGTGATGCAGAAGAAGACCATGGGCTGGGAGGCCTCCACCGAGCGCCTGTACCCCC
GCGACGGCGTGCTGAAGGGCGAGACCCACAAGGCCCTGAAGCTGAAGGACGGCGGC
CACTACCTGGTGGAGTTCAAGTCCATCTACATGGCCAAGAAGCCCGTGCAGCTGCC
CGGCTACTACTACGTGGACGCCAAGCTGGACATCACCTCCCACAACGAGGACTACA
CCATCGTGGAGCAGTACGAGCGCACCGAGGGCCGCCACCACCTGTTCCTGCTGA 
 
 
>Homo sapiens hemoglobin, beta (HBB) 626 bp mRNA 
NM_000518.4  GI:28302128  
 
ACATTTGCTTCTGACACAACTGTGTTCACTAGCAACCTCAAACAGACACCATGGTG
CATCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGT
GGATGAAGTTGGTGGTGAGGCCCTGGGCAGGCTGCTGGTGGTCTACCCTTGGACCC
AGAGGTTCTTTGAGTCCTTTGGGGATCTGTCCACTCCTGATGCTGTTATGGGCAAC
CCTAAGGTGAAGGCTCATGGCAAGAAAGTGCTCGGTGCCTTTAGTGATGGCCTGGC
TCACCTGGACAACCTCAAGGGCACCTTTGCCACACTGAGTGAGCTGCACTGTGACA
139	  
AGCTGCACGTGGATCCTGAGAACTTCAGGCTCCTGGGCAACGTGCTGGTCTGTGTG
CTGGCCCATCACTTTGGCAAAGAATTCACCCCACCAGTGCAGGCTGCCTATCAGAA
AGTGGTGGCTGGTGTGGCTAATGCCCTGGCCCACAAGTATCACTAAGCTCGCTTTC
TTGCTGTCCAATTTCTATTAAAGGTTCCTTTGTTCCCTAAGTCCAACTACTAAACT
GGGGGATATTATGAAGGGCCTTGAGCATCTGGATTCTGCCTAATAAAAAACATTTA
TTTTCATTGC 
 
 
B)	  	  
	  	  	  	  	  	  pETM6T1	  	  Vector	  
	  >	  KSHV	  ORF37	  aka	  SOX	  (Codon	  optimised	  for	  E.coli	  /	  sent	  by	  Bahram	  Ibrahimi)	  >	  Nucleotide	  sequence	  1461nt	  G+C=51%	  >	  Contains	  EcoRI	  (Ala/GCA-­‐Ser/AGC)	  at	  1178	  >	  	  	  	  	  	  	  	  	  	  EcoRV	  (Pro/CCA-­‐Trp/TGG)	  at	  1064	  >	  	  	  	  	  	  	  	  	  	  HindIII	  (xxx/XXX-­‐xxx/XXX)	  at	  105,	  387,	  935	  >	  	  	  	  	  	  	  	  	  	  NdeI	  (Gln/CAG-­‐Asp/GAT)	  at	  918	  >	  	  	  	  	  	  	  	  	  	  NheI	  (xxx/XXX-­‐xxx/XXX)	  at	  97	  >	  Free	  of	  AseI/	  BamHI/	  BspHI/	  NcoI/	  XbaI/	  XhoI	  
	  
pETM6T1	  	  vector	  Restriction	  Map	   	   	   	  	  	  	  	  	  	  	  	   	   	  	  
 
 
                                                                                          
                                   T7 promoter       lac operator            
241     
TCGAGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAA   
320 
241     
AGCTCTAGAGCTAGGGCGCTTTAATTATGCTGAGTGATATCCCCTTAACACTCGCCTATTGTTAAGGGGAGATCTTTATT   
320 
            BglII               VspI                          BsrBI            XbaI        
                                                                                          
 
                                                       His-tag#1 
                          RBS           M  G  S  S  H  H  H  H  H  H  S  S  M  N  K  
E   
321     
TTTTGTTTAACTTTAAGAAGGAGATATACATATGGGCAGCAGCCATCACCACCACCACCATTCTAGTATGAACAAAGAAA   
400 
321     
AAAACAAATTGAAATTCTTCCTCTATATGTATACCCGTCGTCGGTAGTGGTGGTGGTGGTAAGATCATACTTGTTTCTTT   
400 
                                      NdeI                                                
  
                NusA                                His-tag#2                                        
        I  L  A    F  G  D  E  A  T  S  G  S  G  H  H  H  H  H  H  D  Y  D  I  P  T  
T  E  
401     TTTTGGCT  
TTCGGTGACGAAGCGACTAGTGGTTCTGGTCATCATCATCATCATCACGATTACGATATCCCAACGACCGAA   480 
401     AAAACCGA  
AAGCCACTGCTTCGCTGATCACCAAGACCAGTAGTAGTAGTAGTAGTGCTAATGCTATAGGGTTGCTGGCTT   480 
                                SpeI   DrdII                               EcoRV            
 
                                                                                          
     TEV site 
         N  L  Y  F  Q* G  A  M  G  S 
481     
AACTTGTATTTCCAGGGCGCCATGGGATCCGAATTCTGTACAGGCGCGCTTGCAGGACGTCGACGGTACCATCGATACGC   
560 
481     
TTGAACATAAAGGTCCCGCGGTACCCTAGGCTTAAGACATGTCCGCGCGAACGTCCTGCAGCTGCCATGGTAGCTATGCG   
560 
140	  
                                 BamHI        BsrGI   BssHII       SalI          
KpnI  MluI    
                            NcoI       EcoRI                         AatII        
ClaI      
 
 
 
561     
GTTCGAAGCTTGCGGCCGCACAGCTGTATACACGTGCAAGCCAGCCAGAACTCGTCCTGAAGACCCAGAGGATCTCGAGC   
640 
561     
CAAGCTTCGAACGCCGGCGTGTCGACATATGTGCACGTTCGGTCGGTCTTGAGCAGGACTTCTGGGTCTCCTAGAGCTCG   
640 
           NspV       EagI       PvuII      PmlI                                  
XhoI    
             HindIII                BstZ17I                                               
 
 
       His-tag#3 (optional) 
641     ACCACCACCACCACCACTAATGTTAATTAAGTTGGGCGTTCCTAGGCTGATAAAA   695 
641     TGGTGGTGGTGGTGGTGATTACAATTAATTCAACCCGCAAGGATCCGACTATTTT   695 
                                                 AvrII          
                                                                 
 
Note: you can not use NdeI I site for clonning. 
 
 
Vector is Km resistant. 
 
NusA is not present in the map but it is located between His-tag#1 and His-tag#2. 
 
The NusA amino acid missing between A and F are the following: 
 
VVEAVSNEKALPREKIFEALESALATATKKKYEQEIDVRVQIDRKSGDFDTFRRWL
VVDEVTQPTKEITLEAARYEDESLNLGDYVEDQIESVTFDRITTQTAKQVIVQKVR
EAERAMVVDQFREHEGEIITGVVKKVNRDNISLDLGNNAEAVILREDMLPRENFRP
GDRVRGVLYSVRPEARGAQLFVTRSKPEMLIELFRIEVPEIGEEVIEIKAAARDPG
SRAKIAVKTNDKRIDPVGACVGMRGARVQAVSTELGGERIDIVLWDDNPAQFVINA
MAPADVASIVVDEDKHTMDIAVEAGNLAQAIGRNGQNVRLASQLSGWELNVMTVDD
LQAKHQAEAHAAIDTFTKYLDIDEDFATVLVEEGFSTLEELAYVPMKELLEIEGLD
EPTVEALRERAKNALATIAQAQEESLGDNKPADDLLNLEGVDRDLAFKLAARGVCT
LEDLAEQGIDDLADIEGLTDEKAGALIMAARNICW 
	  
	  
C)	  
• SOX 244, Xrn1 & RNA 5 mg/mL  
 
SOX 244, Xrn1& 
51GFP 
SOX 244, Xrn1 & 58HBB SOX 244, Xrn1 & 
51GFP  
 
JCSG-PLUSTM HT-96 MD1-40 
 
D1 A2 A2(-A4A7-A10A12B2-
B5) 
D5 A3 A7 
E6 A4 A10 
E10 A7-A10 A12 B2-B4 B2 
E11 B12 B12 
E12 C1 C12 
F3 C12 D1 
F6 E6 D10 
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G1 E10 D12 
G3 E11 E3 
G9 E12 E5 
H3 F3 E6 
 F6 G1 
 F7 G6 
 G1 G8 
 G3 G9-G10 H3-H6 H8 
 G4-G7 H10 
 G9-G10 H3  
 H8  
 
ProPlex HT-96 MD1-42 
 
A3-A6 A9-A10   
A11   
B2   
B9   
B11   
C3  A1 
C5  A3-A6 A9-A10 
C12 D1-D3 A1-A6 A9-A11 D6-D7 D9 
D6 B4B6-B7 B9-
B11C2C3C5C7 
D11 
D12 D6-D7 D9-D12 D12 
 
 
• SOX 244 & RNA 8 mg/mL  
 
SOX 244 & 
51GFP 
SOX 244 & 
58HBB 
SOX 244 & 
51GFP 
SOX 244 & 
58HBB-FAM 
SOX WT & 
23GFP 
 
JCSG-PLUSTM HT-96 MD1-40 
 
G6 A2 A2 D12 A4 
G7 A3 A8 F3 A5 
G8 A7 A9 G3 A7 
 A8 B11 G6 A8 
 A9 C1 G8 A10 
 A10 C3  A12 
 A12 C4  B2 
 B2 C8  B4 
 B12 C12  B12 
 C3 E10  C9 
 C8 E12  D6 
 C9 G1  E8 
 C10 G6  E9 
 CE3 G7  E10 
 E10 H6  G6 
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 F6 H8  G7 
 G6   H8 
 G7   H11 
 G8   H12 
 H3    
 H8    
 H10    
 
ProPlex HT-96 MD1-42 
 
A6 A6 A1 D12 A3 
 A9 A3  A6 A7 
 A10 A5  A9 A10 
 B3 A6  B3 –B6 
 B4 A9  B10 B11-B12 
 C5 A10  C1 
 D6 B4  C4 
 D11 B7  C6-C7 
 D12 C5  D3-D7 
  C8  D10 
  D3  E4-E5 
  D6  E7- E9 E10 
  D7 D9 D10  E12 
    F2-F3 
    F5-F6 
    G9 
    H6 
    H10 
 
	  
D)	  
	  
The SOX proteins, wild type and mutants, used in the biochemical and 
biophysical experiments were all recombinantly produced and purified to a high 
level of purity. From figure D-1 A below, it can be seen that the lysate supernatant 
contained a variety of proteins of different molecular weights.  The majority of 
these did not bind to the HisTrap column. The major elution product from this 
column was of the same molecular weight as the NusA-SOX construct (114 kDa), 
which predominantly eluted between fractions 1 to 11, however significant 
impurities were nonetheless evident. These fractions were therefore pooled and 
loaded onto a Q-sepharose column to eliminate most small molecular weight 
impurities (Figure D-1 B). Some degradation products of NusA and/or SOX, 
however, were evident. After overnight dialysis and cleavage with TEV protease, a 
second anion exchange step was undertaken to separate NusA (60 kDa) from SOX 
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(55 kDa), which are close in molecular weight (Figure D-1 C). The elution product 
from this column that was of the correct molecular weight for SOX was collected 
and loaded onto a gel filtration column to finally eliminate smaller molecular 
weight impurities (Figure D-1 D). 
 
A  
 L    F  W   1    2   3   4   5   6    7    8    9  10 11 
 
 
B Fractions 
 1  12  13 14 15 16 17 L 18 19 20 
 
 
    
C   
 62  63  66  68  70  71 72  L 73  74 75 76 77 78 79
 
 
D  
 20  21 22 23  L  25  26  27 28 29 30 31  
 
 
Figure D-1: Purification of Recombinant SOX  
 
A) The SDS-PAGE gel of the HisTrap step has the major band of the NusA-SOX 
construct (114 kDa) in fractions 1 to 11. B) The SDS-PAGE gel of the 1st Q-
sepharose step shows the major bands of the NusA-SOX construct (114 kDa) and 
likely degradation products in fractions 15-17 . C) The SDS-PAGE gel of the 2nd Q-
sepharose step shows the two major bands for SOX (55 kDa ) and NusA (60 kDa) 
separating in fractions 62-79. D) SDS-PAGE gel of the gel filtration step, where the 
bands in fractions 25-32 are SOX (55 kDa). L = Molecular weight ladder; F = 
Flow through; W = Wash. 
	  
 
220 kDa 
160 kDa 
120 kDa 
100 kDa 	  
 
 
 
220 kDa 
160 kDa 
120 kDa 
100 kDa 
  90 kDa 
  80 kDa 
  70 kDa 
  60 kDa 
  50 kDa 
  40 kDa                             
   30 kDa 
   25 kDa 
   20 kDa 
   15 kDa 
   10 kDa 	  
 
220 kDa 
160 kDa 
120 kDa 
100 kDa 
  90 kDa 
  80 kDa 
  70 kDa 
  60 kDa 
  50 kDa 
  40 kDa                             
   30 kDa 
   25 kDa 
   20 kDa 
   15 kDa 
   10 kDa 	  
 
50 kDa 
 	  
 
 
     ß SOX- à 
      NusA-Tag  
 
 
 
 
 
ß NusA-Tag  
 
 
 
     
        SOXà          
 	  
 
 
  NusA-Tag à 
            SOXà          
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E)	  
	  
The Xrn1 protein used in the biochemical and biophysical experiments were all 
recombinant produced and purified. From figure E-1 A it can be seen that the lysate 
supernatant contained a variety of proteins of different molecular weights.  The 
majority of these did not bind to the HisTrap column. From the HisTrap step, high 
overexpression of Xrn1 was not obvious, but a band spreading from fraction 27-37 
was consistent with the molecular weight of the Xrn1 construct (144 kDa) (Figure 
E-1 A). These fractions were therefore pooled and loaded onto a gel filtration 
column to eliminate other molecular weight impurities (Figure E-1 B). Following 
this step, a clear band for Xrn1 was visible, though many impurities were still 
present. These were eliminated in the SOX-Xrn1 pull down experiment (See in 
section 5.1.1, Figure 5-1). 
 
A  B 
   F    1    25  26   27   28   29  L  30  31 32 33 
 
 
  17   18  19   20  21  22   23   L   24   25  26  27  28  29  30 
 
 
Figure E-1: Purification of Recombinant Xrn1 (SDS-Page) 
 
A) SDS-PAGE gel of the HisTrap step, where the Xrn1 (144 kDa) band is seen in 
fraction 27-37, along with other impurities. B) In the SDS-PAGE gel of the gel 
filtration step Xrn1 (144 kDa) and other impurities can be seen in fractions 17-30 
contain. L = Molecular weight ladder; F = Flow through. 
	  
	  
	  
	  
	  
	  
	  
	  
220 kDa 
160 kDa 
120 kDa 
100 kDa 
  90 kDa 
  80 kDa 
  70 kDa 
  60 kDa 
  50 kDa 
  40 kDa                             
  30 kDa 
  25 kDa 
  20 kDa 
  15 kDa 
  10 kDa 	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F)	  
 
Figure F-1: Optimal Binding Conditions for SOX and 51 Nucleotides GFP 
RNA 
 
The salt concentration was varied from 100 to 400 mM NaCl in 100mM increments 
and the pH was varied from pH 6-8.5 in pH units of 0.5. The binding experiments 
were run 0 minutes of incubation at 37 °C and 60 minutes of incubation at 37 °C. 
The most discreet band was observed for 100 mM NaCl and a pH of 7; n=3. 
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Abstract 
 
The search for druggable pockets on the surface of a protein is often 
performed on a single conformer, treated as a rigid body. Transient druggable 
pockets may be missed in this approach. A systematic in silico analysis of surface 
clefts across multiple conformers of the metastable protein α1-antitrypsin (A1AT) 
was performed. Pathological mutations disturb the conformational landscape of 
A1AT, triggering polymerisation that leads to emphysema and hepatic cirrhosis. 
Computational screens for small molecule inhibitors of polymerisation have 
generally focused on one major druggable site visible in all crystal structures of 
native A1AT. Solving the highest resolution structure of native A1AT to date 
allowed highly detailed comparison of this cavity’s flexibility demonstrated by 3 
structures at ≤2.0 Å resolution. An alternative approach scanned all surface clefts 
observed in multiple crystal structures of A1AT and in 100 computationally 
produced conformers, mimicking the native solution ensemble. The persistence, 
variability and druggability of these pockets were assessed. Molecular docking of 
publicly available libraries of small molecules was then used to explore scaffold 
preferences for each site. This approach identified a number of novel target sites for 
drug design. In particular one transient site showed favourable characteristics for 
druggability due to high enclosure and hydrophobicity. Hits against this and other 
druggable sites achieved docking scores corresponding to a Kd in the µM-nM range, 
comparing favourably with a recently identified promising lead. Preliminary 
ThermoFluor studies support the docking predictions. In conclusion, this strategy 
shows considerable promise compared with the conventional single pocket/single 
conformer approach to in silico screening. The best-scoring ligands warrant further 
experimental investigation. 
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1'. Introduction 
The desire to modulate protein function with small molecules that can be 
administered as drugs has led to a plethora of studies attempting to define and 
calculate the “druggability” of sites on a protein (An et al., 2005, Halgren, 2009, 
Hajduk et al., 2005, Huang and Jacobson, 2010, Sheridan et al., 2010). Most studies 
have relied on experience from inhibiting enzymes acting on small molecule 
substrates. Here the target sites are well-formed surface pockets, characterized by 
high curvature and low solvent accessibility. Recently “harder” targets have been 
addressed. These include protein-protein interactions and proteins belonging to 
large homologous superfamilies e.g. kinases. In the former, the interfaces are larger 
and flatter (Wells and McClendon, 2007). In the latter, inhibiting the common 
active site risks serious cross-class side effects. Both these issues may be addressed 
by targeting clefts that are not necessarily associated directly with the protein’s 
biochemical function. The idea is that binding of small molecules to such clefts may 
be more favourable and could still allosterically modulate protein function, e.g. via 
preferential stabilization of a particular state within the conformational landscape of 
the protein in solution. 
The search for suitable allosteric clefts requires consideration of functional 
relevance and druggability. Functional relevance is usually less obvious from 
structural snapshots for an allosteric site than an active site. It may be deduced 
experimentally by mutagenesis, or through observation of the binding site of known 
ligands. Druggability has traditionally been indirectly assessed by computational 
studies (docking) or in vitro screening. More recently, quantitative predictors of 
cleft druggability have been devised (Halgren, 2009, Sheridan et al., 2010, Nayal 
and Honig, 2006, Cheng et al., 2007, Schmidtke and Barril, 2010, Hajduk et al., 
2005). These commonly assess the size, shape, buriedness and hydrophobic 
character of a site. However, a major limitation is currently not addressed routinely: 
the transient character of some clefts that may otherwise be of interest in drug 
design. Druggable pockets on a protein’s surface are most commonly assessed 
using a single 3D structure. This is unsatisfactory because proteins undergo 
dynamic changes in solution, sampling multiple conformations, each with 
potentially different surface pockets. The existence of multiple conformers is 
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especially relevant to ligand recognition. Ligand binding inherently tends to 
conformational selection (Ma et al., 2002, Kumar et al., 2000), a process by which 
protein-ligand interactions lower the free energy of a conformer, increasing the 
stability and population of a state that may otherwise rarely be observed. In recent 
years some notable efforts have been made to identify transient sites. In the 
approach pioneered by Eyrisch and Helms (Eyrisch and Helms, 2007), trajectory 
snapshots from molecular dynamics simulations revealed transient pockets on the 
surfaces involved in protein-protein interactions. Transient pockets can be revealed 
using more computationally efficient methods, albeit usually at the cost of reduced 
pocket diversity (Eyrisch and Helms, 2009). Moreover pocket tracking across 
multiple structures with the program fpocket can highlight important changes to a 
pocket, arising from both dynamics of a single protein as well as evolutionary time 
in a family of homologues (Schmidtke et al., 2010). Recently, the importance of 
employing multiple protein conformers in virtual screening has been highlighted 
(Bottegoni et al., 2011, Nichols et al., 2012, Ivetac and McCammon, 2012) and 
there is a growing trend for incorporating notions of flexibility in the docking 
process. Despite these pioneering studies, most current in silico screening starts 
with the selection of a single pocket from a single conformer. Two strategies can 
build upon crystallographic data to improve this situation.  Firstly the solution of 
multiple high-resolution crystal structures in different conditions allows 
interpretation of subtle variations in conformation around druggable pockets.  
Alternatively multiple plausible conformer variants may be generated in silico to 
mimic the native conformational ensemble in solution.  The second approach is 
necessarily less rooted in experimental data, but on the other hand it is more likely 
to identify potential, transiently populated druggable pockets missed in single 
conformer approaches. 
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Figure 1-1’: The Structure of the Wild Type α1-Antitrypsin 
 
Front (A) and back (B) views of the structure of A1AT in cartoon representation 
(PDB entry: 1qlp). The secondary elements are coloured as follows. ß-sheets: A 
(red), B (blue), and C (yellow); helices: A (cyan), B (apricot), C (blue), D (grey-
green), E (purple), F (yellow), G (orange), H (pink), I (olive); loops: reactive centre 
loop (RCL, red), all other loops (green). 
Both approaches were used to study druggable sites in α1-antitrypsin (A1AT), 
the archetypal member of the serpin (serine protease inhibitor) superfamily 
(Silverman et al., 2001). Its characteristic native fold (Figure 1-1’) is metastable and 
this is key to its antiprotease function (Huntington et al., 2000). It is an excellent 
candidate system in which to assess these strategies. Firstly, A1AT is a medically 
important target. Its metastability is subverted by pathogenic mutations that cause 
A1AT to polymerise. This causes diseases of the liver (neonatal hepatitis, cirrhosis 
and hepatocellular carcinoma) and lung (early-onset emphysema) through loss- and 
gain-of-function mechanisms (Gooptu and Lomas, 2008). Secondly, the biological 
function and dysfunction of serpins is coupled to marked conformational changes 
involving large rearrangements of their structure (Gooptu and Lomas, 2009). 
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Moreover, extensive mutagenesis experiments demonstrate that mutations around 
surface clefts can significantly alter the stability of native A1AT (Seo et al., 2000). 
Metastability is therefore related to pocket vacancy, indicating that ligand binding 
in a range of allosteric sites may modulate stability, and hence, pathological 
conformational change. Lastly, a range of high-resolution crystallographic datasets 
are available for wild type and mutant A1AT species in native, metastable (or 
stressed ‘S’) and relaxed (‘R’), hyperstable states, allowing comparison of 
computationally derived conformers with structural data. Following docking 
studies, the most promising findings have been assessed experimentally, identifying 
small molecule ligands with potential for development as novel therapeutics. 
 
2'. Materials and Methods 
 
a'. α1-Antitrypsin Purification, Crystallography and Assessment  
 pQE31 plasmid containing cDNA encoding hexahistidine-tagged recombinant 
wild-type A1AT was transfected into XL1 Blue Escherichia coli cells (Stratagene). 
The proteins were expressed and purified as described previously (Parfrey et al., 
2003). They were characterized using SDS–PAGE, nondenaturing PAGE and 
transverse urea gradient (TUG) PAGE, circular-dichroism (CD) spectroscopy and 
enzyme-inhibitory activity and kinetics assays (Stone and Hofsteenge, 1986, 
Dafforn et al., 2004). 
 
 Crystals of A1AT were grown in 0.1 M MMT buffer (1:2:2 dl-malic 
acid:MES:Tris base) pH 6.0, 20%(w/v) PEG 1500, 330 mM N-{4-hydroxy-3-
methyl-5-[(1H-1,2,4,5-tetrazol-3-yl)sulfanyl]phenyl}-4-methylbenzenesulfonamide 
by hanging-drop vapour diffusion at 293 K. These crystals were then loop-mounted 
and cryocooled in cryoprotectant buffer [0.1 M MMT pH 6.0, 20%(w/v) PEG 1500, 
20%(v/v) glycerol]. Synchrotron diffraction data were collected on beamline 23.1 at 
the ESRF, Grenoble, France. Processing of the X-ray diffraction data was 
performed using iMOSFLM (Battye et al., 2011) and SCALA (Evans, 2006). The 
structure of A1AT was solved by molecular replacement with Phaser (McCoy et 
al., 2007) to a resolution of 1.8 Å using the coordinates of the native A1AT crystal 
159	  
structure (PDB entry 1qlp; (Elliott et al., 2000)) as a search model. An initial model 
was constructed using Coot (Emsley and Cowtan, 2004) and the structure was 
refined using REFMAC5 (Murshudov et al., 1997). Iterative cycles of model 
building and refinement were carried out until the R factors stabilized. The 
stereochemistry of the final model (PDB entry 3ne4; (Patschull et al., 2011)) was 
checked using PROCHECK (Laskowski et al., 1994). 
  
 The cavity flanking α-sheet A in the new structure was assessed and 
compared with those observed in the two structures of nearest resolution (PDB 
entries 1qlp and 2qug; (Pearce et al., 2008)) using the program SiteMap 2.5 and 
other programs from the Schrödinger suite (Schrödinger LLP, New York, USA). 
The crystal structures were prepared using the Protein Preparation Wizard protocol 
in the Maestro program. Ligands, waters and other cocrystallized agents were 
deleted and H atoms were added. The protassign script was used to optimize 
intramolecular contacts. The impref script was used to perform restrained 
minimization of the protein (default settings in Maestro v.9.2). All structures were 
superposed using the structalign utility from Schrödinger. A site was defined as an 
enclosed region comprising at least 15 site points (default settings in SiteMap 
v.2.5). SiteMap uses an algorithm to identify and characterize favourable sites in a 
protein structure for drug binding. Probe-based and energy based methods are used 
to estimate the interaction energy between probe and protein along a three-
dimensional grid that samples the space around the structural model. These values 
are combined with geometry terms to give a druggability scoring function that is a 
function of volume and site enclosure (solvent exclusion). A penalty factor is 
calculated for hydrophilicity. Other parameters that are calculated for each site are 
volume, solvent exposure, contacts, hydrophobicity and hydrogen-donor/acceptor 
sites. 
 
b'. Selection of α1-Antitrypsin Crystal Structures 
A1AT structures were retrieved from the PDB using the SAS tool available 
in PDBsum (Laskowski, 2009). The amino acid sequence of the structure with PDB 
id 1qlp was used to search the PDB, and all sequences with percentage sequence 
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identity higher than 97% were kept (this very high cut-off was used to retain only 
A1AT structures). Among identical sequences representing identical states, the 
highest resolution available was kept. Structures with cleaved chains, where the 
break in the chain was not in the RCL were removed. The final dataset (summarised 
in Table 2-1’) comprised structures that sampled different features, such as the 
stressed and relaxed forms, point mutations, and ligands that induce stability. More 
specifically, there are six native stressed and two relaxed A1AT structures, all with 
resolution better than or equal to 2.6 Å. The six native stressed structures can be 
separated into two groups. The first group comprises PDB entries 1qlp (Elliott et 
al., 2000), 2qug  (Pearce et al., 2008)and 3cwm (Pearce et al., 2008), which have no 
mutations and share nearly 100% sequence similarity (except for minor variations 
in the length of the C- and/or N-terminus). A partially stabilising ligand, citrate, is 
present in 3cwm. The second group comprises 1hp7 (Kim et al., 2001), 1oph 
(Dementiev et al., 2003) and 3drm (Gooptu et al., 2009), all representing the native 
stressed fold but with partially stabilising mutations in the sequence. Finally, of the 
two relaxed structures, one is an uncleaved kinetic trap of A1AT (1iz2 (Im et al., 
2002)) with ten mutations, and the other is a cleaved form, with no mutations in its 
sequence, and co-crystallised with the substrate (1ezx (Huntington et al., 2000)). 
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Table 2-1’: The Dataset of Selected Crystal Structures of A1AT used in this 
Study 
 
Description PDB id Resolution (Å) Mutations 
Stressed – Native wild type 1qlp (Elliott et al., 2000) 2.00 None 
Stressed – Native wild type 
2qug 
(Pearce et 
al., 2008) 
2.00 None 
Stressed – Native with 
citrate bound 
3cwm 
(Pearce et 
al., 2008) 
2.51 None 
Stressed – Native mutant 1hp7 (Kim et al., 2001) 2.10 Ala70Gly 
Stressed – Native mutant 
3drm 
(Gooptu et 
al., 2009) 
2.20 Thr114Phe 
Stressed – Native mutant 
1oph 
(Dementiev 
et al., 2003) 
2.30 
Ph351Leu, 
Thr59Ala, 
Thr68Ala, 
Ala70Gly, 
Cys232Ser, 
Met358Arg, 
Met374Ile, 
Ser381Ala, 
Lys387Arg 
Relaxed – Uncleaved RCL 
(Latent - kinetic trap) 
1iz2 (Im et 
al., 2002) 2.20 
Phe51Leu, 
Thr59Ala, 
Thr68Ala, 
Ala70Gly, 
Arg101His, 
Val364Ala, 
Met374Ile, 
Glu376Asp, 
Ser381Ala, 
Lys387Arg 
 
Relaxed – Cleaved reactive 
loop 
1ezx 
(Huntington 
et al., 2000) 
2.60 None 
 
 
 
162	  
c'. Identification of Surface Pockets and Calculation of their 
Properties 
One protein chain from each crystal structure in the dataset was prepared 
using the Protein Preparation Wizard protocol available in the Schrödinger suite 
(Maestro package version 9.0 from Schrödinger, LLC). Ligands, waters and other 
co-crystallised agents were deleted and hydrogen atoms were added. The protassign 
script was used to optimise intramolecular contacts. The impref script was used to 
perform a restrained minimisation of the protein, with a maximum root mean square 
deviation (RMSD) of 0.30 Å.  
All structures were superimposed on the native wild type protein (1qlp) 
using the structalign utility from Schrödinger. The site recognition software 
SiteMap 2.3  (Maestro package version 9.0 from Schrödinger, LLC) was run on all 
8 crystal structures to identify the top 10 ranked potential ligand-binding sites. 
SiteMap uses an algorithm analogous to the Goodford’s GRID algorithm (Weber et 
al., 1991), which uses interaction energies between the protein and grid probes to 
locate energetically favourable sites. Sites were kept if they comprised at least 15 
site points. A restrictive hydrophobicity definition, a standard grid (1.0 Å) and the 
OPLS2005 force field were used (default settings in SiteMap 2.3).  
The following physicochemical properties of the sites were calculated by the 
SiteMap program: size, volume, degree of enclosure⁄exposure, degree of contact, 
hydrophobic⁄-philic character, hydrophobic⁄-philic balance and hydrogen-bonding 
possibilities (acceptors/donors). In addition, SiteMap calculates two scores for each 
site; the SiteScore  (Equation 2-1’) and Dscore  (Equation 2-2’).  
 
Equation 2-1’: The SiteScore is defined as 
SiteScore = 0.0733 n + 0.6688e—0.20p  
where , 
n = the number of site points (capped at 100), 
e = enclosure, 
p = hydrophilicity of the site (capped at 1.0). 
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Equation 2-2’: The druggability score, Dscore, is defined as: 
Dscore = 0.094 n + 0.60e—0.324p  
where,  
n = the number of site points (capped at 100), 
e = enclosure, 
p = hydrophilicity of the site (uncapped). 
The developers of SiteMap suggest that a cut-off in the SiteScore of 0.80 
can be used to differentiate between drug-binding and non-drug-binding sites, with 
scores higher than 1.0 being indicative of highly promising sites (Wang et al., 
2005). The Dscore can help to distinguish between undruggable and druggable 
sites, by penalising highly hydrophilic sites, as ligands binding to such sites would 
be very polar, and would be quickly eliminated by the organism. This does not 
mean that the site cannot bind any ligands, but that it would be difficult to find high 
affinity drug-like ligands for such a site (Halgren, 2009).   
Nine sites were identified in the dataset of crystal structures of A1AT. These 
sites were labelled A to I. The geometric centre of each site as seen in the native 
wild type protein (1qlp), or, in the case of the I site, as seen in the structures bearing 
the Ala70 to Gly mutation (1oph, 1iz2 and 1hp7), was calculated and it was used to 
identify sites in all other crystal structures and computationally produced 
conformers. This was done as follows: If the geometric centre of a site k was within 
3.75 Å of the geometric centre of any site s (where s ∈ {A,B,C,D,E,F,G,H,I}) then 
site k was assigned the letter of the site s (i.e. the two sites were thought to 
coincide). This cut-off is strict and it was chosen after manual inspection of several 
cases where sites were very close to each other, but where it was still possible to 
discriminate between them. Sites C and E overlap in many conformers and in these 
cases they were assigned the label “C_E”. If the calculated distances for a new site 
were between 3.75 and 10 Å, the sites were inspected and assigned manually. If all 
distances were above 10 Å, the site was categorised as being new. Inspection of all 
“new” sites found in conformers of 1qlp led to approximately half of these sites 
being reassigned to one of the original nine sites (A to I). The remaining unassigned 
sites included mostly low-scoring sites, which were ignored in the present analysis.  
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d'. Generation of Protein Conformers using CONCOORD  
CONCOORD 2.0 (de Groot et al., 1997) was used to produce alternative 
conformations for the native wild type proteins (1qlp and 2qug). The input 
structures were prepared with Schrödinger’s Protein PreparationWizard, as detailed 
above. CONCOORD builds a library of distance constraints based on the observed 
interatomic distances in the original structure. Interactions deemed to be stronger 
are given tighter constraints. The program then produces randomly a large number 
of potential conformations, and attempts to correct structures with atom-pair 
distances falling outside the allowed regions. 1000 iterations were applied of the 
correction algorithm per structure, and the structures were rejected whose 
interatomic distances violated the original distances by more than 3 nm in total. 
CONCOORD was set to an output of 100 novel conformations for the native wild 
type proteins (1qlp and 2qug), which fulfilled the distance constraints. The 
maximum RMSD from the original structure was 2.96 Å. CONCOORD was also 
run to produce 5000 conformers based on the 1qlp structure. These were only used 
for comparison to the more limited 100 runs. All computationally produced 
conformers were superimposed on the native wild type (1qlp) using the structalign 
program.  
The quality of the CONCOORD conformers was evaluated using the 
PROSESS server (Laskowski et al., 1994) available at http://prosess.ca. Table 2-2’ 
contains a summary of these results.  
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Table 2-2’: Overall Quality Results for Crystal Structures and in Silico 
Conformers of A1AT Selected for Docking Assessed by the PROSESS Server 
(http://prossess.ca) 
 
PDB_ID/ 
Conformer ID 
Overall 
quality 
score 
Covalent 
bond quality 
Non-covalent/ 
packing quality 
Torsion 
angle quality 
1qlp 9.5 7.5 7.5 8.5 
2qug 1.5 7.5 7.5 5.5 
3cwm 7.5 7.5 7.5 7.5 
3drm 9.5 7.5 8.5 7.5 
1oph 9.5 7.5 8.5 7.5 
1iz2 9.5 7.5 7.5 7.5 
1ezx 9.5 7.5 8.5 7.5 
Conf_77 (used 
for sites A, C) 
6.5 7.5 7.5 7.5 
Conf_85  
(used for site B) 
7.5 7.5 7.5 7.5 
Conf_95 (used 
for site D) 
6.5 7.5 6.5 7.5 
Conf_53 (used 
for sites E, F) 
6.5 7.5 7.5 7.5 
Conf_20 (used 
for site G) 
7.5 7.5 7.5 7.5 
Conf_87 (used 
for site H) 
7.5 7.5 7.5 7.5 
Conf_57 (used 
for site I) 
7.5 7.5 6.5 8.5 
 
e'. Automated Assessment and Visualisation of Surface Pocket 
Variability 
For each of the 100 CONCOORD conformers potential druggable sites were 
identified using SiteMap 2.3, as detailed previously. The SiteMap output files were 
then merged into single PDB files containing all predicted site sphere coordinates 
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and were used as input to the in-house pocket variability visualisation method 
Provar. The Provar method is explained briefly here: For each conformation, 
residues within 3.75Å of any SiteMap sphere were considered as being pocket-
lining and assigned a score of 1, all other residues were assigned a score of 0. These 
scores were summed across all conformations and divided by the number of 
conformers (100) to assign each residue a probability value representing the 
likelihood that it borders a predicted site.  These values were written to the B-factor 
column of the PDB file (1qlp), and results were displayed using Chimera.  Residue 
atoms and ribbons were rendered on a continuous colour scale from white (low 
probability set to the value of the first quartile of the distribution) to red (high 
probability set to the value of the third quartile). 
 
f'. Docking  
Each of the nine sites (A to I) was used as a target for docking small 
molecules. For each site, the CONCOORD conformer that was selected to dock to 
was the one with the highest volume among the ones with the top five SiteScores as 
predicted by SiteMap. This selection was justified on the grounds that the highest 
SiteScore was not always associated with the largest cavity, but in rigid receptor 
docking a larger cavity, which allows more room for ligands to bind can potentially 
make up for the lack of side-chain flexibility during docking. Receptor grids were 
calculated with Glide (Maestro package version 9.0 from Schrödinger, LLC), 
keeping default settings. The grid box was centred on the calculated geometric 
mean of the particular site. The box side lengths were set to the maximum value of 
14 Å.  
All ligand libraries used in this study were prepared using LigPrep (Maestro 
package version 9.0 from Schrödinger, LLC). The preparation involved the 
generation of up to 32 stereoisomers (where these were not defined), tautomers, and 
protonation states corresponding to a pH of 7± 2 (using epik), as well as an energy 
minimisation of the 3D structure using the OPLS2005 force field. The DrugBank 
3.0 (Wishart et al., 2008, Chang and Woolsey, 2006) library comprised 5897 entries 
after filtering to remove entries larger than 500 Daltons. Following LigPrep 
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preparation, this library consisted of 12115 small molecules. The library referred to 
as “ZINC fragments” is a representative library of fragments, based on the 3632 
ZINC “clean fragments” subset clustered at the 60% Tanimoto similarity 
(downloaded from ZINC on the 05/06/2011). These clean fragments dataset obeyed 
the following criteria: xlogP<= 2.5, molecular weight <= 250 Daltons and number 
of rotatable bonds <= 5. Following LigPrep preparation, this library contained 5324 
small molecules. Finally, a small subset of the PubChem library (1326 ligands 
related to thymol and extracted from PubChem, using the “Similar Compounds 
Search” on the web entry for thymol) was also prepared using LigPrep.  
 Glide with standard precision (SP) scoring was used for docking. Epik 2.0 
state penalties were used in the final scoring. The highest scoring pose per ligand 
was kept and post-docking minimisation was switched on. 
 
g'. Induced Fit Docking 
 A small number of molecules were selected for induced fit docking (IFD). 
All these molecules had shown promising Glide SP scores in preliminary docking 
trials, but some had poor scores following the inclusion of a protein preparation 
step. This suggested that IFD might be able to restore or even improve on the 
original scores, as it allows the protein side chains to optimise their position in the 
presence of the ligand. The IFD protocol (Maestro package version 9.0 from 
Schrödinger, LLC) available within the Schrödinger suite was employed (Sherman 
et al., 2006). Briefly, this protocol involves docking the ligand using a softened 
potential, and refining selected docked poses using Prime side-chain prediction and 
minimisation (Sherman et al., 2006). The refined protein conformations are then 
used for the final Glide docking step, where ligands are redocked, keeping the 
protein rigid. Default values were used for all Glide and Prime parameters. As the 
protein was prepared in advance no additional refinement was performed at this 
stage. For the initial Glide docking both the receptor and ligand van der Waals 
scaling were set to 0.50.  Up to 20 poses were kept. The Prime induced fit step 
refined residues within 5.0 Å of the ligand poses by optimising their side chains. In 
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the final step, the ligand poses were redocked using Glide SP into structures within 
30.0 kcal.mol-1 of the top 20 structures.  
The IFD protocol was applied to a small selection of ligands docked in the I 
and C sites. This procedure was also applied to dock the CG compound (Mallya et 
al., 2007) to the A site in the native wild type A1AT (1qlp).  
h'. ThermoFluor Studies 
The ThermoFluor (fluorescent dye-based thermal shift) assay was 
performed using the iQ5 Real Time detection System (Bio-Rad – PCR Machine). 
Protein unfolding was monitored by measuring the fluorescence of the 
solvatochromic fluorescent dye SYPRO Orange, signalling unfolding of the protein. 
The compounds to be screened were dissolved in 100 % dimethyl sulfoxide 
(DMSO) to give a stock solution of 20 mM. The assay was performed in 96- well 
plates, each well totalling a volume of 25 µL. Every assay had a final concentration 
of 1 mg.mL-1 of A1AT, 1 mM of compound giving a final DMSO concentration of 5 
%, to which 1 µL SYPRO Orange (1:200 dilution) was added. Furthermore, the 
influence of DMSO and A1AT concentration on the thermal shift were analysed. 
The DMSO concentration was varied to 5 %, 10 % and 15 % and the concentration 
of A1AT from 1 mg.mL-1 to 5 mg.mL-1. Each trial was repeated 6 times (except the 
5 mg.mL-1 concentration of A1AT, n=2). The starting temperature for each run was 
10 °C increasing to 95 °C in 0.5 °C steps. 
 
3'. Results 
 
a'. α1-Antitrypsin High Resolution Structure  
 
 Lakshmi Segu (Gooptu group, ISMB/Birkbeck) had previously obtained a 
crystal, that was shot and its data collected at the Diamond Synchrotron (Didcot, 
UK). This data was then used to determine the highest resolution (1.8 Å) 
crystallographic structure of native A1AT to date (PDB entry 3ne4; (Patschull et al., 
2011); Figure 3-1’a). Refinement statistics are listed in Table 3-1’. As expected, its 
overall fold and the positioning of secondary-structure elements were highly similar 
to the previous 2.0 Å resolution structure ((Elliott et al., 2000); PDB entry 1qlp; Cα 
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RMSD 0.3 Å ; Figure 3-1’b). However, the higher resolution was associated with a 
reduction in B factors overall (Figure 3-1’c) and improved confidence in details 
such as the positioning of side-chain atoms and water molecules. 
 
Table 3-1’: X-ray Data Collection and Processing Statistics for Native 
Wildtype α1-Antitrypsin Crystal Structure 3ne4 
 
Space group C2 
Cell dimensions (Å, °) a=114.4, b=38.9, c=88.8, 
β = 104.3 
Resolution (Å) 42.11 - 1.81 (1.91 – 1.81) 
No. of reflections 92961 total 
34169 unique 
Rmerge 0.07 (0.274) 
Completeness  (%) 98.5 (99.1) 
Multiplicity 2.7 (2.6) 
(I/σ(I)) 10.0 (3.4) 
R-cryst (%) 18.7 
Rfree (%) 23.3 
Bave (Å2) 
Mainchain 
Sidechain 
 
23.9 
28.8 
No. of Water Molecules 217 
RamachandranPlot, Residues: 
- Preferred region 
- Allowed region 
- Disallowed region 
 
96.5 % 
3.3 % 
0.3 % 
RMSD from ideal 
Bond lengths (Å) 
Bond angles (°) 
 
0.015 
1.5 
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b'. Variability in the Solvation α1-Antitrypsin 
 
 
 
Figure 3-1’: 1.8 Å Resolution Crystal Structure of α1-Antitrypsin 
 
(a) 1.8 Å resolution crystal structure of A1AT (PDB entry 3ne4) with α-helices and 
β -strands labelled (e.g. helix A, hA; strand 1 of β-sheet A, s1A). Strands within a β-
sheet are colour-coded together (A, blue; B, bronze; C, green). Detail is shown for 
the following. Box I, the reactive centre of the molecule in the canonical 
conformation. Box II, the ‘breach’ position that is the site of initial intramolecular 
loop insertion during monomeric conformational transitions. Box III, the fit of the 
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hD–s2A turn. The upper panel shows the rigid fit of 1qlp (gold) together with the 
initial OMIT map (Fo - Fc at 3σ density when residues 105–110 are omitted; 
positive difference density in green, negative in red). The lower panel shows the 
final fit of 3ne4 (orange) to the final map (blue, 2Fo - Fc at 1σ density). (b) RMSD 
for observed A1AT residues in 3ne4 compared with 1qlp (upper panel) and 2qug 
(lower panel) calculated using the SUPERPOSE program from the CCP4 suite 
(Winn et al., 2011). (c) Comparison of B factors in 1qlp (above) and 3ne4 (below). 
Low/high values are indicated by rainbow-spectrum colouring by PyMOL using a 
preset scale (blue for low to red for high). Whilst overall B factors are lower in 
3ne4 (range 9.60–83.99 Å2, mean 23.9 Å2) than 1qlp (range 13.82–96.92 Å2, mean 
38.4 Å2), the hD–s2A turn is associated with increased values in both relative to the 
global values. Other regions that show relative increases in B factor are the C-
terminal end of helix A and the upper turn of helix F, which is believed to be 
dynamic in solution and to remodel during formation of the intermediate. 
 
 
 Occupancy of alternative rotameric orientations for Val216 and Ile340 
became apparent during refinement. These are found on β-strand s4C and in the 
hinge region between β-strand s5A and the reactive loop. Coordination of the 
canonical inhibitory conformation at the reactive centre of the molecule by a water 
molecule between the side chain of Ser283 and the main-chain carbonyls of the P2 
and P10 residues is confirmed in the new structure (Figure 3-1’a, box I). This water 
is observed in only one (PDB entry 1qlp) of the 2.0 Å resolution crystal structures 
of native A1AT solved previously. In the other case (PDB entry 2qug; (Pearce et 
al., 2008)), similarly to the 2.1 Å resolution structure (PDB entry 1hp7; (Kim et al., 
2001)), this water is not seen and the canonical conformation of these residues is 
distorted. Accordingly, the RMSD is greater for 3ne4 and 2qug across the reactive-
loop residues (340–362) than between 3ne4 and 1qlp (Figure 3-1’b). Moreover, the 
solvation environment between Trp194 and the plane of β-sheet A is clearly seen to 
involve three water molecules (numbered 7, 49 and 54) whose centroids lie within 
3–5 Å of the Trp side chain (Figure 3-1’a, box II). They are coordinated by nearby 
main-chain carbonyl O atoms. This is of interest since changes around Trp194 are 
reported by changes in intrinsic fluorescence spectrometry of A1AT. It is therefore 
commonly used as a reporter residue for conformational change involving 
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rearrangements around its position underlying the top of β-sheet A (Dafforn et al., 
1999, Tew and Bottomley, 2001). High-resolution structures of latent (Im et al., 
2002) and cleaved (Yamasaki et al., 2010) A1AT clearly show the exclusion of 
solvent in this region. Previous structures of native wild-type A1AT (Pearce et al., 
2008, Elliott et al., 2000) have indicated the presence of zero, one or two waters in 
this region. In 3ne4 one of the three water molecules hydrogen bonds to the 
carbonyl O atom of Thr339. This interaction prevents the formation of a typical 
interstrand hydrogen bond between the carbonyl of residue Thr339 at the top of s5A 
and Gly192 at the top of s3A. It therefore facilitates the opening of the upper s4A 
insertion site, which necessitates separation of these residues at the top of s3A and 
s5A. The upper s4A site superficially appears to be less accessible to reactive-loop 
or peptide annealing in A1AT compared with other native serpins. However, this 
finding shows how initial insertion of a residue in this ‘P14 position’ (Schechter and 
Berger notation) does not come at the cost of breaking an interstrand hydrogen bond 
in native A1AT. 
  
 
c'. Conformational Variability in the A site 
 
 The most significant difference in main-chain conformation between the new 
structure and the search model 1qlp occurs at the hD–s2A turn (residues 105–110, 
Figure 3-1’b) that forms the upper boundary of the hydrophobic pocket targeted for 
allosteric polymerization blockade (Figure 1-1’ and 3-3’; (Mallya et al., 2007)). 
This region is typically less well ordered than the overall fold in crystal structures 
of many native serpins, including A1AT. The improved resolution obtained in the 
current study aided confident fitting into observed density through use of an OMIT 
map (Figure 3-1’a, box III). The hD–s2A region is associated with relatively low B 
factors in latent (Im et al., 2002) and cleaved (Yamasaki et al., 2010) species in 
which the cavity is filled, but high B factors relative to other regions in crystal 
structures of native A1AT. 
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Figure 3-2’: SiteMap Analysis of the A site in 1qlp, 2qug and 3ne4  
  
The A sites in the 3 crystal structures at ≤2.0 Å of native A1AT (PDB 1qlp, 2qug 
and 3ne4) are shown as identified by SiteMap in a surface representation (top). The 
total surface (grey) is shown above the component parts that can participate in 
ligand binding through hydrophobic interactions (yellow), via hydrogen-bond 
acceptance (red) or via hydrogen-bond donation (blue). Green dashed lines 
demarcate dynamic channel topologies implied by the three structures. 
 
 Despite this and the differences observed here between the 1qlp and 3ne4 
structures, they are both based upon data to high resolution and have good enough 
bond geometries to be reasonably confident of the accuracy of model building in 
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each case. Moreover, the turn is not near lattice contacts in either structure. The 
differences between 1qlp and 3ne4 are therefore likely to reflect alternative 
conformations of this region that are involved in conformational exchange. 
 
Table 3-2’: Cavity Characteristics as Calculated by the Program SiteMap for 
the A site 
 
Structure 
Size 
(No. of 
site 
points) 
 
Vol. 
(Å3) 
 
SiteScore 
 
Dscore 
 Exp. Enc. 
1qlp 123 252 1.009 1.029 0.606 0.709 
2qug 78 183 0.937 0.945 0.639 0.703 
3ne4 90 162 1.019 1.052 0.583 0.726 
‘Tight 
binders’ N/C N/C ≥0.8 
Sub-mM 
Kd 
correlates 
with ≥1.01 
≤0.49 ≥0.78 
       
Structure Contact  
Phob. 
 
Phil. 
 
Bal. 
 
Don/Acc 
  
1qlp 0.908 0.713 1.033 0.691 0.714  
2qug 0.905 0.557 0.943 0.591 0.967  
3ne4 0.861 1.028 0.843 1.219 1.056  
‘Tight 
binders’ 
Mean 
1.0 
Mean 
1.0 Mean 1.0 Mean 1.6 N/C  
 
SiteMap output values are given for volume (Vol.), exposure (Exp.), van der Waals 
contacts (Contact), hydrophobicity (Phob.), hydrophilicity (Phil.) and the weighted 
balance of these characteristics (Bal.) and also for hydrogen-bond donor/acceptor 
ratio (Don/Acc). Overall scores and those for the general ligand (SiteScore) and 
drug-like compound (Dscore) binding characteristics are also shown. ‘Tight 
binders’ refers to values derived from observed correlation with or deliberate 
calibration against database of binding sites and ligand interactions characterized 
in vitro (Halgren, 2009). N/C, not calibrated by these studies. 
 
 Variability in the allosteric cavity (A site) was assessed by SiteMap analysis 
of high-resolution structures: 1qlp (which was first used to define it; (Elliott et al., 
2000)), 2qug (Pearce et al., 2008), another 2.0 Å resolution crystal structure of 
native A1AT, and 3ne4 (Figure 3-2’). In addition to the variability in the hD–s2A 
turn region, the major differences observed between the A site in 1qlp and 3ne4 are 
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the topology at its upper and lower poles and, where topology is conserved, in the 
hydrogen-bond acceptor characteristics (Figure 3-2’, red). The hD–s2A turn 
movement observed in 3ne4 relative to 1qlp abolishes an upper recess within the A 
site in the latter structure (top left panel, green ellipse). In contrast, in 3ne4 a groove 
at the lower pole of the A site entrance becomes continuous with it (top right panel, 
green ellipse). An innermost hydrophobic (Figure 3-2’, yellow) chamber shows 
similar topology between 1qlp and 3ne4, as do the hydrogen-bond donor (blue) 
characteristics in the conserved core region. 
 The hD–s2A turn in 2qug more closely resembles that seen in 3ne4 than the 
same region in 1qlp (Figure 3-1’b). However, this feature alone does not appear to 
entirely dictate the overall cavity characteristics assessed by SiteMap. Thus, while 
the allosteric A site in 2qug displays a truncated upper channel relative to 1qlp, it 
does not become continuous with a channel at its lower pole. Moreover, the central 
region of the hydrophobic chamber seen in the other structures is lost in 2qug, 
dividing it. 2qug maintains similar hydrogen-bond acceptor characteristics of those 
cavity regions that are shared with the other two structures. However, the hydrogen-
bond donor characteristics in the 2qug cavity are more concentrated within a 
narrower distribution than that in either 1qlp or 3ne4. SiteMap also scores sites for a 
number of parameters that have been correlated with tight ligand binding and 
druggability (i.e. tight binding of drug-like molecules; (Halgren, 2009)). These 
outputs are listed for the A sites assessed in the three different structures, together 
with cutoffs and mean values correlated with observed behaviour (Table 3-2’). The 
overall scores for ligand-binding propensities (SiteScore) and drug-like molecule 
binding propensities (Dscore) are also listed. These data are consistent with the 
topological observations in Figure 3-2’ in quantifying variability around favourable 
characteristics for drug binding. 
 
 
d'. Identification of Surface Pockets Present in Crystal Structures of 
α1-Antitrypsin 
 
The eight top-ranking surface clefts identified by SiteMap (Halgren, 2009) 
were denoted A-H and are shown on the structure of native A1AT (PDB entry: 
1qlp) in Figure 3-4’. Sites A, D and G are each clearly distinct from other cavities, 
whereas sites C, B and E, as well as F and H are very close in space. The B, D and 
176	  
G sites are all defined by loop regions. In the case of site B, the loop involved is the 
reactive centre loop (RCL). It is also interesting to note that sites C and E are 
proximal to the glycosylation site Asn247, whereas D is proximal to glycosylation 
site Asn46. The largest predicted site on the native wild type A1AT (1qlp) is site A, 
adjacent to strand 2 of β-sheet A. This site scores the highest for tight binding of 
drug-like ligands with SiteMap scores  (SiteScore 1.03, Dscore 1.03) highly 
consistent with those observed in sites binding drugs with a submicromolar Kd 
(mean 1.01) (Halgren, 2009).  
 
 
Figure 3-4’: The Nine Top-Ranking Surface Pockets Identified by SiteMap on 
α1-Antitrypsin 
 
Coloured spheres represent the SiteMap predictions for eight top-ranking surface 
clefts on the wild type A1AT (PDB entry 1qlp, in grey cartoon representation): site 
A: green, B: cyan, C: blue, D: purple, E: fuchsia, F: orange, G: slate blue, H: 
brown. The yellow spheres correspond to the ninth site, I, a cleft identified on 
crystal structures of A1AT containing the Ala70Gly mutation. 
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Having identified potentially interesting sites on a single crystal structure, 
the persistence of these sites was assessed across the dataset of different crystal 
structures of A1AT (Table 2-1’ and Figure 3-5’A). In structures containing the 
stabilizing mutation Ala70Gly (PDB entries: 1hp7, 1oph and 1iz2), an additional 
site was identified (here referred to as site “I”), located between the H-helix, the s4-
s6 of the B ß-sheet and the A-helix. This site is small (45 Å3), and very hydrophobic 
(the ratio of hydrophobic to hydrophilic character measured by SiteMap’s “balance” 
property is 5.1, with 1.6 being the average balance for tight-binding sites (Halgren, 
2009)). Despite the small size of this site, the corresponding Site- and Dscores (0.92 
and 0.92 respectively) calculated by SiteMap indicate a promising pocket for 
targeting with small molecule drug-like ligands. Although site I is present as a 
cavity in the remaining non-mutated structures, it is not solvent-accessible, and so is 
not identified by SiteMap. Interestingly, in PDB entry 1hp7, sites E and I are 
combined by SiteMap into one site, indicating that a ligand could possibly straddle 
both. Of the remaining eight sites, four are present in both the stressed and relaxed 
forms of A1AT (C, D, E, F), and four are only found in the stressed form (A, B, G 
and H). Results for the properties of each site are summarised in Figure 3-5’. 
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Figure 3-5’: Properties of Surface Pockets in Crystal Structures and in Silico 
Conformers of α1-Antitrypsin 
 
Persistence of clefts A-I among A1AT crystal structures (A) and computationally 
produced conformers (B). Where the sites C and E overlapped, the data are 
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presented under the label “C_E”. The distribution of SiteMap calculated properties 
for the 100 in silico conformers are shown as boxplots: SiteScore (C), DScore (D), 
site volume (E) and hydrophobic vs. hydrophilic character balance (F). The 
corresponding data for crystal structures are shown as red symbols superimposed 
on the boxplots; 1qlp (circle), 2qug (plus sign), 3cwm (square), 1hp7 (diamond), 
3drm (triangle point up), 1oph (triangle point down).  Data are shown only for sites 
identified within PDB entries for native (stressed, ‘S’) forms of A1AT, as these are 
likely to be the appropriate target states for the design of polymerization inhibitors. 
 
 
A large variation is observed in the volumes of all the larger sites among the 
eight crystal structures studied reflecting significant conformational changes across 
this dataset. However, even the largest of these sites (1qlp, site A: 234 Å3) is small 
compared with the average volume of drug-binding sites (reported as 600 to 900 Å3, 
depending on the method used to measure them (Perot et al., 2010)). Nevertheless, 
six of the sites (A, B, C, D, E and I) have a median SiteScore higher than 0.8, the 
recommended value for distinguishing drug-binding from non-drug binding sites 
(Halgren, 2009). Sites A, C, and E demonstrate SiteScores >1.01, consistent with 
submicromolar drug-binding, in at least one crystal structure (Halgren, 2009).  
 
 
e'. Incidence and Variability of Surface Pockets within a 
Computationally-Generated Conformer Ensemble 
 
An ensemble of 100 A1AT conformations was generated from the native 
wild type structure 1qlp using the distance constraints-based method within 
CONCOORD (de Groot et al., 1997)  (Figure 3-6’). SiteMap was then used to assess 
pockets A-I across the entire computationally generated native-like ensemble. The 
frequency of occurrence of each site across all conformers is summarised in Figure 
3-5’B. The boxplots in Figures 3-5’C-F summarise selected SiteMap property 
results for these sites. Similar trends for the volumes and site scores are observed 
for conformations produced using more extensive sampling, or a different structure 
of native wild type A1AT (2qug) as the starting point for the CONCOORD 
simulation (data not shown). The majority of the values for the Site- and DScores 
(Figures 3-5’C and 3-5’D respectively), volume (Figure 3-5’E), and 
hydrophobic/philic balance (Figure 3-5’F) for pockets in the crystal structures are 
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within the boxplot limits. Thus the A1AT cavity characteristics explored by the 
computational conformers are supported by crystallographic observations. In 
addition, more detailed assessment of the computational conformers demonstrating 
the maximum Dscore for each cavity using the PROSESS server (Berjanskii et al., 
2010) indicated they were of comparable quality to experimental structures in the 
dataset in terms of geometry and packing (Table 2-2’).  
 
 
Figure 3-6’: Exploration of Conformational Space of A1AT using CONCOORD 
 
CONCOORD-generated conformers from a native wild type A1AT structure ((PDB: 
1qlp). (A) All 100 conformers used to analyse druggability of sites and their 
occurrence. (B) The 7 structures used for docking to sites A-I; colours for 
conformers are: white (site G), magenta (sites E and F), cyan (site I), yellow (sites 
A and C), red (site B), blue (site H), green (site D). (C) Three selected conformers 
depicting the extent to which structural variation was simulated.  
 
The behaviour of the A site across the computationally generated 
conformeric ensemble demonstrates the conservative nature of the conformational 
lability simulated by the program CONCOORD. Within the dataset of crystal 
structures of native A1AT the A site is largest and most druggable in 1qlp, the 
starting template for this CONCOORD simulation. The site is retained in 96% of 
the generated ensemble (Figure 3-5’B) and displays higher volumes (Figure 3-5’E) 
and druggability scores (Figures 3-5’C & D) across these conformers than observed 
across the crystallographic structures. Despite this conservative approach, the 
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ensemble generated by CONCOORD demonstrates that even these small 
fluctuations can have major consequences for surface clefts in A1AT, simulating 
pocket “breathing” in solution. Thus pocket volumes varied ≤ 3-fold for many sites 
(Figure 3-5’E) and druggability scores showed up to 2-fold variation (Figure 3-
5’D). For many sites a source of high variability was their merging with other sites 
via formation of a channel of interconnected subsites. In particular, a channel ran 
from the RCL to the H-helix incorporating sites B, C, E and I in various 
combinations across several conformers (Figure 3-7’). 
 
 
 
Figure 3-7’:  A Channel of Interconnecting Pockets on the Surface of A1AT 
 
(A) A channel of interconnecting surface pockets (blue spheres) defined by the RCL 
at the top and the H-helix at the bottom can be seen in several in silico produced 
A1AT conformers. (B) This channel is split up into separate sites in most 
conformers: B (cyan), E (fuchsia), I (yellow). These subsites themselves 
occasionally overlap as in the case shown here, e.g. site E can “spill into” the 
spaces usually occupied by sites I and B. 
 
A number of other sites have the potential to achieve druggability scores 
comparable to site A within the ensemble. However, the spread of scores across the 
conformational ensemble (Figure 3-5’C) indicates that the ligand-favouring 
properties of these sites are subject to greater fluctuation than the A site. Only three 
sites (F, G and H) have median SiteScores below the 0.8 recommended cut-off for 
promising drug targets. In general, the SiteScore for a pocket correlates with the 
volume of that pocket, but it is interesting that site I, although relatively small, 
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scores very highly (its median druggability score is highest after site A, among sites 
not defined by the RCL). This is probably due to its strongly hydrophobic 
environment (see Figure 3-5’F), which has highly favourable drug binding 
characteristics. 
 
 
f'. Surface Cleft Variability Assessed by Provar  
 
 The variability of each predicted site in terms of the residues that line the 
site was assessed using Provar (Ashford et al., 2011), a method recently developed 
in the Nobeli group for the calculation and depiction of surface cleft variability. 
Provar uses an ensemble of conformers and their predicted pockets as input, 
calculates the propensity of each residue to line a pocket, and aids visualization by 
mapping the results on a single conformer structure. Provar results for the 100 
CONCOORD conformers of A1AT are summarized in Figure 3-8’. The Provar 
analysis is consistent with SiteMap analysis data (Figure 3-5’B), and provides 
additional information about which residues are consistently part of a pocket and 
which are only occasionally so. For example, the majority of the residues lining the 
A pocket appear to be persistently part of a cleft across the CONCOORD conformer 
ensemble (Figure 3-8’C). By contrast, of the residues surrounding the I pocket, only 
three are consistently pocket-lining: Leu276, Ile375 and Lys380 (Figure 3-8’D). As 
the I pocket is only identified in about a quarter of all conformers, these residues 
must be often part of a different pocket that incorporates part of the I site. 
Moreover, Provar offers an insight into how conformational changes affect a 
pocket: pockets that have many of their residues coloured red (e.g. site A, Figure 3-
8’C) are likely to be changing in volume (as evidenced also in Figure 3-5’) by 
“breathing”-style motions that inflate and deflate the site without having much 
effect on which residues are pocket-lining. Sites that have many residues 
surrounding them coloured pink (e.g. site I) are either transiently observed, or 
change shape and volume by burying and exposing different parts of the site in 
different conformers. Such sites are consequently more likely to be missed by 
software that identifies pockets, if only one conformation or poor sampling of 
conformers is used. 
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Figure 3-8’. The Pocket-Lining Propensity of the Residues of α1-Antitrypsin 
Calculated with Provar 
 
Ribbon representation of A1AT (front, A and back, B) coloured by the residue-
based Provar probabilities. Provar colours each protein residue according to its 
probability of being pocket-lining in an ensemble of conformers (here, 100 
CONCOORD-produced conformations of A1AT). The first (0.05) and third quartile 
(0.92) of the probability distribution are used as the white and red limits of the 
spectrum respectively. Hence, residues appearing red belong to the top quartile 
distribution, i.e., in this case, they are pocket-lining in more than 92% of the 
conformers. (C) and (D): The SiteMap predictions for two pockets (A and I 
respectively) are shown as solid spheres, and every residue with an atom within 
3.75 Å of any sphere is shown in stick representation coloured by its Provar value. 
Depth-cueing has been switched off in these figures to preserve the variation in the 
colouring of the residues. 
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g'. Global Fragment and DrugBank Library Docking Studies  
 
 To further characterize the A-I pockets a set of representative fragments 
from the ZINC database and compounds from the DrugBank library were docked to 
each of the sites on A1AT using Glide. The in silico fragment screen identified 
high-scoring fragments for each site, highlighting chemotypes that may be used as 
starting points for future in vitro exploration. The ZINC identification codes for the 
5 top-scoring fragments against each site are provided in Table 3-3’.  
 
Table 3-3’: Results for Top-Ranking Fragments against each of the Sites A-I 
on A1AT 
 
Site Rank 1 (score) 
Rank 2 
(score) 
Rank 3 
(score) 
Rank 4 
(score) 
Rank 5 
(score) 
A ZINC015811
30 (-8.0) 
ZINC003470
00 (-7.8) 
ZINC137287
63 (-7.7) 
ZINC087465
11 (-7.6) 
ZINC572187
70 (-7.5) 
B/C/
E ZINC49587279 (-7.72) 
ZINC045210
93 
(-7.68) 
ZINC020284
26 (-7.35) 
ZINC132837
74 (-7.32) 
ZINC016456
71 (-7.29) 
D ZINC022936
61 (-7.3) 
ZINC003396
59 (-7.1) 
ZINC173772
81 (-7.0) 
ZINC015594
84 (-7.0) 
ZINC160373
56 (-7.0) 
F/H ZINC132174
56 (-7.1) 
ZINC016789
57 
(-6.9) 
ZINC055455
29 
(-6.9) 
ZINC052861
28 (-6.7) 
ZINC259499
41 (-6.7) 
G ZINC086279
28 (-7.9) 
ZINC046291
71 (-7.1) 
ZINC149836
15 (-7.0) 
ZINC387010
09 (-6.9) 
ZINC124030
09 (-6.9) 
  
The ZINC molecule identification codes and Glide SP docking score (within 
brackets, in kcal/mol) for each of the five top-ranking fragments docked to sites on 
A1AT are listed. Results for sites B, C, E and F, H are merged.  
 
The docked poses of these fragments can be used to define pharmacophores 
for each site. Encouragingly, the top scoring fragments for the A site clustered in 
the area identified in a previous proof-of-principle study as a target for 
pharmacophores capable of blocking polymerization of A1AT while preserving 
inhibitory function (Figure 3-9’). The area of the pharmacophore is defined by 
Asn104, Thr114 and His139, and several of the fragment poses favour hydrogen 
bonds to the threonine and histidine residues. 
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Figure 3-9’: Fragment Docking to the A Site Targets the Pharmacophore 
Defined by Asn104, Thr114, and His139 
 
Best poses of the top-scoring 20 fragments (coloured sticks) from the ZINC dataset 
docked in the A site of A1AT (cartoon, blue). The majority of these fragments fill the 
pocket defined by Thr114 and Asn104 at the top, and His139 at the bottom (thin 
sticks, cyan), identified in a previous study as a potential allosteric site for targeting 
A1AT polymerization. Some of the fragments take advantage of hydrogen bonding 
opportunities presented by His139 and Thr114. 
 
 
 The protein-fragment interactions within the other, less well 
characterized, sites provide great insight into the ligand-binding capabilities of these 
pockets. For example, the top 10 fragments in the I site have at least one hydrogen 
bond to one of three residues: Thr273 (side-chain oxygen OG1 acts as an acceptor 
to 5 ligands), Lys380 (backbone oxygen O acts as donor to 7 ligands) and His269 
(ND1 acts as donor to 4 ligands). Moreover two areas within the site are often 
occupied by hydrophobic rings. These findings can be used to build a 
pharmacophore template for further searches of additional ligand databases.  
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Figure 3-10’:  Site Specificity of High-Scoring Fragment Molecules  
 
Red diamonds represent the docking scores for the top 5 scoring fragments for each 
of the sites A, BCE, D, FH, G, and I. The boxplots summarise the corresponding 
(merged) distributions of docking scores for the same five fragments docked to all 
other sites. 
 
 Overall the sites identified by SiteMap analysis demonstrated specificity 
even when probed with small fragment compounds, that are intrinsically more 
likely than larger compounds to bind promiscuously (Chen and Shoichet, 2009). 
Top-scoring fragments for each site typically scored better for binding at that site 
than against any other site (Figure 3-10’). 
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Figure 3-11’: Results from Docking the DrugBank Collection against Nine 
Pockets on α1-Antitrypsin 
 
(A) Boxplot distributions of docking scores for DrugBank molecules docked to each 
of the nine sites A to I. Only the top-ranking pose is included for each ligand and 
only ligands of molecular weight less than 500 Daltons are included in this plot.  
(B) The best-scoring ligand for each site is assigned a worse score when docked 
against each of the other sites. The red diamonds represent the best docking score 
for each ligand depicted in Table 3-4’, when docked to the site where it is ranked 
top. The black diamonds correspond to the scores for each of these ligands when 
docked to all other sites. The x-axis labels correspond to the DrugBank ID of the 
ligand and, in brackets, the site against which it is selected as “best-scoring”, e.g. 
07124(A) refers to DrugBank entry DB07124 which achieves its best score against 
site A. 
 
 In the second docking experiment scanned all pockets with the DrugBank 
collection of small molecules in an effort to identify any high-ranking ligands that 
are already used, or being tested as drugs for different targets. 12,115 small 
molecule ligand structures based on 5,897 molecules from the DrugBank library 
were docked using Glide (see Methods for details) to each of the nine surface clefts 
A-I. Docking scores for each ligand successfully docked to each site are 
summarized in Figure 3-11’. In these plots the distribution of docking scores for 
sites B, C and E (labelled as site BCE) and those for sites F and H (FH) are 
combined, as the necessity of using a reasonable-size receptor grid in docking 
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permits ligands to dock within neighbouring sites to that upon which the grid is 
centred.  As is usual for docking calculations, the majority of the ligands interacted 
in silico with relatively poor predicted binding energies (-3 to -5 kcal/mol), 
indicating poor potential for drug development. However, promisingly, low energy 
outliers in these distributions achieve scores in the range of -7.5 to -8.8 kcal/mol for 
each site (Table 3-4’ and Figure 3-12’). These scores are comparable to the score of 
compound “CG”, a molecule identified in a previous study as an inhibitor of A1AT 
polymerization (CG achieves a score of -8.7 kcal/mol against its target site (A) after 
induced fit docking using Glide). Moreover, the best-scoring ligand for each site 
appeared highly selective for that site (Figure 3-11’B). The best overall scores were 
achieved for sites BCE and FH. The highest-scoring ligand interaction was for 7,8-
dihydro-7,7-dimethyl-6-hydroxypterin (DrugBank ID DB02278). Despite the 
relatively small size (209 Da) of this ligand, it achieved a score of -8.8 kcal/mol 
against the BCE site. However in the simulations, this molecule bound the RCL 
with likely adverse effects on the enzyme inhibitory function of A1AT.  
 
Table 3-4’: The Best-Scoring and “Best-Efficient” Small Molecules from 
DrugBank Docked against each of the Sites A-I on A1AT 
 
 Best overall docking score Best scoring within ten most efficient 
Site DrugBank ID 
Glide SP 
score 
(kcal/mol) 
Molecular 
Weight 
(Daltons) 
DrugBank 
ID 
Glide SP 
score 
(kcal/mol) 
Molecular 
Weight 
(Daltons) 
A DB07124 -8.3 384.4 DB00610 -7.9 167.2 
B/C/E DB02278 -8.8 209.2 Same as 
best 
overall 
  
D DB04861 -7.9 405.4 DB02377 -7.2 150.1 
F/H DB08003 -8.3 486.5 DB00529 -6.8 126.0 
G DB07597 -7.9 163.2 Same as 
best 
overall 
  
I DB03536 -7.5 379.4 DB03329 -6.2 111.2 
Diagrams, IUPAC names and PubChem CIDs for all DrugBank entries in this table 
can be found in Figure 3-12’. 
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Figure 3-12’: Top-Scoring DrugBank Molecules against the α1-Antitrypsin 
Sites 
 
IUPAC names and PubChem CIDs for the DrugBank IDs in Figure 3-11’ and Table 
3-4’ are: 
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DB07124: 3-[(2S)-2-amino-3-[(5-{7H-pyrazolo[3,4-c]pyridin-5-yl}pyridin-3-
yl)oxy]propyl]-6H-indole, PubChem CID: 46937052;  
DB00610: 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol, PubChem CID: 5906 
DB02278: 2-amino-6-hydroxy-7,7-dimethyl-3,4,7,8-tetrahydropteridin-4-one, 
PubChem CID: 3340355; 
DB04861: 1-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2-{[2-(6-fluoro-3,4-
dihydro-2H-1-benzopyran-2-yl)-2-hydroxyethyl]amino}ethan-1-ol, PubChem CID: 
71301; 
DB02377: 2-aminopurin-6-one, PubChem CID: 764; 
DB08003: (2S)-2-acetamido-N-[(2S)-1-amino-1-oxo-3-[4-[(5S)-1,1,3-trioxo-1, 
2-thiazolidin-5-yl]phenyl]propan-2-yl]-3-phenylpropanamide, PubChem CID: 
9547915; 
DB00529: phosphonoformic acid, PubChem CID: 3415; 
DB07597: (1R,2S)-2-amino-1,2,3,4-tetrahydronaphthalen-1-ol, PubChem CID: 
6420129; 
DB03536: benzyl N-[(1S)-4-[(diaminomethyl)amino]-1-{[(2S)-3-oxobutan-2-
yl]carbamoyl}butyl]carbamate, PubChem CID: 6398520; 
DB03329: pyridine-2-thiol, PubChem CID: 2723698. 
 
 
 Since larger compounds (>350 Da) are considered unfavourable as leads 
for drug design, ligand efficiency was used to identify the 10 best performing 
ligands for each site. Ligand efficiency is traditionally defined as the docking score 
divided by the number of heavy atoms, but the natural logarithm of the ligand 
efficiency, is proposed to give a better fit to experimental data (Halgren, 2009, 
Sheridan et al., 2010) and so this measure was used instead. Within these best 
ligand efficiency sets the ligand with the best overall docking score was selected to 
avoid overcompensating for size at the expense of docking score. Some of these 
(‘best-efficient’) ligands conserved interactions that are important in the binding of 
the highest scoring ligand overall (‘best-overall’). Thus, within the I site, hydrogen 
bonding of a charged amine group to the backbone of Ser140 was seen with both 
the best-efficient (DrugBank ID: DB00610) and best-overall (DB07124) ligands. 
Similarly the aromatic ring of the most efficient ligand for the I site (DB03329) 
overlaps with the positions of all other aromatic rings in the top 10 scoring ligands. 
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h'. Induced Fit Screening for Promising I Site Ligands 
 
For a flexible protein, like A1AT, rigid receptor docking is likely to miss 
many ligands that require small structural rearrangements in order to fit some of the 
smaller sites. In this case, docking calculations that allow for induced fit are 
recommended. The induced fit protocol was applied to the I site, as this is the 
smallest of all and more likely to benefit from such a protocol. Hereby ligands are 
docked into sites in a soft mode (repulsive forces are very much reduced), then the 
protein and the ligand are allowed to relax. Finally the ligand is redocked to the 
relaxed conformer of the receptor. The induced fit docking protocol dramatically 
changes the results for some ligands.  
 
Two natural compounds that gave promising results were menthol and 
thymol. Menthol (DB000825) is a natural compound of mint oils that scores 
reasonably well (-6.6 kcal/mol) in the original docking trial (with the receptor kept 
rigid) and, more importantly, ranks eighth out of the 10,000 reported ligand poses. 
Following induced fit docking, this score improves dramatically to -8.5 kcal/mol, 
aided by a small rearrangement of His269, which results in an additional hydrogen 
bond to the ligand. Thymol is another interesting hit against site I. In preliminary 
docking experiments (without prior protein refinement in Glide) thymol was the 
fourth best scoring molecule against this site. Thymol is a natural product of thyme 
and a known protein binder (Vincent et al., 2000) that is used as a stabilizer in 
pharmaceuticals as well as an antiseptic, vermifuge, antibiotic and fungicide, so it 
may be an interesting ligand to explore. Unlike many of the larger ligands that were 
found bound mostly on the outside of the cavity, thymol docked inside and showed 
a good complementarity to the site. Following protein refinement (a recommended 
procedure in Glide), thymol could not be docked inside the I site, resulting in a very 
poor docking score (Figure 3-13’A).  However, after induced fit docking thymol 
could enter the cavity and achieved a Glide score of -8.3 kcal/mol (Figure 3-13’B). 
Finally, a series of molecules comprising the thymol scaffold resulted in several 
good hits, the top-scoring one being 5-ethyl-2-(4-ethyl-2-hydroxy-phenyl)phenol 
(PubChem CID: 19850961), which binds the I site with an impressive score of -10 
kcal/mol. This score is equivalent to a Kd prediction in the nanomolar range (Figure 
3-13’C). 
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Figure 3-13’:.  Induced Fit Docking allows the Discovery of High Affinity Hits 
for Site I 
 
(A) Thymol (DrugBank ID DB02513, in wire representation) docks on the outside 
of the main cavity of the I site (small white spheres) and does not reach the 
hydrophobic pocket within the cavity (yellow surface), resulting in a poor docking 
score (-3.2 kcal/mol). 
(B) After induced fit docking, thymol (in stick representation) enters the site, which 
now comprises a larger hydrophobic cavity; the docking score is consequently 
greatly improved to -7.8 kcal/mol. The initial docked pose of thymol before the 
application of IFD is shown superimposed in wire format. 
(C) A derivative of thymol, 5-ethyl-2-(4-ethyl-2-hydroxyphenyl)phenol, (PubChem 
CID 19850961, sticks coloured by element) achieves an impressive score of -10 
kcal/mol after induced fit docking, whilst retaining the original thymol pose (in 
blue) for the substructure that is common to both molecules. 
(D) Best-ranking pose for DrugBank ID DB07263 ([{2-bromo-4-[(2R)-3-oxo-2,3-
diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid, in stick representation) 
following induced fit docking. In this protein conformer, the channel connecting 
sites I and C has been opened creating two hydrophobic subpockets (predicted by 
SiteMap and depicted here in yellow semi-transparent surface). Two of the 
aromatic rings of this ligand are placed in these subpockets. This ligand achieves a 
very good docking score (-9.5 kcal/mol), despite the fact that several hydrogen 
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bonding opportunities (depicted by the blue and red surfaces, corresponding to H-
bond donor and acceptor, respectively) are not satisfied in the case of this ligand. 
 
Interestingly a further hydrophobic pocket may transiently form next to the 
originally identified I site  and in some conformers, is continuous with it. This can 
allow larger ligands with two rings connected by a flexible linker to dock in a way 
that takes advantage of both hydrophobic patches. For example docking DrugBank 
entry DB07263 using the induced fit protocol, gives the pose depicted in Figure 3-
13’D where two of the aromatic rings are placed in the two hydrophobic subpockets 
making up the site in this conformer (yellow surfaces in Figure 3-13’D). This pose 
achieves a very respectable Glide score of -9.5 kcal/mol. As this particular ligand 
does not take full advantage of the hydrogen bonding opportunities clearly depicted 
in the SiteMap surfaces of the site (Figure 3-13’D surfaces in blue and red).  It is 
therefore reasonable to hypothesise that the affinity could be further improved by 
adding suitable functional groups that could interact with polar residues on the 
receptor. 
 
 
i'. ThermoFluor Experiments Validate Interactions Predicted in 
Silico 
 
A small number of hits from the docking studies were assayed using thermal 
shift experiments (ThermoFluor). All compounds selected for testing had shown 
promising docking scores either using the induced fit protocol, or in preliminary 
docking studies using rigid receptor docking. Table 3-5’ summarises the results for 
the three of the eight ligands tested that demonstrated significant thermal shifts (4-
nitrocatechol, 2,6-diisopropylphenol and thymol), compared with the control 
substance (DMSO). The corresponding ThermoFluor graphs for these three ligands 
can be found in Figure 3-14’; they show the difference between the assayed melting 
temperature of the incubation with compound and the average melting temperature 
of an appropriate A1AT control incubated under the same conditions (in this case, 
DMSO concentration). One of the eight compounds assayed (4-nitrocatechol, 
predicted to bind at the I site) demonstrated an average thermal shift exceeding 1 
°C. Interestingly, two of the compounds representing hits to the I site (thymol, and 
2,6-diisopropylphenol) appeared to destabilise the protein, causing a negative shift 
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in the melting temperature, which was particularly pronounced for thymol (average 
of -1.66 °C). Negative shifts may also be due to the hydrophobic nature of the 
compounds, which under the assay conditions may induce non-specific 
destabilization of the folded state (Cimmperman et al., 2008). Whether stabilizing 
or destabilizing, the observed shifts in the melting temperature of A1AT support the 
docking results and indicate that the compounds assayed are most likely interacting 
with A1AT. 
 
Table 3-5’: Shifts in Melting Temperature of A1AT in the Presence of Selected 
Small Molecule Ligands (ThermoFluor Assay) 
 
Molecule Name DrugBank ID 
Average 
Thermal 
Shift in °C 
(p-value) 
Predicted 
site of 
binding 
Best Glide 
SP score 
after IFD 
(kcal/mol) 
Thymol DB02513 -1.66 (0.0089) I -7.8 
4-Nitrocatechol DB03407 1.92 (0.0002) I -6.9 
2,6-Diisopropylphenol DB00818 -1.21 (0.0021) I -8.3 
 
The quoted p-values are the result of a Welch two-sample t-test (performed using 
the R statistical software) testing the null hypothesis that the difference in the mean 
values of the distribution of the thermal shift values for DMSO and the distribution 
of the thermal shift values observed for each ligand is zero. The null hypothesis was 
rejected for p-values < 0.01.  
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Figure 3-14’: Thermal Shift and Melting Temperature Assays for A1AT 
Incubated with Selected Ligands 
 
Fluorescence-based (Thermofluor) thermal shift assay curves for A1AT incubated 
with small molecule ligands. Only ligands with significant thermal shifts are shown. 
Representative curves obtained in the presence of these ligands (solubilised in 
DMSO, final concentration 5% (v/v)) are shown in plots A to D (control with 5% 
DMSO in grey, data from incubation with ligands in red). The mean ΔTm is shown 
for A1AT incubated with each ligand: (A) 5% DMSO control, (B) 4-nitrocatechol, 
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(C) 2,6-diisopropylphenol, (D) thymol. (E) Mean melting temperatures and 
standard deviations for A1AT incubated with these three ligands (red) or 5% 
DMSO control (grey). 
 
4'. Discussion  
 
 The use of relatively low-resolution crystal structures as a supplement to high-
resolution structures has been proposed as a promising strategy for sampling the 
conformational space explored by drug targets and thus aiding drug design 
(Furnham et al., 2006). In the case of the site A, comparison between the 1qlp, 2qug 
and 3ne4 structures of A1AT provides the benefit of this outcome without the 
potential inaccuracies of model building inherent at lower resolutions. 
Transiently druggable pockets on the surface of proteins can be missed by in 
silico screens to identify the most promising target site on a protein, commonly 
based upon a single structural snapshot. Such pockets are of particular interest in 
cases where the protein target undergoes large conformational variations, as in the 
archetypal serpin A1AT. The alternative methodology presented here characterizes 
more pockets, and simulates their solution behaviour in greater detail than a single 
conformer/single pocket approach.  
In this study, efforts were focused upon identifying druggable pockets on the 
surface of native A1AT that could be the targets of inhibitors blocking 
polymerization. Previous in silico attempts to identify small molecules that can act 
as inhibitors of polymerisation have concentrated on one prominent allosteric site 
(defined here as the A site), a large cavity between the ß-sheet A and the D-helix 
(Elliott et al., 2000). This site was seen as a good drug target, as the space filling 
Thr114Phe mutation situated in the A site reduces polymerisation and preserves 
inhibitory function of native wild type A1AT in vitro, and increases secretion in a 
mammalian cell model of disease (Parfrey et al., 2003, Gooptu et al., 2009). Drug 
design studies based on the Thr114Phe mutant and in silico research focusing on 
this site have led to ligands that blocked polymerisation of A1AT in vitro (Chang et 
al., 2011). However, they did so irreversibly and with the undesirable side effect of 
blocking the inhibitory action of A1AT (Gooptu et al., 2009, Mallya et al., 2007). 
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To improve targeting to this site, the new 3ne4 structure that was solved provides 
direct observational data defining breathing motions of the A-site.   
However, there is both scope and need for targeting alternative sites on A1AT. 
A recent attempt at identifying such sites across a range of serpins has revealed at 
least one site where selected sugars and amino acid derivatives may bind, acting as 
chemical chaperones that reduce polymerization (Singh et al., 2011). Therefore in 
parallel potentially druggable sites on A1AT were identified, that have not yet been 
targeted in in silico screens. 
To validate alternative potentially druggable sites identified by in silico 
exploration of multiple conformeric variants derived from high resolution structures 
of native A1AT their presence in the larger set of lower resolution structures was 
investigated. Indeed, crystal structures of A1AT allow us a glimpse of the variety of 
conformations sampled by this protein. This inherent flexibility, intimately linked to 
function, is dispersed across the whole protein (Im et al., 1999, Im et al., 2002, Seo 
et al., 2000, Seo et al., 2002, Ryu et al., 1996) and thus potentially reflected in the 
properties of pockets on the surface. Analysis of available crystal structures 
revealed considerable variability in the surface clefts between different conformers, 
and suggested that this variability should not be ignored in structure-based drug 
design. The work showed that the variability of potential druggable pockets could 
be extensively probed using a relatively cheap, constraints-based computer 
simulation that efficiently explores part of the protein conformational space. 
Additionally, this approach identified both novel (transient) sites, and also pre-
existing pockets deemed non-druggable in a single crystal structure that could attain 
druggable characteristics in the solution ensemble. Identification of such sites is the 
first step towards a structure-based drug design strategy that would seek to stabilize 
conformations where these sites are present and druggable. Such an approach may 
be particularly fruitful in proteins like A1AT, where the design of small molecule 
modulators has to strike a delicate balance between stabilizing the stressed state in 
order to reduce the protein’s tendency to polymerise, and preserving the protein’s 
antiprotease function.  
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Provar analysis of the variability of each pocket provides insight into the basis 
of this variability. This is useful for in silico induced-fit type screening within high 
throughput studies, where it is necessary to keep the number of residues that are 
allowed flexibility as low as possible.  The combination of druggability and 
variability predictions may be relevant for many proteins that are deemed difficult 
to target due to their flexibility. Therefore, automating this process is now an 
ongoing goal of the Nobeli group. 
The conformers in which each pocket achieved its highest druggability score 
were selected for docking studies, employing the publicly available database of 
marketed and experimental drugs DrugBank. These docking experiments 
highlighted several low molecular weight ligands that scored well on individual 
sites and were specific for these sites. Promisingly, several of the docking scores of 
the best-scoring ligands at the novel targets are comparable to the docking score of 
compound “CG”, a molecule previously identified as an inhibitor of A1AT 
polymerization in vitro and in mammalian cells (Mallya et al., 2007).  
This approach has revealed sites with potential for future in vitro studies. A 
small but very hydrophobic site (site I) that is present in about one fifth of the in 
silico-produced conformers was initially identified by SiteMap in three crystal 
structures, carrying the Ala70Gly mutation. This mutation is known to increase the 
stability of the stressed state, oppose the propensity to polymerisation and retain the 
functionality of the protein, while inducing widespread changes in cavity sizes 
within A1AT.  Further analysis showed that this site is present in all other 
crystallographic structures but it is not solvent accessible. Crucially it became 
solvent accessible in about one fifth of the conformers generated in silico from the 
wild type native structure 1qlp, indicating that transient solvent accessibility may be 
feasible in solution in the absence of mutations. Site I is therefore a potential ligand 
target site with some characteristics suggesting that ligand binding might induce 
local, stabilising conformational change. Support for this idea comes from 
mutagenesis studies that showed 13 mutations in the region of the I site (e.g. the 
space-filling mutation His269Tyr) increased stability, while preserving inhibitory 
function (Seo et al., 2000). Thymol and menthol are both small, hydrophobic 
natural products that showed high complementarity to the I site, and are considered 
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safe for use in the pharmaceutical industry. Following induced fit docking they 
achieved scores comparable to the score for the compound “CG”, previously 
identified as an inhibitor of A1AT polymerization in vitro and in mammalian cells 
(Mallya et al., 2007). Some thymol derivatives achieved even better results, 
although the effect of their binding could be destabilizing, as suggested by 
preliminary ThermoFluor experiments.  
The channel of interconnecting sites B, C and E is also potentially interesting as 
the druggability scores for these pockets are persistently high, and some of the best 
docking scores are results of docking ligands to these sites. However, the obvious 
caveat of docking to this site is that many of the ligands will interact with the RCL 
loop, thus potentially interfering with A1AT’s antiprotease function. Indeed, 
mutation experiments have shown that the sequence between Arg196 to Glu279 can 
carry 9 mutations that increase the stability of the A1AT, but in several cases also 
decrease functional activity (Seo et al., 2002). Some of the other sites explored in 
the study may be more promising in terms of their position on the surface and lower 
likelihood of affecting inhibitory function. 
There are obvious caveats in the approach presented here. The conformers 
generated using CONCOORD are artificially produced.  Nevertheless they appear 
realistic when assessed for geometry and packing by the structure validation server 
PROSESS (Berjanskii et al., 2010). Moreover, the range of cavity characteristics 
observed was consistent with the variation observed between crystal structures. 
Although the conformational space of the protein is unlikely to be fully explored 
using CONCOORD, this technique did identify interesting pocket variations. The 
more recent program tCONCOORD, may further improve exploration of larger 
variations in molecular structure in future work (Eyrisch and Helms, 2009). The 
definition of pockets on the protein surface can vary significantly between 
programs, thus results presented here are specific to SiteMap predictions. Similarly 
the calculation of pocket volume and other properties are very much dependent on 
the definition of pocket boundaries, which varies widely across different software. 
Calculations of druggability have an empirical basis and are derived from previous 
correlations of scoring function predictions with in vitro observations of drug-like 
ligand binding. They do not guarantee in vitro binding affinity in a new system but 
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provide a reasonable starting point for docking studies in silico and in vitro. Finally, 
the docking calculations are subject to many approximations. They should therefore 
be considered as a screening tool, based upon goodness of fit of certain ligands 
against each site, to enrich true positive hits among the ligand rankings. 
In summary, this promising strategy utilizes multiple protein conformer 
structures to identify both persistent and transiently druggable surface pockets. This 
approach was applied to A1AT, whose conformational flexibility suggests that the 
usual one conformer/one pocket approach to screening is likely to be inadequate. 
Pockets identified on the surface of A1AT show considerable variability across 
conformers. Moreover, a novel, transient pocket with druggability potential was 
identified (Patschull et al., 2012). Hits to this and other sites identified by this work 
compare favourably with a previously identified promising lead. An unusually high 
proportion of the limited set of in silico hits targeted at the I site and assayed by the 
ThermoFluor method alter the melting temperature of A1AT. These data are 
consistent with an in vitro interaction and warrant further experiments to pursue 
these ligands and I site targeting. 
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6'. ’Appendix 
 
A’. – ConCoord 2.0 Script 
 
#!/bin/tcsh -f 
#$ -cwd 
#$ -j y 
#$ -S /bin/tcsh 
#$ -V 
setenv DATA /d/d640/u/ubcgw9ap/1qlp_concoord_run/pdb 
setenv PDB 1qlpHydSuperposed 
setenv DSSP_EXE /d/d640/u/ubcgw9ap/dsspcmbi 
 
unlimit 
limit coredumpsize 0 
 
source /d/d610/s/concoord/concoord.csh 
cd /d/d640/u/ubcgw9ap/1qlp_concoord_run/ 
 
if (-e ATOMS.DAT) then 
   rm -f ATOMS.DAT 
endif 
if (-e BONDS.DAT) then 
   rm -f BONDS.DAT 
endif 
if (-e MARGINS.DAT) then 
   rm -f MARGINS.DAT 
endif 
 
/bin/rm disco* 
/bin/rm dist* 
 
dist -dssp $DSSP_EXE -r -p ${DATA}/${PDB}.pdb <</eoi 
2 
2 
/eoi 
 
echo "DIST DONE" 
 
disco -ox ./disco.${PDB}.xtc -op ./disco.${PDB} -n 100 -i 1000 -viol 3. -bump -t 
1000.0 
 
 
B’ & C’.- C-Shell and Perl Script  
 
 C-Shell Script executing the Perl Script: 
 
#!/bin/csh 
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echo "site_Alpha\t Protein_Name\t site_Number\t Balance\t Contact\t Don_Acc\t 
Dscore\t Enclosure\t Entry_Name\t Exposure\t Hydrophilic\t Hydrophobic\t 
site_score\t Size\t Volume\t Coordinate_X\t Coordinate_Y\t Coordinate_Z\t 
Distance_A\t Distance_B\t Distance_C\t Distance_D\t Distance_E\t Distance_F\t 
Distance_G\t Distance_H \t Distance_LL \n"> 1qlpConCoo_SM_score.txt 
 
foreach file (rot*1qlp*.mae) 
 
./SiteMapData1qlp.pl $file >> 1qlpConCoo_SM_score.txt 
 
end 
 
 Executed Perl Script: 
 
#!/usr/bin/perl -w 
 
use strict;   
 
die "Usage: script.pl maestro_file_with_sites\n" unless (1<=scalar(@ARGV)); 
my $maefile = $ARGV[0]; 
open(MAEFILE, $maefile) || die "Could not open file $maefile\n"; 
 
my @array; 
 
$array[0] = "Entry_name"; 
$array[1] = "sitescore"; 
$array[2] = "Size"; 
$array[3] = "Dscore"; 
$array[4] = "Volume"; 
$array[5] = "Exposure"; 
$array[6] = "Enclosure"; 
$array[7] = "Contact"; 
$array[8] = "Phobic"; 
$array[9] = "Philic"; 
$array[10] = "Balance"; 
$array[11] = "DonAcc"; 
 
my $protein; 
my $site; 
my $x; 
my $y; 
my $z; 
my $sumx; 
my $sumy; 
my $sumz; 
my $Cx; 
my $Cy; 
my $Cz; 
 
#my $sNa; 
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#my $sNb; 
#my $sNc; 
#my $sNd; 
#my $sNe; 
#my $sNf; 
#my $sNg; 
#my $sNh; 
 
 
while (my $line = <MAEFILE>) { 
   if ($line =~ /^\s+(.+?)_site_(\d+)/){ 
      $protein = $1; 
      $site = $2; 
      $Cx=0.0; 
      $Cy=0.0; 
      $Cz=0.0; 
      $sumx=0.0; 
      $sumy=0.0; 
      $sumz=0.0; 
  
      my %hash=(); 
      for (my $i = 0; $i < 12; $i++) { 
         $line = <MAEFILE>; 
         chomp($line); 
         $line =~ /\s+(\d+)/g; 
         $hash{ $array[$i] } = $line; 
      }   
 
      do { 
         $line = <MAEFILE>; 
      } until ($line =~ /\s+\:\:\:/); 
 
         
      for (my $i = 0; $i < $hash{ $array[2] }; $i++) { 
            $line = <MAEFILE>; 
            chomp($line); 
             
          $line =~ /^\s+\d+\s+\d+\s+(\S+)\s+(\S+)\s+(\S+)/; 
     $x = $1; 
          $y = $2; 
     $z = $3; 
  
 
     $sumx += $x; 
     $sumy += $y; 
          $sumz += $z; 
 
       } 
       $Cx = $sumx/$hash{ $array[2] }; 
       $Cy = $sumy/$hash{ $array[2] }; 
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       $Cz = $sumz/$hash{ $array[2] }; 
 
        
       my $da= sqrt(((23.6945454545455-$Cx)*(23.6945454545455-
$Cx))+((7.47181818181818-$Cy)*(7.47181818181818-
$Cy))+((22.8463636363637-$Cz)*(22.8463636363637-$Cz))); 
       my $db= sqrt(((6.10666666666666-$Cx)*(6.10666666666666-
$Cx))+((13.9974074074074-$Cy)*(13.9974074074074-
$Cy))+((41.3433333333334-$Cz)*(41.3433333333334-$Cz))); 
       my $dd= sqrt(((-5.39870967741936-$Cx)*(-5.39870967741936-$Cx))+((-
12.1035483870968-$Cy)*(-12.1035483870968-$Cy))+((29.3809677419355-
$Cz)*(29.3809677419355-$Cz))); 
       my $de= sqrt(((3.29294117647059-$Cx)*(3.29294117647059-
$Cx))+((13.825294117647-$Cy)*(13.825294117647-$Cy))+((23.9805882352941-
$Cz)*(23.9805882352941-$Cz))); 
       my $dh= sqrt(((3.54344827586207-$Cx)*(3.54344827586207-$Cx))+((-
12.7893103448276-$Cy)*(-12.7893103448276-$Cy))+((16.1479310344828-
$Cz)*(16.1479310344828-$Cz))); 
       my $df= sqrt(((13.2971428571429-$Cx)*(13.2971428571429-$Cx))+((-
12.5171428571429-$Cy)*(-12.5171428571429-$Cy))+((25.8314285714286-
$Cz)*(25.8314285714286-$Cz))); 
       my $dc= sqrt(((1.26758620689655-$Cx)*(1.26758620689655-
$Cx))+((11.8313793103448-$Cy)*(11.8313793103448-
$Cy))+((33.6651724137931-$Cz)*(33.6651724137931-$Cz))); 
       my $dg= sqrt(((36.8685714285714-$Cx)*(36.8685714285714-$Cx))+((-
9.73142857142857-$Cy)*(-9.73142857142857-$Cy))+((4.97428571428572-
$Cz)*(4.97428571428572-$Cz))); 
       my $dll= sqrt(((6.01853997-$Cx)*(6.01853997-$Cx))+((5.30592851-
$Cy)*(5.30592851-$Cy))+((16.3633573-$Cz)*(16.3633573-$Cz))); 
 
       my $sN= "NA"; 
       if ($da<=3.75) {  
         $sN= "A"; 
       } 
        
       if ($db<=3.75) {  
         $sN="B"; 
       } 
               
       if ($dc<=3.75) {  
         $sN="C"; 
       }       
        
       if ($dd<=3.75) {  
         $sN="D"; 
       } 
        
       if ($de<=3.75) {  
         $sN="E"; 
       } 
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       if ($df<=3.75) {  
         $sN="F"; 
       } 
        
       if ($dg<=3.75) {  
         $sN="G"; 
       } 
               
       if ($dh<=3.75) {  
         $sN="H"; 
       } 
        
       if ($dll<=3.75) {  
         $sN="LL"; 
       } 
               
       if ($da>=10 and $db>=10 and $dc>=10 and $dd>=10 and $de>=10 and 
$df>=10 and $dg>=10 and $dh>=10 and $dll>=10) {  
         $sN="NEW"; 
       } 
        
        if ($da>=20 and $db>=20 and $dc>=20 and $dd>=20 and $de>=20 and 
$df>=20 and $dg>=20 and $dh>=20 and $dll>=20) {  
         $sN="!NEW!"; 
       } 
 
       print "$sN\t$protein\t$site\t"; 
       foreach my $key (sort keys %hash) { 
          print "$hash{$key}\t"; 
       } 
       print "$Cx\t$Cy\t$Cz\t$da\t$db\t$dc\t$dd\t$de\t$df\t$dg\t$dh\t$dll\n"; 
    }  
} 
 
 
D’. Statistics on Site Frequency in eight PDB Crystal Structures of α1-Antitrypsin 
 
Table: Description of Sites and Frequency of Occurrence in Eight α1-Antitrypsin 
Structures 
 
Sit
e 
Numb
er of 
Sites 
§ 
PDB 
Code 
where 
Sites are 
present 
Max. 
Site 
Dsco
re 
Max
. 
Site-
Scor
e 
Min
. 
Site-
Scor
e 
Mean 
Site-
Score 
(±SD) 
Max. 
Site 
Volu
me 
(in 
Ǻ3) 
Min. 
Site 
Volu
me 
(in 
Ǻ3) 
Mean 
Site 
Volum
e 
(±SD) 
(in Ǻ3) 
A(S
) 6 
1qlp, 
2qug, 
1.031
a 
1.02
9a 
0.67
7c 
0.876 
(±0.12 234
a 98c 164.583 
211	  
1oph, 
1hp7, 
3drm,3c
wm. 
6) (±41.55
) 
B(S
) 6 
1qlp, 
2qug, 
1oph, 
1hp7, 
3drm,3c
wm. 
0.968 
d 
0.98
2d 
0.56
7e 
0.830 
(±0.13
0) 
326 d 76 e 
210.65
9 
(±75.08
9) 
C 5 
1qlp, 
1oph, 
3drm,3c
wm, 
1ezx. 
0.989
c 
1.03
4c 
0.82
4a 
0.972 
(±0.07
8) 
173 c 59a 
122.17
7 
(±43.47
) 
D 6 
1qlp, 
2qug, 
1hp7, 
3drm, 
3cwm, 
1ezx. 
0.907 
f 
0.88
3f 
0.72
7h 
0.795 
(±0.05
4) 
205 f 136a,e 
174.51
8 
(±26.17
9) 
E 4 
1qlp, 
2qug, 
1oph, 
1ezx. 
1.014 
d 
1.02
0d 
0.68
7h 
0.831 
(±0.14
1) 
273 d 60 h 
133.59
9 
(±83.05
5) 
F 5 
1qlp, 
1hp7, 
3cwm, 
1iz2, 
1ezx. 
1.005
g 
0.98
4g 
0.58
6h 
0.693 
(±0.14
7) 
249 g 64 h 
125.81
2 
(±63.56
1) 
G(
S) 5 
1qlp, 
2qug, 
1hp7, 
3drm, 
3cwm. 
0.602
b 
0.63
2b 
0.51
1d 
0.588 
(±0.04
2) 
83b 42 d 
74.088 
(±16.35
5) 
H(
S) 1 1qlp. 
0.482
a 
0.58
5a - - 46
 a - - 
I 2 
1oph, 
1iz2 , 
(1hp7)*. 
0.917
c 
0.94
4c 
0.84
8g 
0.896 
(±0.04
8) 
90 g 45 c 
67.228 
(±22.29
5) 
 
Key:  
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* this site was cropped to another site and hence not included in the count, 
but the cavity is solvent accessible in this structure. 
 § number of structures out of 8, in which sites were identified by SiteMap2.3. 
 (S) is present in the stressed form, but absent in the relaxed form.  
 a-h score obtained from the following structure: a 1qlp, b 2qug, c 1oph, d 1hp7 
,e 3drm, f    3cwm, g 1iz2 or h 1ezx. 
 
 
E’ – Statistics on Site Frequency in 1qlp ConCoord Conformers of α1-Antitrypsin 
 
 
Table: Description of Sites and Frequency of Occurrence in New native WT (1qlp) 
 Conformations 
 
Sit
e 
Numbe
r of 
Sites§ 
Max 
Dscor
e 
Max. 
Site-
Scor
e 
Min. 
Site-
Score 
Mean 
Site-
Score 
(±SD) 
Max. 
Site 
Volum
e (in 
Ǻ3) 
Min. 
Site 
Volum
e (in 
Ǻ3) 
Mean site 
Volume 
(±SD) (in 
Ǻ3) 
A 96 1.072 1.082 0.9425 
1.002 
(±0.022
) 
435.61 173.21 298.038 (±67.478) 
B 59 1.057 1.010 0.610 
0.876 
(±0.096
) 
450.70
2 80.605 
215.648 
(±83.215) 
C 33 0.977 1.083 0.824 
0.956 
(±0.081
) 
518.95
9 51.45 
151.003 
(±117.222
) 
D 92 0.983 0.980 0.601 
0.820 
(±0.089
) 
228.43
8 86.436 
159.394 
(±34.637) 
E 40 1.009 1.083 0.663 
0.931 
(±0.145
) 
313.84
5 77.861 
189.173 
(±81.772) 
F 91 0.767 0.800 0.592 
0.683 
(±0.047
) 
164.64 69.972 119.270 (±17.086) 
G 58 0.781 0.751 0.501 
0.636 
(±0.050
) 
128.28
2 54.88 
87.879 
(±13.083) 
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H 69 0.714 0.744 0.528 
0.602 
(±0.044
) 
89.18 41.503 59.076 (±9.878) 
I 21 0.937 0.953 0.726 
0.871 
(±0.059
) 
96.726 37.387 
52.428 
(±11.026) 
 
Key:  
 § number of conformers out of 100, in which sites were identified by 
SiteMap2.3. 
 
F’.– Statistics on Site Frequency in 2qug ConCoord Conformers of α1-Antitrypsin 
 
Table: 2qug Description of Sites and Frequency of Occurrence in New 
Conformations 
 
Site Number of Sites§ 
Max 
D-
score 
Max. 
SiteScore 
Min. 
SiteScore 
Mean 
SiteScore 
(±SD) 
Max. 
Site 
Volume 
(in Ǻ3) 
Min. 
Site 
Volume 
(in Ǻ3) 
Mean 
Site 
Volume 
(±SD) (in 
Ǻ3) 
A 97 1.099 1.078 0.895 
0.987 
(±0.039) 
425.32 203.515 
203.515 
(±68.430) 
B 27 0.994 0.972 0.655 
0.816 
(±0.089) 
322.42 141.316 
205.470 
(±51.183) 
C 31 0.912 1.048 0.814 
0.922 
(±0.099) 
191.737 43.218 
94.668 
(±55.634) 
D 53 0.975 0.967 0.630 
0.777 
(±0.094) 
363.58 87.122 
161.890 
(±62.046) 
E 22 0.887 1.042 0.754 
0.890 
(±0.072) 
173.215 78.204 
114.422 
(±17.684) 
F 12 0.736 0.747 0.552 
0.616 
(±0.052) 
140.287 72.373 
85.979 
(±22.398) 
G 38 0.713 0.719 0.513 0.612 (±0.043) 142.345 55.223 85.208 
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(±15.567) 
H 35 0.691 0.746 0.535 
0.647 
(±0.045) 
116.963 69.629 
91.267 
(±11.006) 
I 14 0.903 0.930 0.786 
0.858 
(±0.043) 
62.083 32.928 
45.08 
(±8.073) 
 
Key:  
 § number of conformers out of 100, in which sites were identified by 
SiteMap2.3. 
 
 
G’. – Procheck Results for 3ne4 
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H’.– 18 Compounds from DrugBank Library ‘Hits’ used for the ThermoFluor 
Assay 
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Compound Structure 
 
Molecula
r Weight 
in  g.mol-
1 
 
GlideScor
e in 
kcal.mol-1 
Site 
Targe
t 
Thymol 
 
150.22 -6.85 I 
2-Bromophenol 
 
173.01 -6.17 I 
4-
Methylcatechol 
 
124.14 -6.18 I 
2'-Deoxyinosine 
 
252.23 -7.69 I 
(−)-Menthol 
 
156.27 -6.75 I 
4-Nitrocatechol 
 
155.11 -6.41 I 
4-Methyl-2-
Nitrophenol 
 
153.14 -6.31 I 
Isatin 
 
147.13 -6.30 I 
2,6-
Diisopropylphen
ol 
 
178.27 -6.53 I 
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L-Rhamnose 
Monohydrate 
 
182.17 -8.10 C 
5-Acetyluracil 
 
154.12 -6.73 I 
Procaterol 
Hydrochloride 
 
326.82 -7.11 D 
Oxypurinol 
 
152.11 -7.16 D 
(±)-Sotalol 
Hydrochloride 
 
308.82 -7.16 E 
Tizanidine 
Hydrochloride 
 
290.17 -7.12 E 
Mebendazole 
 
295.29 -8.93 C 
D-Allose 
 
180.16 -7.67 C 
3,4-
Dihydroxybenzo
ic Acid 
 
154.12 -6.32 I 
 
 
I’. – ThermoFluor Data – Each Graph Contains the Repeats for Each Compound 
Assayed 
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Controls 1 - 96 Well Plate 1 (α1-Antiprypsin vs. α1-Antiprypsin in either 5 
%, 10 % or                                      15 % DMSO) 
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Controls 2 - 96 Well Plate 2 (α1-Antiprypsin vs. α1-Antiprypsin in either 5 
%, 10 % or      15 % DMSO ) 
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Controls 2 - 96 Well Plate 2 – Ethanol (α1-Antiprypsin vs. α1-Antiprypsin in 
either 5           %, 10 % or 15 % Ethanol) 
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Compounds - 96 Well Plate 1 (α1-Antiprypsin in 5 % DMSO vs. α1-
Antiprypsin and         Compound at 1 mM in 5 % 
DMSO) 
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Compounds - 96 Well Plate 2 (α1-Antiprypsin in 5 % DMSO vs. α1-Antiprypsin 
and          Compound at 1 mM in 5 % DMSO) 
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Compounds - 96 Well Plate 2 (α1-Antiprypsin in 5 % DMSO vs. α1-Antiprypsin 
and          V1-LTM in 5 % DMSO) 
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